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Abstract 
 
This project focuses on two important topics which may pose hazards to 
human health. Firstly, drinking water disinfection by-products (DBPs), which 
are generated by the chemical disinfection of water have been investigated. 
What has not been shown is the effect of DBPs in human germ cells as well 
as somatic cells and whether oxidative stress is involved in the mechanism of 
genotoxic action. Three different DBPs (halo acetic acids: HAAs), together with 
the antioxidants – catalase and butylated hydroxyanisole (BHA), were 
investigated in peripheral blood cells and sperm from healthy individuals using 
the Comet assay and lymphocytes only using the micronucleus assay. 
Secondly, nanoparticles of the non-steroidal anti-inflammatory drugs 
(NSAIDs), aspirin and ibuprofen, have been investigated in patients with 
respiratory diseases, in the micronucleus assay and the Comet repair assay. 
NSAIDs inhibit cyclooxygenase enzyme activity, which plays part in tumour 
progression. In the Comet assay, BHA and catalase were able to reduce DNA 
damage in both cell types compared to HAAs alone. Similarly, in the 
micronucleus assay, micronuclei were reduced with the antioxidants, 
suggesting oxygen radical involvement in both assays. With the NSAIDs, 
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reductions were seen for DNA damage in the micronucleus assay with aspirin 
and ibuprofen nanoparticles compared to their bulk forms. Using the Comet 
repair assay, aspirin and ibuprofen nanoparticles aided repair of DNA to a 
greater extent than their bulk counterparts, which in turn showed better repair 
compared to samples repaired without NSAIDs. These observations show the 
importance of DBPs and NSAIDs in genotoxic public health issues. 
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Chapter 1 - Introduction 
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Introduction 
1.1 Overview of Project 
 
This PhD project involves studies of the genotoxic damage to DNA caused in 
human cells that are diploid, more specifically, peripheral lymphocytes and 
whole blood cells or haploid, sperm. These cells are from healthy control 
individuals or patients and the general theme is to determine and analyse the 
impact certain chemicals have on DNA and cell damage.  Blood cells are of 
interest because damage to the DNA could give rise to cancer, and damage 
to the DNA in germinal cells could give rise not only to cancer but also to 
heritable defects. 
This project focuses on two important topics. The first one is the side effects 
of by-products of disinfectants used in the treatment of drinking water. These 
effects are investigated in human peripheral blood cells and sperm using the 
Comet assay as a means of testing genotoxicity by observing the % tail DNA 
and Olive tail moments of Comets. The micronucleus assay is also used to 
assess the cytogenetic damage of these by-products in lymphocytes by 
observing the number of micronuclei (MNi) in mononucleated and binucleated 
cells. Findings from these studies will help to establish health related 
implications for DBPs and will further contribute to the existing literature 
pointing to the needs for greater regulation of DBPs in drinking water. The 
second topic investigates the effects of nanoparticles in human peripheral 
blood cells. Nanoparticles of the non-steroidal anti-inflammatory drugs, aspirin 
and ibuprofen, have been investigated in patients with respiratory diseases, 
using the micronucleus assay and a Comet repair assay. Determining the 
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toxicity of nanoparticles is very important because nanotoxicology lags behind 
nanotechnology and recently there has been a boom in the latter. 
1.2 History and increasing use of disinfectants 
 
Water disinfection has become one of the biggest health improvements of the 
last century which has reduced the transmission of waterborne infectious 
diseases (Akin et al., 1982). Today millions of people around the world receive 
clean, safe and quality drinking water each day through their public water 
systems. Most developed nations have systems and procedures in place for 
treating water, such as the U.S EPA (Environmental protection agency) 
(Richardson et al., 2007). In untreated water, the transmission of pathogenic 
microorganisms like Vibrio chloerae, Salmonella typhi and Enteromoeba 
histologica, are responsible for the rise of waterborne infectious diseases such 
as cholera, typhoid fever, and amoebic dysentery, to name a few (Akin et al., 
1982; Dziuban et al., 2006). Pathogenic transmissions can occur through 
drinking water, washing, bathing, swimming, ingestion, preparation and 
consumption of food with infected water. According to the World Health 
Organization (WHO), diarrhoeal infections account for 4.1% of the total DALY 
burden (Death and disability-adjusted life year) of disease in developing 
nations, causing 1.8 million deaths annually. The WHO also reports that 88% 
of the burden is due to, lack of hygiene, sanitation and unsafe/untreated water 
(World Health Organization., 2010b). 
Fortunately, chemical disinfectants have helped to eliminate many of these 
diseases by effectively killing harmful microorganisms found in drinking water 
(Richardson et al., 2008; Richardson et al., 2007). These disinfectants are 
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capable of oxidising organic matter and naturally occurring bromide and iodide 
present in waters of reservoirs, lakes and rivers (Plewa et al., 2002; 
Richardson et al., 2008; Richardson et al., 2007). Chlorine is the most 
commonly used disinfectant to treat drinking water and is also used in 
swimming pools (Kogevinas et al., 2010). It inactivates bacterial, viral and 
protozoal pathogens and prevents algal/biological growth (Akin et al., 1982; 
Sadiq and Rodriguez, 2004). Other disinfectants include; chloramines, 
chlorine dioxide and ozone treatment (Plewa et al., 2002; Richardson et al., 
2007). The benefit of treating drinking water has a major impact on improving 
health and wellbeing. However their use has led to the formation of unwanted 
drinking water disinfection by-products (DBPs). DBPs are formed from the 
reaction between the chemical disinfectant and organic constituents, bromide 
and iodide that are naturally present in water (Richardson, 2011).  
1.3 Emergence of DBPs 
 
In 1974, Rook and other researchers identified the first DBPs found in 
chlorinated drinking water. The first two classes identified were chloroform and 
trihalomethanes (THMs), and halo acetic acids (HAAs) were identified soon 
after. Over 30 years later, some 600 DBPs have been identified, as reviewed 
by Richardson et al. (2007). 
There are several different classes of DBPs (Richardson et al., 2007): 
1. THMs – Trihalomethanes (chloroform, bromoform, 
bromodichloromethane and dibromochloromethane), 
2. HAAs – halo acetic acids, including iodoacids (iodoacetic acid, 
bromoiodoacetic acid, chloroacetic acid, bromoacetic acid, 
dichloroacetic acid and trichloroacetic acid). 
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3. Other halo acids (bromochloroacetic acid, bromodichloroacetic acid), 
dibromochloroacetic acid and tribromoacetic acid). 
4. Iodo-THMs (dichloroiodomethane, bromochloromethane) 
5. Oxyhalides (bromate and chlorate). 
6. MX Compounds (3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone) and EMX compounds (E)-2-chloro-3-(dichloromethyl)-4-
oxobutenoic acid). 
7. Haloamides (iodoacetamide, bromoacetamide and chloroacetamide). 
8. Haloacetnitriles (iodoacetnitrile, bromoacetnitrile and chloroacetnitrile). 
9. Halopyroles, Nitrosamines and Aldehydes. 
Although it has been possible to identify a large number of DBPs, only a few 
of these DBPs have been analysed for their cytotoxic and genotoxic potential 
and impact on health issues (Cemeli et al., 2006; Krasner et al., 2006; Muellner 
et al., 2007; Plewa et al., 2002; Plewa et al., 2008; Plewa et al., 2010; Plewa 
and Wagner, 2011; Plewa et al., 2004). As far as the regulations of DBPs are 
concerned, only a small number with genotoxic and cytotoxic potentials are 
regulated, however many DBPs with similar consequences remain 
unregulated (Plewa et al., 2010; Richardson et al., 2007). As with all common 
DBPs, HAAs can form from usage of chlorine, chloramine, chlorine dioxide 
and ozone treatment; however, amongst them chlorination use produces 
higher levels of HAAs (Krasner et al., 2006; Richardson et al., 2007). 
1.3.1 Halo acetic acids (HAAs) 
 
Several different classes of DBPs are found in finished drinking water as 
mentioned above but two of the well-known classes are the haloacetic acids 
(HAAs) (Bougeard et al., 2010; Cemeli et al., 2006; Plewa et al., 2002; Plewa 
et al., 2010) and the trihalomethanes (THMs) (Kogevinas et al., 2010; Liviac 
et al., 2010).  
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The US Environmental protection agency (EPA) regulates five out of nine 
HAAs to a maximum containment level of 60 µg/l. These are known as the 
HAA5 group consisting of; bromoacetic acid (BAA), dibromoacetic acid 
(DBAA), chloroacetic acid (CAA), dichloroacetic acid (DCAA) and 
trichloroacetic acid (TCAA). The other four compounds include four further 
chloro-bromo-HAAs which form part of a larger HAA9 group (Plewa et al., 
2010). In the UK, THMs are the only class of DBPs which are subject to 
regulation, regulated to levels <100 µg/L. Although HAAs are equally prevalent 
as THMs, they are not subject to regulation but the EU is considering starting 
regulating the HAA9 group to a maximum level of 80 µg/L, and there is further 
interest into HAAs calling for regulation (Bougeard et al., 2010).  
Drinking water subject to chlorination contains HAAs at low to mid-range 
concentrations (µg/l), similar to regulated levels of THMs. Further to this, the 
total concentration of the entire HAA9 group is also comparable to that total 
concentration of the THM group (known as the THM4) (Krasner et al., 2006).  
Drinking water typically contains chloro-HAAs, such as DCAA and TCAA, but 
if the source waters particularly contain high levels of bromine > 50 µg/L, then 
bromo-HAAs, such as the DBAA and BCAA are the sub types that dominate. 
However, other factors like residence time, pH, and temperature and 
disinfection procedure can also impact the types and compositions of HAAs 
(Cemeli et al., 2006; Plewa et al., 2010). Bougeard et al., (2010) have also 
reported the shift to bromo-HAAs in source waters containing higher levels of 
bromine in the United Kingdom. Bromo-HAAs are more likely to be found in 
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source waters from coastal locations, due to saltwater intrusion (Cemeli et al., 
2006; Nieuwenhuijsen et al., 2000). 
HAAs, including iodoacetic acid (IAA), bromoacetic acid (BAA), and 
chloroacetic acid (CAA) have previously been reported to be genotoxic and 
cytotoxic in various studies, (Plewa et al., 2004; Richardson et al., 2007). 
These HAAs have been reported to be carcinogenic and toxic in experimental 
animals but there is no such evidence of similar effects in humans; however, 
many in vitro testings have demonstrated HAA’s cytotoxic and genotoxic 
potential (DeAngelo et al., 1996; Richard and Hunter, 1996). 
1.3.2 Chemical reaction and Structure of Halo acetic acids (HAAs) 
 
HAAs are carboxylic acids where the hydrogen atoms from the alpha-carbon 
chain are replaced by one or more of halogen atoms. These electronegative 
halogens enhance and help stabilise the negative charge of the conjugate 
base, resulting in higher levels of acidity in these compounds (Plewa et al., 
2010). 
 
Figure 1: Structure of haloacetic acids: Figure shows the chemical structure of halo 
acetic acids, the halogen atoms replace the hydrogen atoms on the alpha carbon 
chain. 
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1.4 Health related issues of DBPs 
 
DBPs are classed as environmentally hazardous chemicals which can have 
many health related implications in humans (Cemeli et al., 2006). Increased 
amounts of THMs and HAAs uptake have been detected in people through 
activities such as tap water ingestion, showering, bathing and swimming 
(Kogevinas et al., 2010; Nieuwenhuijsen et al., 2000). This is supported by 
several epidemiological studies that show a correlation between consumption 
of disinfected water with increased risk of bladder, kidney and brain cancers 
(Cantor et al., 1999; Koivusalo et al., 1994) and consumption of drinking tap 
water by pregnant women was found to be associated with early miscarriages 
and spontaneous abortion (Swan et al., 1998; Waller et al., 1998). However 
Arbuckle et al. (2002) have shown that epidemiological studies may pose 
shortcomings, for example the characterisation of DBPs exposures in all 
studies is not necessarily the same and other factors like, surface water, 
ground water, whether the water was chloraminated or chlorinated are 
different. All these factors can lead to inconsistencies; however, it was 
established that there was a greater need to keep these factors as similar as 
possible. 
It has previously been demonstrated that the HAAs, - iodoacetic acid (IAA), 
bromoacetic acid (BAA) and chloroacetic acid (CAA) are cytotoxic and 
genotoxic DBPs when analysed in the Ames test, and in the mammalian CHO 
cell system (Plewa et al., 2002; Plewa et al., 2010; Richardson et al., 2008). 
Cemeli et al. (2006) have also shown the involvement of oxygen radicals with 
IAA in these cells. In addition, HAAs have also been found to be cytotoxic in 
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human lymphocytes but not genotoxic in the Micronucleus assay in TK6 cells 
(Liviac et al., 2010). IAAs have also been reported to induce chromosomal 
aberrations in CHO cells (Hilliard et al., 1998). Plewa et al. (2004) have shown 
responses amongst the HAAs for IAA, BAA and CAA when analysing HAA-
induced genomic DNA damage in CHO cells. Their studies have shown that 
bromo-HAAs [brominated HAA] were more cytotoxic and genotoxic than 
chloro-HAAs [chlorinated HAA] analogues and that iodo-HAAs [iodinated 
HAA] analogues were more cytotoxic and genotoxic when compared to both 
bromo-HAAs and chloro-HAAs (Plewa et al., 2002; Plewa et al., 2004). These 
HAAs were toxic in the same order, following 24 hour exposure to mice (iodo-
HAAs > bromo-HAAs > chloro-HAAs) for the induction of neural tube defects 
in mouse embryos. Exposure also produced malpositioned and/or hypoplastic 
pharyngeal arches and affected the heart and optic development (Hunter et 
al., 1996). 
Toxicogenomic implications of HAAs were shown in studies in which mice 
were exposed to chloro and bromo-chloro-HAAs. Altered gene expression was 
found in pathways involving cell communication, cell cycle and proliferation, 
metabolism, signal transduction, spermatogenesis and male fertility in mice 
exposed to dichloroacetic acid (DCAA) (Thai et al., 2003). Mice that were 
subject to bromo-chloro acetic acid (BCAA) exposure, exhibited cellular 
damage and altered gene expression in different pathways involving fatty acid 
metabolism, angiogenesis, and tissue remodelling (Tully et al., 2005). Another 
study on HAA toxicogenomic showed that BAA was able to alter transcriptome 
profiles for genes involved in DNA repair, including the cell cycle regulation of 
double stranded DNA strand breaks (dd-DSBs) (Muellner et al., 2010). In non-
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transformed human cells toxicogenomic analyses of the HAAs, the major 
pathways involved with altered gene expression were ATM, MAPK, p53, 
BRCA1, BRCA2, and ATR. These latter pathways highlight the involvement of 
DNA repair, especially the repair of double strand DNA breaks (Attene-Ramos 
et al., 2010). 
In human lymphocytes, Kogevinas et al. (2010) reported damage with THMs 
in lymphocytes using the micronucleus assay, but not in the Comet assay. 
These studies involving HAAs in both in vitro and in vivo experiments, 
demonstrate the need for further studies to address and raise the importance 
of health implications posed by HAAs. The present study further determines 
toxic effects in in vitro of HAAs in human somatic cells and for the first time 
also in germ cells. Samples were taken from participating consented 
volunteers. The Comet assay and the micronucleus assay were used to detect 
any genotoxic damage in these cells. 
 
1.5 Antioxidants: Catalase and butylated hydroxyanisole. 
 
1.5.1 Uses and functions of catalase and butylated hydroxyanisole 
 
Catalase, (also known as hydroperoxidases) is a common enzyme involved in 
the reactive oxygen species detoxification pathways. The enzyme has been a 
subject of study in a vast number of different organisms. The ubiquity of the 
enzyme, have made it an attractive protein to work with. It is used in foods and 
prevents oxidation of foods via its use in food packaging. Oxygen radical break 
down is split into two reactions: Metabolic reactions generate O• radicals which 
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are converted to hydrogen peroxide (H2O2) by super oxide dismutase. 
Catalase then works by catalysing the decomposition of toxic H2O2 to H2O & 
O2 (Chelikani et al., 2004).  
 
2H2O2 → 2H2O + O2 
 
Butylated hydroxyanisole (BHA) is a synthetic antioxidant. It consists of a 
mixture of two compounds, 3-tert-butyl-4-hydroxyanisole (3-BHA) and 2-tert-
butyl-4-hydroxyanisole (2-BHA). BHA plays its role as a free radical 
scavenger. It contains a conjugated aromatic ring in its structure, which 
sequesters free radicals in order to stabilise them (See Figure 2). It has 
primarily been used as an antioxidant to preserve the freshness of food, food 
colouring and maintain flavour. BHA used in foods consists of 85% of 3-BHA 
and 15% 2-BHA (Williams et al., 1999). BHA does not produce DNA reactivity 
in assays for DNA adduct detection and most genotoxic studies have shown 
negative responses with BHA induction, and BHA used at current food additive 
levels does not represent any cancer risk, as reviewed by Williams et al. 
(1999). Moreover, it has previously been suggested to reduce cancer and 
provide additional benefits (Williams et al., 1999). 
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Figure 2: Structure of butylated hydroxyanisole (BHA): Figure shows the chemical 
structure of 3-tert-butyl-4-hydroxyanisole (3-BHA). The 2-tert-butyl-4-hydroxyanisole 
(2-BHA) simply has the C(CH3)3 group located on the third carbon of the aromatic ring 
(closer to the OCH3 structure). 
 
1.5.2 Catalase and butylated hydroxyanisole impact on HAAs 
 
Cemeli et al. (2006) have shown that catalase and butylated hydroxyanisole 
were able to reduce IAA induced mutagenicity of S. typhimurium and IAA 
induced genotoxicity in CHO cells. It was reported that this reduction was 
significantly different (*** p = < 0.001), when compared to the IAA positive 
control. Catalase played a protective role in reducing mutagenicity in S. 
typhimurium by 26.8% and genotoxicity in CHO cells by 42.5%. This suggests 
that IAA-induced genomic DNA damage must have involved an oxidative 
stress mechanism, via increase in hydrogen peroxide as catalase was able to 
reduce this damage.  
Butylated hydroxyanisole was found to be highly effective in comparison to 
catalase. It was able to act as an effective modulator of IAA induced DNA 
damage; there was 33.5% reduction of mutagenicity in S. typhimurium and 
86.5% reduction of genotoxicity in CHO cells.  Furthermore, Plewa et al. 
(2004), demonstrated the ranking order of monohalogenated acetic acids. It 
was reported that IAA was 2.6 × and 523.3 × more mutagenic in S. 
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typhimurium TA100 than BAA and CAA, respectively. IAA was found to be 2.0 
× and 47.2 × more genotoxic than BAA and CAA, respectively in CHO cells. 
In Cemeli et al. (2006), their findings warrant the possibility of analysing similar 
conditions in lymphocytes and sperm to determine oxygen radical involvement 
by observing BHA levels via single cell-gel electrophoresis (known as the 
Comet assay) under alkaline conditions > pH 13. Following genotoxic analysis 
in the Comet assay, the cytotoxicity and genotoxicity of lymphocyte cells will 
be examined in the micronucleus assay.  
1.6 Introduction to nanoparticles 
 
1.6.1 Background to Nanomaterials  
 
Nanomaterials, including nanoparticles have become an important part of 
genetic toxicology studies. Owing to their vast compound properties, they have 
become increasingly popular in recent years for commercial and medical 
products (Osman et al., 2010). Several consumer products are currently using 
NP, such as additives to cosmetics, surface-coatings of clothes, food 
colourants, substrates in electronics and many more. As such new products 
are regularly being launched on a daily basis. In genetic toxicology and most 
medical studies for that matter, they have an important role in oncology, 
molecular diagnostics, cardiovascular medicine and the discovery and delivery 
of drugs (Haase et al., 2012; Kubik et al., 2005; LaVan et al., 2003).  
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1.6.2 Uses of Nanoparticles in Industry / Types of Nano 
compounds 
 
Nano compounds or particles are classified into two different groups; natural 
and anthropogenic nanoparticles (Dhawan and Sharma, 2010). Natural 
nanoparticles are those which have always existed in the environment, long 
before nanotechnology development work had started. Examples of some of 
these compounds include airborne nanocrystals of sea salts, fullerenes and 
soil (consisting of inorganic and organic nanoparticles like metal oxides, 
hydroxides and clay materials) (Nowack and Bucheli, 2007). Natural 
vegetation also contains organic nano compounds (Xia et al., 2010). 
The anthropogenic class of nanoparticles are subdivided into further two 
classes: incidental and engineered. Incidental nanoparticles are those 
consisting of nanoparticles that have been produced unintentionally during 
manmade processes. Examples include: carbon nanotubes, carbon black, 
platinum and rhodium-containing nanoparticles from combustion by-products 
(Nowack and Bucheli, 2007). Engineered/manufactured nanoparticles are 
those produced intentionally due their desirable nano-specific characteristics 
and /or properties – examples of which are mentioned below. 
Nanoparticles are found in variety of everyday consumer products, like tennis 
rackets and baseball bats to improve their strength and reduce weight. Others 
include cosmetics and sunscreens where the use of nanoparticles allows for 
greater transparency and efficacy. Nanomaterials have also found use within 
the textile industry where they have been deployed to produce clothes that are 
stain and wrinkle-free and water resistant (Thomas et al., 2006). The food 
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industry also makes use of nanoparticles such as silver and zinc oxide (ZnO) 
for food packaging (Bouwmeester et al., 2009). Engineered nanoparticles 
have been extensively investigated in the Comet assay and the micronucleus 
assay both in-vivo and in-vitro (Magdolenova et al., 2014). 
1.6.3 Properties of nanoparticles 
 
Nanoparticles have become popular because of their certain properties. The 
key feature being the difference in size of nano-compounds compared to their 
bulk equivalents. Nanocompounds are defined as those compounds or 
materials, whose size is below 100 nm, however the pharmaceutical industry 
considers sizes up to 1000 nm to be classified as nano compounds (Carlin, 
2014; Teeguarden et al., 2007). As a consequence, their smaller size provides 
for a large surface area to volume ratio and together with their physiochemical 
properties, these particles are capable of easily passing through cell 
membranes (Figure 3). This has toxicological consequences, since the 
behaviour of compounds is unpredictable and a major cause of concern is the 
ability of these compounds to become lodged in the mitochondria (Foley et al., 
2002), whilst some engineered nano compounds can be redox active (Carlin, 
2014; Colvin, 2003). Thus, increasing usage and applications of nano 
compounds / materials in a wide range of fields can cause an increase of nano 
exposure to humans, which in turn may directly increase toxicological effects 
(Osman et al., 2010).  
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Figure 3: Surface reactivity of nanoparticles: Paradigm above, shows the size-
surface area-reactivity for nanoparticles, with the downward and upward arrows 
representing decrease and increase of certain properties of nanoparticles, 
respectively as shown by Dhawan et al. (2009b) Generally, a reduction in size 
increases surface area and therefore leads to increased reactivity. 
 
As has been discovered over the last decade, alongside the advantages of 
nanoparticles, these compounds also have disadvantages which have been 
documented in past studies (Goldston, 2007; Igarashi, 2008). Furthermore, 
increasing production and usage of nanoparticles have led to increased 
concerns and debates surrounding their implications in biological systems by 
public, scientific and regulatory authorities (Dhawan and Sharma, 2010). 
Investigating the challenges and issues presented by nanomaterials in 
biological systems has given rise to the term ‘nanotoxicology’ (Dhawan et al., 
2009).  
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So far nanotoxicology has lagged behind nanotechnology due to a number of 
experimental challenges found in designing toxicological assessments of 
nanomaterials (Dhawan et al., 2009a; Dhawan and Sharma, 2010). Some of 
the most important challenges and issues such as the characterisation, 
agglomeration, surface coating, and dose-response and exposure 
assessment of nanoparticles are mentioned below. 
 
Figure 4: Factors to consider for nanoparticle synthesis: The diagram above 
highlights the key issues and challenges to address when designing new 
nanoparticles (Dhawan et al., 2009b).  
 
1.6.3.1 Characterisation 
 
Characterisation is the first step for nanomaterial preparation. A small amount 
of the test substance or sample of the nano material is characterised before 
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any toxicity screening is commenced. The process of characterising 
nanoparticles can be complex compared to their bulky chemical equivalents 
with known chemical compositions and purities because the exact properties 
of nanoparticles are poorly understood. More so, the reasons for nanoparticle 
toxicity are unknown and understood to a much lesser extent (Dhawan and 
Sharma, 2010). Thus, as part of an extensive characterisation, it is important 
to determine the shape, size, size distribution, surface area and chemistry, 
agglomeration state, and solubility etc. Determining these factors is imperative 
because it allows us to obtain the correct correlation between the 
physiochemical properties of the nanoparticles and the biological effects they 
elicit. A complete characterisation would also ensure reproducibility of 
experimental works as well as reliability i.e. working with ibuprofen nano 
particles, to check and characterise on a regular basis for consistency 
amongst data (Dhawan and Sharma, 2010; Warheit et al., 2009).  
Commercially available nanoparticles can be purchased and used and 
researchers are also able to characterise nanoparticles for themselves. 
However, the process used by them can differ from the commercially produced 
ones, since researchers are more likely to characterise nanoparticles based 
on facilities available to them. The lack of comprehensive equipment, time and 
manual labour means that for researchers, the facilities they have are the 
deciding factor in the type and methods of characterisation performed (Warheit 
et al., 2009). 
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1.6.3.2 Agglomeration 
 
Agglomeration is an important factor to consider when working with 
nanoparticles, Nanoparticles can agglomerate in both the dry form or in the 
wet/liquid form. Nanoparticles tend to agglomerate due to Van der Waal’s 
forces, which have a greater influence due to the large surface area to volume 
ratio of nanoparticles  (Dhawan et al., 2009b; Powers et al., 2007). 
Agglomeration also starts as soon as nanoparticles are produced, and when 
introduced in liquids, the agglomeration of particles is even greater (See Figure 
5) (Murdock et al., 2008). 
Figure 5: Agglomeration of nanoparticles: Diagram shows the process of 
agglomeration as shown by Dhawan et al. (2009b) and adapted from Murdock et al. 
(2008). Agglomeration can result in clumping of nano particles, however surface 
coating (as mentioned in the next section) of the nanoparticles can prevent particles 
from adhering to each other.  
 
Nanoparticles agglomerate in Brownian motion. Particles move in random 
directions, colliding with each other and adhere together, increasing 
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successively, before settling downwards as larger clumps of particles due to 
gravitational forces. Consequently, the number and concentration of 
nanoparticles decreases, surface area decreases while the mass remains 
conserved, and these clumps diffuse much slower than freely moving single 
nanoparticles nearby. These parameters increase gravitational and buoyant 
forces, leading to rapid settlement in liquids (Dhawan et al., 2009b). Hence, it 
is important to consider size, surface area, and concentration of particles when 
addressing issues of agglomeration as they influence the toxicity of particles 
in solutions.  
However, there are other additional factors that can also influence 
agglomeration. These are; the zeta potential, fluid characteristics, sample 
preparation methods, sonication timings and concentration of nanoparticles 
(high concentrations rapidly increase agglomeration due to greater particle 
interactions) (Teeguarden et al., 2007). Murdock et al. (2008) have studied 
nanoparticle agglomeration by examining different sizes of copper 
nanoparticles in deionised water, 1640- RPMI cell culture medium with and 
without serum and found that presences of serum in the RPMI-1640 culture 
medium decreases agglomeration. The proteins released from the serum 
reduce particle to particle interactions by coating over them.  
Since agglomeration can greatly increase the overall size of particles (or the 
forming clump of particles), it is important to ensure that samples are regularly 
checked for their zeta potential and size to ensure they do not exceed beyond 
the nano meter (nm) range (1 nm – 1000 nm), since proceeding with samples 
above nm, work is performed on samples in the millimetre (mm) range, which 
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invalidates the purpose of studying for toxicity of nanoparticles (Balbus et al., 
2007).  
1.6.3.3 Surface coating 
 
As mentioned previously, addressing nanoparticle agglomeration is a major 
challenge when designing and synthesising such particles. Surface coating is 
a key process by which this issue can be addressed. It involves coating by 
homogenously dispersing the particles in solutions prior to usage. Sometimes 
surface coating can also be used to reduce the surface reactivity’s of 
nanoparticles and not just be used for agglomeration. For example zinc oxide 
nanoparticles constituting sunscreens, can be coated, to preventing oxygen 
radicals forming, when exposed to UV light absorption. Nanoparticles can be 
coated with polymers (such as 4-mercaptomethylstyrene coating of metal 
nanoparticles), alveolar surfactants in ionised or deionised solutions (Dhawan 
et al., 2009b; Farah et al., 2008).  
Furthermore, dispersion capabilities of several medium were studied by Sager 
et al. (2007), who found that bronchoalveolar lavage fluid, was the best 
solution in which to suspend nanoparticles without affecting their toxic or 
inflammatory potential, when compared to other mediums such as phosphate 
buffer solution (PBS) or PBS containing mouse serum albumin. A study by 
Skebo et al. (2007) has shown that by adding 0.1 % sodium dodecyl sulphate 
(SDS) to silver nanoparticles, agglomeration can be reduced, with increased 
uptake of particles in cells. The addition of SDS also required washing of 
particles twice in ultrapure water in order to prevent SDS induced toxicity on 
the cell viability prior to introduction into cell cultures.  
22 
 
Surface coating, however does come with its own problems. Modifying 
nanoparticle surfaces may increase or decrease their effect in biological 
systems and the durability and stability of coating is another issue to address 
(Dhawan et al., 2009b). 
1.6.3.4 Dose response and Exposure assessment 
 
Dose-response relationships are an imperative aspect of all toxicological 
experiments. Dose-response testing, allows for the correct dosage to be 
established and used in toxicological studies. The dose metric is the critical 
factor that determines this dose-response relationship. This is usually based 
on exposure concentration of the chemical being investigated, whilst in 
nanoparticles finding the right dose-metric has been an issue of debate. This 
is because the relationships of nanoparticles and their physiochemical 
properties are not understood. Some studies, however, have considered the 
surface area to be the best parameter for assessing cellular response to 
exposure to nanoparticles, due to the reduction in size of particles resulting in 
an increased surface area, leading to increased reactivity. Thus the surface 
area is used as the dose metric choice for studies (Nel et al., 2006). 
The safety and toxicity assessment of a nanoparticle is another challenging 
factor. The biological effects of a nanoparticle are more complex as this can 
differ based on the chemical composition, size, shape and structure of surface.  
It is also difficult to track nanoparticles within the body in in vivo experiments, 
although radiolabelling and fluorescent labelling can aid this to some degree 
(Dhawan and Sharma, 2010; Dhawan et al., 2009b). 
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All these factors amongst others are important to consider when working with 
nanoparticles. The nascent nature of nanoparticles, particularly rising over the 
last decade, has given rise to many uses of nano particles in everyday life. For 
toxicology, it has opened up a whole new means through which to test 
genotoxicity of compounds as part of finding new ways to help diagnose 
patients with disease and cancer. The potential of nanoparticle use has been 
demonstrated in this project. The studies where nanoparticle are concerned, 
have been conducted taking some of the above factors into account, such as 
sonication of nanoparticles before use and regular checking for zeta potential 
and size of nano particles.  
1.7 Non-steroidal anti-inflammatory drugs (NSAIDs) 
 
1.7.1 History of NSAIDs 
Non-steroidal anti-inflammatory drugs, abbreviated as NSAIDs, are important 
drugs which were first introduced, starting with salicylic acid around 1860 as 
an anti-septic drug and as aspirin towards the end of the 19th century. NSAIDs 
have now become the most widely used and prescribed drugs, despite 
problems of patient tolerability and gastrointestinal toxicity (Donnelly and 
Hawkey, 1997). Aspirin and sodium salicylate were recognised in the early 
1900s, as drugs that were anti-inflammatory, antipyretic and analgesic. 
Following their discovery, several drugs with similar functions such as 
acetaminophen (paracetamol) was discovered. These were later followed by 
recent discoveries like fenamates, ibuprofen and naproxen. These drugs have 
different structures, however share the same therapeutic properties. These 
drugs were also different from the glucocorticosterioids group of inflammation 
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treating drugs and they eventually became known as NSAIDs (Vane Dsc and 
Botting PhD, 1998). Today, most common drugs sold or prescribed are: 
diclofenac, ibuprofen, naproxen, celecoxib, mefenamic acid, etoricoxib, 
indomethacin and aspirin (Day and Graham, 2013; Peterson et al., 2010).  
1.7.2 Impact of NSAIDs on health 
 
NSAIDs help to reduce pain, reduce inflammation (swelling and redness), 
reduce body temperature and have antithrombotic effects. The drugs are 
commonly used to treat acute short term conditions of, headaches, back pain, 
toothaches, infections, common colds (in particular – symptoms of colds) and 
help treat soft tissue injuries such as sprains and strains. Chronic long term 
conditions like arthritis back and neck pain and minor ailments, can also be 
treated with these drugs (Peterson et al., 2010). However alongside the 
benefits, are the disadvantages of NSAIDs. NSAIDs can have adverse effects, 
including gastrointestinal bleeding (Traversa et al., 1995), hypertension, 
oedema (Johnson et al., 1994) and renal disease and more recently, including 
association to myocardial infarctions (Peterson et al., 2010). 
1.7.3 Role of NSAIDs in Prostaglandin synthesis 
 
These drugs act by inhibiting the enzymes cyclo-oxygenase-1 and cyclo-
oxygenase-2 (COX-1 and COX-2) found in the joints and muscles of the body, 
which contribute to pain and inflammation of the body. COX-1 is constitutively 
expressed at high levels in cells and tissues such as platelets, monocytes, the 
endothelium, renal collecting tubules and seminal vesicles (Smith and Dewitt, 
1996). In contrast, COX-2 is induced by inflammatory stimuli and cytokines 
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liposaccharides, interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α) 
in migratory cells, like the endothelium, monocytes, macrophages and 
osteoclasts. Both, COX-1 & COX-2, are involved in prostaglandin synthesis 
(Day and Graham, 2013; Rao and Knaus, 2008).  
There are two kinds of NSAIDs – non-selective NSAIDs, act by blocking both 
COX-1 & COX-2, causing a reduction in the production of prostaglandins. 
Another class of NSAIDs are known as the ‘selective COX-2 inhibitors’, which 
block the COX-2 enzymes only. The COX-2 inhibitors are known to be safer 
and effective than their non-selective equivalents (Donnelly and Hawkey, 
1997). Blocking of COX-1 enzyme can cause bleeding, as COX-1 has a 
protective role at the lining of the stomach, which protects it from acids. Hence, 
NSAIDs, with selective COX-2 inhibition have the benefit of reducing pain and 
inflammation, but leave the stomach lining unaffected, by not blocking the 
COX-1 enzyme (Peterson et al., 2010).  
Various NSAID drugs differ in their selectivity for COX-2, in terms of how much 
they affect the COX-2 enzyme, relative to the COX-1 enzyme (Peterson et al., 
2010). NSAIDs such as aspirin, indomethacin and ibuprofen are non-selective 
inhibitors of COX enzymes, whereas celecoxib and rofecoxib are inhibitors 
which have a greater selection for COX-2 inhibition (Rao and Knaus, 2008). 
COX-1 and COX-2 play a role in prostaglandin synthesis. Arachidonic acid 
(AA) is a precursor of prostaglandin synthesis. AA is an unsaturated 20-carbon 
fatty acid embedded in the cell membranes as a phospholipid ester, as shown 
in Figure 6. AA is released in response to stimuli, which is subsequently 
converted via the enzymes, lipoxygenase (LOX), COX and cytochrome P450 
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into lipid mediators called eicosanoids. The production of eicosanoids is 
dependent on the amount of freely available AA (Rao and Knaus, 2008; Smith 
et al., 2000).  
 
Figure 6: Role of cyclooxygenase enzymes in prostaglandin synthesis. Diagram 
above shows the pathway of prostaglandin biosynthesis from arachidonic acid and 
the role of COX-1 & COX-2 and prostaglandin synthase enzyme in the production of 
the final primary prostaglandins (Rao and Knaus, 2008).  
 
The COX-1 and COX-2 enzymes catalyse two reactions as shown in Figure 6, 
above. In the first reaction, COX-1 & COX-2 convert AA to prostaglandin G2 
(known as PGG2), a subsequent peroxidase reaction results in the reduction 
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of PGG2s to prostaglandin H2 (known as PGH2). Enzymes like synthases and 
isomerases then convert PGH2s into five primary and biologically active 
prostaglandins. These are prostaglandin D2 (known as PGD2), prostaglandin 
E2 (known as PGE2), prostaglandin F2α (known as PGF2α), prostacyclin 
(PGI2) and thromboxane A2 (known as TxA2) (Figure 6) (FitzGerald and 
Patrono, 2001; Rao and Knaus, 2008; Smith et al., 2000). The prostaglandins 
play a role in promoting tumour growth via increased cell proliferation and 
causing stimulation of angiogenesis (Skriver et al., 2005). 
 
1.7.4 NSAIDs in Cancer and Respiratory disease. 
 
The implications of NSAIDs in cancer have been well documented by various 
studies. In general, several studies have shown that NSAIDs exhibit anti-
cancer activities on several hallmarks of cancer, such as, cell proliferation, 
evasion of apoptosis and cell cycle regulation (Burn et al., 2011; Park et al., 
2014). The majority of studies on NSAIDs have been conducted on 
gastrointestinal cancer, such as colorectal, gastric and in the oesophagus, etc. 
NSAIDs have been investigated in much detail, such as a study, that has 
examined the potential role aspirin may play in improving survival and reducing 
recurrence in patients with a potentially curative colorectal cancer, with a 
particular focus on their effects at the local and systemic inflammatory 
responses (Mansouri et al., 2013). 
Furthermore, some studies have shown, greater evidence of aspirin and other 
NSAIDs like sulindac and indomethacin all exhibiting a chemo preventative 
effect on colorectal cancer (Coghill et al., 2011; Cuzick et al., 2009; Waddell 
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and Loughry, 1983). Similar protective anti-cancer effects of NSAIDs have 
been found in prostate cancer (Kawahara et al., 2010), oesophageal cancer 
(Kang et al., 2013), and breast cancer (Brasky et al., 2011; Retsky et al., 2012). 
However, the association between renal cell carcinoma and NSAIDs was 
found to be inconsistent (Liu et al., 2013).  
Since the discovery of COX-2 enzyme, many studies have shown that this 
isoform is highly expressed in cancers of the breast, pancreas and the 
prostate. Such expression has been associated with controlling many cellular 
processes in these cancers. As such, NSAIDs with inhibition for COX-2 have 
been well investigated in studies aimed at treatment and prevention of cancers 
(Kanaoka et al., 2007; Penning et al., 1997; Thill et al., 2014). For example, 
celecoxib – a selective COX-2 inhibitor induces apoptosis in human prostate 
cancer cell lines that are expressing COX-2, blocking the activation of anti-
apoptotic kinase (Hsu et al., 2000; Liao et al., 2007).  
This project focuses on respiratory diseases (asthma and COPD) and lung 
cancer and several studies have shown the implications of NSAIDs in patients 
from these groups. Harris et al. (2002), ran a case control study of NSAIDs 
among 489 lung cancer patients and 978 control subjects. Cases in the study 
were matched for age, gender, pack-years of cigarette smoking. In order to 
assess the effects of NSAIDs on tobacco carcinogenesis, only heavy smokers 
were included in the control group. Findings from the study indicated that daily 
intake of NSAIDs for at least 2 years prior to interview was associated with a 
68% reduction in the relative risk of lung cancer, with a significance of p = < 
0.01. Considering these results with molecular evidence suggested that 
regular NSAID intake may prevent carcinogenesis through COX-2 enzyme 
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blockade (Harris et al., 2002). The vast catalogue of studies appear to show 
protection of NSAIDs usage in colorectal and stomach cancers, however in 
people with respiratory diseases of asthma and COPD, the protective role of 
NSAIDs is unclear, with conflicting data, although many population studies 
indicate a relatively low risk of NSAIDs intake and incidence of these health 
conditions. The increasing developments of the nano industry, and therefore 
nano toxicology, has allowed for the testing of nanoparticles. Two of these 
nanoparticles are aspirin and Ibuprofen, which are discussed below as a 
summary and their capabilities as nanoparticles. 
 
1.7.4 Aspirin  
 
As mentioned above, aspirin, also known as acetylsalicylic acid, is non-
steroidal anti-inflammatory drug (NSAID) that is used to relieve fevers, 
headaches, pain, and inhibits synthesis of prostaglandins, via the COX 
enzyme pathways. Various studies have reported reduction of cancer 
(including growth and metastasis) and mortality in association with aspirin 
intake, adding to the case for aspirin in prevention of cancer (Rothwell et al., 
2012a; Rothwell et al., 2012b). Side effects of aspirin include, bleeding of the 
stomach lining, ringing in the ears of patients. In children and adolescents, 
aspirin is not recommended due to its association with Reye’s syndrome – a 
condition that affects all organs of the body, however mostly the brain and the 
liver with raised intracranial pressure or liver failure (Macdonald, 2002). Aspirin 
is listed as one of the most essential medicines needed in a basic healthcare 
system, according to a report by WHO (World Health Organization., 2014). 
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1.7.5 Ibuprofen 
 
Ibuprofen is the other NSAID that is the focus of this study. Like aspirin, 
ibuprofen is used to reduce fevers and pain and reduce inflammation, via its 
function as a cyclooxygenase inhibitor. Reduced cytokine production, 
modulation of leucocyte activity, inhibition of free radicals and signalling 
transduction as some of the anti-inflammatory properties of ibuprofen 
(Rainsford, 2003). Ibuprofen is a derivative of 2-(4-isobutylphenyl) propionic 
acid, which was first discovered over 50 years ago, as part of research into 
finding treatment for rheumatoid arthritis (Halford et al., 2012). Initially sold as 
a prescription medicine, further studies and better understanding of drug lead 
to it becoming the first licensed NSAID drug sold over the counter in the UK 
(Halford et al., 2012; Rainsford, 2003). Lung cancer is the leading cause of 
cancer in both males and females, accounting for 30% of all cancer-related 
deaths in the US (Jemal et al., 2010) and is much the same for Europe 
(Tyczynski et al., 2003). Epidemiological studies have shown that daily 
administration of ibuprofen reduces the risk of cancer (Harris et al., 2007) and 
in comparison to other NSAIDs, the side effects (like gastrointestinal, stomach 
ulcers, myocardial infarction) are significantly less (Cheng et al., 2014). 
Ibuprofen has also been found to have chemo protective effects of cancer and 
also helps in treating Alzheimer’s disease. (Rainsford, 2003).  
1.7.5 Aspirin and Ibuprofen nanoparticles and nano-carriers 
 
The advantages of nanoparticles have been discussed above in a general 
context. Both aspirin and ibuprofen nanoparticles are of great interest to 
scientists, since the advantages of nanoparticles combined with the benefits 
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of NSAIDs have opened the door to whole new phenomena of research. 
Nanoparticles possess the unique capability to accumulate at the site of 
inflammation, and thus are suitable for targeted drug delivery (Elzoghby et al., 
2012). Aspirin and ibuprofen, like many other nanoparticles, are delivered to 
their targeted site in the body via several nano-carriers. Polymeric 
nanoparticles, magnetic nanoparticles, ceramic nanoparticles, polymer drug 
conjugates, nanotubes and nanowires, to name some of these are being 
analysed for their capability to act as suitable drug carriers for nanoparticles 
(Elzoghby et al., 2012). Even protein such as albumin, collagen and whey 
protein have been studied for drugs and nutrient deliveries (Bryant and 
McClements, 1998; Elzoghby et al., 2011; Lu and Chen, 2004). Advantages 
of such systems are that they protect drugs from degradation and enhance 
drug absorption by facilitating diffusion through cell epithelium. They also allow 
modifications of pharmacokinetic properties and drug tissue profiles, and 
penetration of and better distribution of drugs. These systems can also 
withstand physiological stress or improved biological stability and alter the 
release pattern of the drug (Elzoghby et al., 2011). With these benefits in mind, 
this project examines how effective nanoparticles are compared to their bulk 
equivalents when introduced into cells. To develop nanoparticle solutions, 
suspension solutions of aspirin and ibuprofen are prepared with solid loads of 
4% and 3% (w/w), respectively in deionised water as done in a method 
described by (Plakkot et al., 2011). The suspension solution of deionised water 
also contains hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone K-
30 and sodium lauryl sulphate (Plakkot et al., 2011). This is followed by 
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process in which milling of these compounds are carried out using Lena 
Nanoceutics Technology DM-100 machine (Sulaiman 2007).  
 
1.8 Genotoxicity Assays 
 
1.8.1 Comet assay 
1.8.1.1 Development and principles of Comet assay 
 
The Comet assay, also known as the single-cell gel electrophoresis (SCGE), 
was first developed by Östling and Johanson in 1984 as a micro-
electrophoretic technique for direct visualisation of DNA damage in 
mammalian cells (Ostling and Johanson, 1984). This was later modified by 
Singh et al. (1988) as the alkaline version. The Comet assay has been 
recognised for its time efficiency, simplicity, sensitivity, and cost effectiveness 
for analysing genotoxic DNA damage in sperm and lymphocytes as shown in 
previous studies (Anderson et al., 1997a; Anderson et al., 1998a; Anderson et 
al., 1997b; Anderson et al., 1997c; Anderson et al., 2003; Singh et al., 1988; 
Tice et al., 2000). It is considered to be an indicator for assessing and 
detecting genotoxic damage (Eastmond et al., 2009; Gopalan et al., 2011). In 
the Comet assay, DNA damage is measured following conversion of the DNA 
into double and single DNA strands. The process involves several stages. 
Firstly, cells are embedded in agar layers and “sandwiched” on slides coated 
between thin layers of agarose gel. Cells are then lysed with a detergent and 
salt which acts to remove all cellular protein content except the DNA. 
Nucleoids are formed containing supercoiled loops of DNA. Then, either under 
alkaline or neutral pH conditions, the DNA is allowed to unwind before being 
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electrophoresed. The electrophoresis creates an electric field in which the 
DNA fragments and loose DNA ends migrate away from the nucleus moving 
from cathode to anode. Under alkaline conditions only, the DNA double helix 
is denatured and the nucleoid becomes single stranded. Cells are then 
neutralised down to pH 7 with buffer. A DNA-intercalating fluorochrome, such 
as ethidium bromide (EtBr) is then applied to stain the DNA. The amount of 
fluorescence is then quantified within the head and the tail regions and 
assessed together with the length of the tail. EtBr based staining thus allows 
for the analysis of an image that resembles a Comet with a distinct head and 
tail. The head contains undamaged/intact DNA, whilst the tail consists of 
fragmented and/or damaged DNA segments (Collins, 2004). Thus, the 
quantity of DNA found in the tail region would indicate the amount of damage 
DNA in proportion to the undamaged DNA in the head region (Figure 7). When 
considering the length of the comet, then the parameter Olive tail moment 
(OTM) is used.
 
 
 
 
 
 
 
Figure 7: An image of a 
comet, showing parts of 
Head (undamaged DNA) 
and tail (damaged DNA). 
Image is adapted from 
Comet assay India 
(Organisation). 
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1.8.1.2 Genotoxic studies involving Comet assay. 
 
The Comet assay has been used in many genotoxic studies, both in vitro and 
in vivo studies and in human monitoring to investigate genetic damage with 
the objective of measuring human exposure to genotoxic agents due to 
occupational exposure, drug treatments and environmental pollution (Faust et 
al., 2004). It has also been deployed to assess DNA repair ability, radiation 
biology, environmental bio-monitoring, genetic toxicology and human 
epidemiology (Faust et al., 2004; Wagner et al., 2003). 
The Comet assay works well with most cell types, including lymphocytes, 
whole blood cells and sperm. The assay is ideal with these cells because of 
several advantages including; no requirement for large numbers of cells, much 
data can be generated in short amounts of time, these cells can easily be 
collected in relatively non-invasive procedures (Faust et al., 2004). 
Lymphocytes, whole blood cells and sperm were used because DNA damage 
in somatic cells can potentially result in the development of cancer and 
damage to sperm cells can give rise to not only cancer, but can also result in 
heritable defects (Gopalan et al., 2011). 
1.8.2 Comet repair assay 
 
1.8.2.1 Repair of DNA. 
 
The Comet or SGCE assay is a simple method for measuring DNA strand 
breaks in cells. The assay has been a useful method to access chemicals for 
their genotoxicity, usage in human biomonitoring, epidemiology, and 
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importantly, also in DNA damage and repair (Collins, 2004). Monitoring the 
repair of DNA is one of important determinants of cancer susceptibility (Gaivao 
et al., 2009). All cells possess mechanisms of repairing or correcting DNA 
damage before there are permanent changes made to DNA. The method of 
DNA cellular repair is also sometimes known as the challenge assay (Au et 
al., 2010; Azqueta et al., 2014). 
There are various pathways which deal with DNA repair, the repair of single-
strand breaks (SSBs) is rapidly achieved in most cells, consisting of a little 
more than ligation. One of these repair mechanisms is base excision repair 
(BER), which works to repair small altered bases, whilst the other process is 
the Nucleotide excision repair (NER), which recognises and repairs bulky 
adducts or helix distortions (Azqueta and Collins, 2013; Azqueta et al., 2014). 
However the repair of double strand brakes (DSBs) is more complex, since 
the double helix of DNA is continuously disrupted. Homologous recombination 
restores the correct DNA sequence, using DNA from the homologous 
chromosome or sister chromatid as a template. On the other hand, non-
homologous end-re-joining is less precise and can therefore result in loss of 
sequence. 
1.8.2.2 Principle of the Comet repair assay 
 
There are two ways of measuring the repair of cellular DNA damage. Firstly, 
the repair of DNA from cells is monitored by exposing cells to a DNA damage 
inducing agent and then the damage is measured after a short interval(s) of 
time (Collins, 2004). Usually cells undergoing treatment are exposed to 
chemicals such as hydrogen peroxide or ionising radiation, and the repair rate 
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is measured at certain time intervals, usually short period of time following 
treatment. This is the most common way of measuring lesions such SSBs in 
all cells. In addition to SSBs, other lesions  like UV-induced pyrimidine dimers 
(using NER) and oxidised bases (using the BER) can be monitored by using 
specific enzymes that recognise the lesions and convert these into strand 
breaks (Azqueta and Collins, 2013; Azqueta et al., 2014). The enzyme 
formamidopyrimidine DNA glycosylase (FPG) is used to convert 8-oxoguanine 
and other oxidised purines into SSB, Alk A convert the alkylated bases and 
the T4 endonuclease V is used to convert cyclobutane pyrimidine dimers 
(induced by UV) (Collins, 2004). Thus, overall this assay allows us to monitor, 
SSB – re-joining (repair after exposure), BER (by monitoring removal of 
oxidised and alkylated bases) and NER (by monitoring removal of UV-induced 
cyclobutane dimers (Collins, 2014; Collins and Horvathova, 2001).  
The Comet repair assay in this thesis monitors the repair rate of the re-joining 
of SSBs. DNA is organised as a series of (supercoiled) loops attached to the 
nuclear framework. Damage to the DNA, in the form of strand breaks, causes 
the relaxation of the supercoil. The alkaline nature of the Comet assay used, 
means that DNA can be damaged at higher pH, and in particular, the APsites 
are also converted to breaks. The greater the presence of breaks, the greater 
the relaxation of loops and therefore the fluorescence is even greater of the 
tail in the Comet, relative to the head region (nucleoid core). On the basis of 
observing this tail DNA damage, it would be possible to determine the amount 
of damage caused and subsequent repair of DNA following bleomycin 
exposure and additionally, also including exposure to NSAIDs, both in the bulk 
and the nano form (Azqueta and Collins, 2013). 
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1.8.3 Micronucleus assay 
 
1.8.3.1 Principle of the Micronucleus assay 
 
The study of DNA damage at the chromosome level is an essential part of 
genetic toxicology because chromosomal mutation is an important event in 
carcinogenesis. The micronucleus assay has emerged as one of the preferred 
methods for assessing chromosome damage because it enables both 
chromosome loss and chromosome breakage to be measured reliably. 
The understanding of DNA damage at the chromosome level is a key element 
of genetic toxicology. The mutations of chromosomes in carcinogenesis are 
an important event and the micronucleus assay is one particular technique 
that allows for the analysis of chromosomal damage (Fenech, 2000). The 
assay has been defined as a simple test designed to detect genotoxic damage 
by chemical exposure in cells at the interphase stage of the cell cycle. Certain 
chemicals can be mutagenic and may lead to the induction of micronuclei in 
cells at the interphase stage. This occurs as a consequence of interference 
with chromosome structure and/or segregation (Fenech, 2007). 
1.8.3.2 How MN are formed in the assay 
 
Micronuclei in erythrocytes have been identified for over 100 years as the 
Howell-Jolly bodies seen in haematology. The first induced micronuclei were 
first seen in Vicia faba root tips exposed to X-rays (Evans et al., 1959), whilst 
in 1975, the bone marrow micronucleus assay was used to examine 
micronuclei in immature young polychromatic erythrocytes and were found to 
be sensitive, simple and reliable (Schmid, 1975). Micronuclei found in 
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erythrocytes were achieved using an in vivo assay, whereas in the present 
studies, micronuclei have been observed using an in vitro/ex vivo approach. 
The micronucleus test is essentially a mutagenic test system able to detect 
cytotoxicity of certain chemicals.  The cytotoxicity is manifested through 
generation of DNA fragments seen within the cytoplasm in the interphase cells 
which are separate from the main nucleus (Fenech, 2002, 2007). These 
fragments originate from whole chromosomes/centric and acentric fragments, 
lacking centromere regions. Consequently, during the anaphase stage of the 
cell cycle division, they are unable to migrate in synchronisation with the rest 
of the chromosomes, thereby giving rise to micronuclei. Thus, micronuclei 
represent damage that has been transmitted to daughter cells. Chemical 
exposure to cells that results in micronuclei formation would hence 
demonstrate that they are genotoxic and affect the chromosome structure or 
alter segregation patterns. The number of micronuclei would represent the 
toxic potential of a chemical (Fenech, 2002; Kirsch-Volders et al., 1997; 
Kirsch-Volders et al., 2000). 
1.8.3.3 Cell culture of Micronucleus assay 
 
The general process of micronuclei involves 72 hour cell cycle division which 
includes stimulation by addition of the plant lectin and mitogen - 
phythaemagglutinin at 0 h., Cytochalasin B at 44 h., cell fixation at 72 h. and 
staining with dye, fixation of slides, followed by scoring under a microscope.  
Cell culture is imperative when working with the Micronucleus assay, in order 
to obtain micronuclei at the interphase. The cells must undergo a nuclear 
division to show chromosome damage following exposure to a genotoxic 
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agent in vitro. Cell cultures are started off with the addition of lymphocytes (or 
other cells) to flasks containing medium and phythaemagglutinin (PHA). PHA 
stimulates cells, by selectively stimulating T lymphocytes to enter mitosis of 
cell division (Baumgartner et al., 2004; Fenech, 2000). Cytochalasin B, a 
microfilament-assemble inhibitor is added to cells in vitro at 44 h.  to block 
cytokinesis, thus leading to formation of bi-nucleated cells. At 72h., cells 
undergo hypotonic shock followed by cell fixation. Cell fixation is performed as 
a methodology to preserve the cytoplasm, cytoplasmic boundaries and 
minimise clumping of cells (Kirsch-Volders et al., 2000). Cells are dropped 
onto slides according to methods used by Fenech (2002) Fenech (2007) and 
stained in Giemsa stain and scored under a microscope.  
The addition of Cytochalasin B, as described above is imperative to halt cells 
division in the Micronucleus assay. This special method in known as the 
cytokinesis block micronucleus (CBMN) assay. The bi-nucleate presence of 
cells, confirms the cell has either divided in or following the presence of a test 
agent, and therefore it is possible to score the expressed micronuclei for these 
cells (Doherty, 2012; Fenech, 2002). 
1.8.3.4 Advantages of CBMN Assay 
 
The CBMN assay can be applied to various cell population types including 
primary or transformed cell lines such as mouse lymphoma cell line and 
primary human lymphocytes. Using general morphological criteria, the CBMN 
assay makes it possible to measure genotoxicity and cytotoxicity by observing: 
chromosome breakage, chromosome loss, chromosome rearrangement 
(including nucleoplasmic bridges), cell division, inhibition, apoptosis and 
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necrosis (Figure 8) (Fenech, 2000, 2002, 2006; Kirsch-Volders et al., 1997). 
The assay provides an alternative option to the chromosome aberration testing 
and the data obtained is not confounded by altered cell division kinetics 
caused by sub optimal cell culture conditions or cytotoxicity by agents tested. 
Interphase cells can be accessed relatively objectively, which means the cells 
are much faster to score, thus making it practical in scoring hundreds of cells 
per each treatment group, resulting in data with strong statistical power. 
Furthermore, automated processes can be used to reduce scoring time even 
further (Doherty, 2012; Fenech, 2002).  
 
 
 
 
Figure 8: Possible fates of cells after division: Figure shows the various possible 
fates of cultured cytokinesis-blocked cells following exposure to cytotoxic/genotoxic 
agents (Fenech, 2007). 
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The CBMN assay is therefore ideal for working with lymphocytes and 
micronuclei formation can be used as substitution to analyse and assess toxic 
damage posed by all three HAAs (IAA, BAA, and CAA).  
 
1.8.3.5 Types of Micronuclei (MNi) in CBMN assay 
 
There are various forms of MNi that can form. Firstly the cell type is 
determined. The cells can either be mono nucleated (contain one nucleus), bi 
nucleated (two nuclei) or multi nucleated (more than two nuclei). In addition, 
these cell types may contain one or several MNi (See Figures 9 and 10). In 
addition CBMN assay can be used to measure nuclear buds (NBUDs), 
nucleoplasmic bridges (NPBs) (Figure 10 for NBUD and Figure 9 and 10 for 
NPBs), and cell death (necrosis or apoptosis) as well as nuclear division rate 
(Fenech, 2002, 2006). NBUDs presence shows amplified DNA/ DNA repair 
complexes are absent whilst NBPs demonstrate DNA mis-repair and/or 
telomere end fusions (Thomas and Fenech, 2011).  
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Figure 9: MNi formation: Figure 9a shows an example of the development of 
micronuclei from lagging whole chromosomes and acentric chromosome fragments 
at the anaphase stage. Figure 9b: A dicentric chromosome, centromeres are pulled 
to opposite ends eventually form into a nucleoplasmic bridge. The acentric parts in 
both figures 5a and 5b eventually become micronuclei (MNi). At 44 h. the addition of 
Cytochalasin B is used to prevent further cell divisions at the binucleate stage 
(Fenech, 2002).  
 
 
 
Figure 10: Types of MNI: Figure shows various types of MNi. The criteria for 
successfully scoring MNi is that it must be no more than a 1/3rd  in diameter 
compared to the bi-nucleate but can be as small as 1/9th (a). MNi may also overlap 
but not touch the bigger nuclei (b), while MNi can also be found around bi-nucleated 
containing NPB (c). In other cases (d) there can be several MNi of different sizes, 
thought these are only typically found in cells that have been exposed to chemicals 
(Fenech, 2007). 
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1.9 Aims of study (HAAs) 
 
Disinfection of drinking water gives rise to disinfection by products (DBPs). 
Various publications and literature have shown that DBPs have health 
implications and provide a cause for concern. DBPs have been associated 
with the development of certain cancers (kidney, brain bladder) (Villanueva et 
al., 2004; Villanueva et al., 2007). It has previously been demonstrated that 
the HAAs, - iodoacetic acid (IAA), bromoacetic acid (BAA) and chloroacetic 
acid (CAA) are cytotoxic and genotoxic DBPs when analysed in the Ames test, 
and in the mammalian CHO cell system (Plewa et al., 2002). Cemeli et al. 
(2006) have also shown the involvement of oxygen radicals with IAA in these 
cells.  In addition, HAAs have also been found to be cytotoxic in human 
lymphocytes but not genotoxic in the Micronucleus assay in TK6 cells (Liviac 
et al., 2010). What has not been shown is the effect of the 3 HAAs in human 
somatic and germ cells and whether oxidative stress is involved in their 
mechanism of genotoxic action.  
Contributing to a vast catalogue of information and genotoxicity posed by 
DBPs, the aim of this project was to investigate and examine both somatic and 
germ cells as peripheral blood lymphocytes and sperm. The effects of three 
HAA compounds, IAA, BAA and CAA have been investigated. After 
determining appropriate dose responses in lymphocytes and sperm, oxidative 
radical involvement has been investigated, with the anti-oxidant butylated 
hydroxanisole (BHA) and the enzyme catalase in the single cell gel-
electrophoresis assay (Comet assay) under alkaline conditions, > pH 13. 
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The Comet assay was used in this study for its simplicity and being a sensitive 
assay for analysing genotoxic DNA damage in sperm and lymphocytes as 
shown in previous studies (Anderson et al., 1997a; Anderson et al., 1998a; 
Anderson et al., 1997b; Anderson et al., 2003; Singh et al., 1988; Tice et al., 
2000). The Comet assay is considered to be an indicator for assessing and 
detecting genotoxic damage (Eastmond et al., 2009; Gopalan et al., 2011). 
These primary cells were used because the detection of DNA damage in 
somatic cells can potentially result in the development of cancer and damage 
to sperm cells can give rise to cancer, and could also cause heritable defects 
(Gopalan et al., 2011). 
 With lymphocytes, a similar approach using the CBMN assay was deployed 
as a means of analysing cytotoxicity and genotoxicity of these cells. 
Micronuclei formation will be observed and the aim will be to determine 
whether micronuclei are reduced following antioxidant induction to HAAs. This 
study may show findings that may contribute to existing literature arguing for 
the need to regulate HAAs, which are regulated in the United States but not 
the United Kingdom. With these notions in mind, important information can be 
obtained on these cells that is directly relevant to human beings, as damage 
detected in-vitro can predict damages in-vivo and help address issues facing 
health of human beings. 
 
 
 
45 
 
1.10 Aims of study (nano and bulk aspirin and ibuprofen) 
 
A limited number of studies have shown direct effects and associations of non-
steroidal anti-inflammatory drugs (NSAID) on tumour biology, with an increase 
of anti-tumour effects on several hallmarks of cancer, such cell proliferative 
capacity, evasion of apoptosis and cell cycle regulation and invasive capability 
of cancerous cells (Park et al., 2014). Clinical evidence has also shown that 
NSAIDs result in down-regulating systemic inflammatory responses, whilst 
favourably influencing the local inflammatory response within tumour 
microenvironment regions (Hussain et al., 2012). Generally, the majority of 
epidemiological studies have found that individuals who take NSAIDs have a 
reduced risk of colorectal adenomas and carcinomas. Such effects have been 
observed for aspirin (Burn et al., 2011; Cook et al., 2013).  
Since most studies on NSAIDs have focussed on gastrointestinal cancers 
(such as colorectal, gastric and cancers of the oesophagus), this current 
investigation is concerned with the effect of two NSAIDs in blood samples from 
patients with respiratory diseases in two different studies.  
In the first study, DNA damage in peripheral whole blood lymphocytes of 
healthy individuals and respiratory disease patients (asthma, chronic 
obstructive pulmonary disease (COPD) and lung cancer) have been compared 
following treatment with the bulk and nanoparticle versions of aspirin and 
ibuprofen in the micronucleus assay (Fenech, 2000, 2007). Further to this, the 
standard bulk versions of aspirin and ibuprofen were compared directly with 
their equivalent nano forms. The aim was to observe for MNi found in 
binucleated cells from controls and disease patients and therefore analyse this 
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information in order to determine whether the NSAIDs - aspirin and ibuprofen, 
show an increase or decrease in DNA damage. The objective of using the 
nano versions of these NSAIDs were to determine whether nano particles can 
cause a reduction or increase in DNA when compared to their respective bulk 
versions.   
The second study similarly involves investigations of aspirin and ibuprofen and 
their effect on the repair of DNA using the Comet assay. Fellow member of the 
faculty (Dr. Mojgan Najafzadeh, University of Bradford - Paper currently in 
publication process) has investigated the DNA damage in peripheral 
lymphocytes of healthy individuals and respiratory disease patients (asthma, 
COPD and lung cancer), which have  been compared  before and after  
treatment with the bulk and nanoparticle versions of aspirin and ibuprofen 
using the SCGE or Comet assay (Tice et al., 2000).  
The Comet repair assay also allows for DNA damage to be monitored by 
incubating cells after treatment with a damaging agent and measuring the 
damage remaining at different time intervals (Collins, 2004). For this part of 
the study, peripheral whole blood from healthy individuals and disease 
patients were obtained and treated with DNA damage inducing agent 
bleomycin and then repaired for a brief period of time with aspirin and 
ibuprofen, both bulk and nano forms, to determine whether these compounds 
can increase or reduce damage in cells and influence DNA repair of cells.  
These three studies above are the first of their kind, to our knowledge in which 
the nano form of aspirin and ibuprofen NSAIDs, have been investigated at the 
cellular level ex vivo/ in vitro.  The use of lymphocytes is supported by the 
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observations of the WHO/IPCS who reported that lymphocytes are suitable 
surrogate cells for the detection of cancer. Lymphocytes can be used as 
surrogates for somatic cells in in vitro genotoxicology tests. When challenged 
with UV as an external stressor they can also act as biomarkers to diagnose 
cancer of certain states (Najafzadeh et al., 2012). 
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2. Materials & Methods 
2.1 Ethical approval 
 
Ethical approval was obtained for performing both the Comet assay, Comet 
repair and the micronucleus assay for the studies on HAAs and NSAIDs, 
including sample collection of all cells. All work was undertaken after approval 
by the University of Bradford Subcommittee for Ethics in Research involving 
Human Subjects (Ethics Reference number: 0405/8). The study was also 
approved by Leeds (Central) Research Ethics Committee (REC Reference 
number: 09/H1313/37) and Research support & Governance office, Bradford 
Teaching Hospitals. 
2.2 Materials and Methods for testing HAAs using the Comet 
assay 
 
2.2.1 Reagents.  
General Laboratory reagents and RPMI - 1640, FBS Medium was purchased 
from Fisher Scientific Co. (Itasca, IL) and Sigma Chemical Co. (St. Louis, MO, 
U.S.A).  The three HAA compounds, (iodoacetic, bromoacetic and 
chloroacetic acids) were kindly gifted by Professor Michael Plewa, University 
of Illinois, Urbana, Illinois 61801, United States. HAAs were dissolved in 
dimethyl sulfoxide (DMSO) and stored at -20OC. The antioxidant, butylated 
hydroxyanisole (BHA) (CAS# 25013-16-5) was dissolved in DMSO and 
catalase (EC 1.11.1.6) in double distilled water (ddH2O). Both antioxidants 
were purchased from Sigma Chemical Co. Ethidium Bromide was also 
purchased from Sigma chemical co. (Sigma, Poole, Dorset, UK: E-8751). 
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2.2.2 Lymphocyte and Sperm sample collection 
 
Ethics: See section 2.1 (above) for ethical approval for the Comet assay. 
 
2.2.2.1 Lymphocytes: Healthy volunteers donated blood. Isolation of 
lymphocytes was achieved by adding 6 ml of blood above 3 ml of 
LymphoprepTM (Axis-Shield, Oslo). Samples were centrifuged and 
lymphocytes that were concentrated at the interface were isolated. Isolated 
lymphocytes were then washed with 0.9% saline and centrifuged again. The 
supernatant was discarded and cells from each tube were suspended in foetal 
bovine serum (FBS) with 10 % DMSO (900 µl FBS, 100 µl DMSO) and 
transferred to 1.5 ml Eppendorf® tubes. The tubes were initially frozen at -
20OC before freezing at -80OC for future use. 
 
2.2.2.2 Sperm: Healthy volunteers provided semen samples through 
masturbation after abstinence for a minimum of 3 days, as recommended by 
WHO guidelines (World Health Organization., 2010a). The samples were 
brought to the laboratory within 30 minutes of ejaculation. Conventional semen 
analysis was carried out, according to WHO guidelines using a 100 µl sample. 
Using a phase-contrast microscope, the sample was analysed for motility, 
morphology, pH, concentration (in million cells per ml), and general 
appearance.  The remainder of the sperm samples were transferred into 
Eppendorf® tubes in aliquots of 25 µl prior to flash freezing in liquid nitrogen 
and then subsequent storage at -80OC for future use. 
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2.2.3 Cell Viabilities 
 
For both lymphocytes and sperm, cell viability was measured in samples up to 
a cut-off point of 75% using trypan blue exclusion, so avoiding artefacts due 
to toxicity. Generally, the viability was in excess of 90%. Viability was 
measured in lymphocytes and sperm samples on the day they were freshly 
obtained and in lymphocytes (only) also checked before and after treatment. 
For sperm, after freezing, it was not possible to analyse and check viability 
due to reduced viabilities of frozen sperm samples (Gopalan et al., 2011; 
Henderson et al., 1998). 
2.2.4 Study Cohort for both lymphocyte and sperm Comet assays. 
 
In this study, samples were used from different donors in lymphocyte cells and 
sperm. 
 
Comet assay lymphocytes: a total of 12 blood samples were used. These 
blood samples were obtained from healthy donors, and lymphocytes were 
isolated and stored at -80OC in foetal calf-serum (FCS) and dimethylsolfoxide 
(DMSO). Frozen samples were thawed and then used for experiments. Four 
samples were used in succession to perform the Comet assay with one HAA 
(e.g. IAA). The results from the four experiments were then combined and 
averaged to create a data set (Table 1a).  
 
Comet assay sperm: a spermiogram analysis was performed according to 
WHO guidelines (World Health Organization., 2010a) on samples from four 
donors (Four experiments were performed per HAA, and in each experiment, 
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one aliquoted sample from one of the donors was used, thus using all four 
different donors for each HAA experiment. Samples were aliquoted in amounts 
of 25 µl, immediately flash frozen in liquid nitrogen –at 196OC, then transferred 
to a -80OC freezer and later thawed before usage in the Comet assay. A small 
volume from each sample was retained to perform Spermiogram analysis 
immediately after samples were collected. The viability appeared not to be 
affected since we were able to score slides satisfactorily with both lymphocytes 
and sperm (Table 1b). 
 
Table 1a: Samples used from 
Healthy, non-smoking donors. 
Age Sex 
22 Female 
24 Female 
26 Male 
27 Male 
27 Female 
28 Female 
31 Female 
33 Male 
34 Male 
37 Male 
37 Male 
39 Male 
Table 1b: Sperm Samples used from 
healthy non-smoking donors. 
Age 
29 
36 
37 
40 
 
 
 
 
 
2.2.5 Single cell gel electrophoresis (SGCE) Comet assay 
2.2.5.1 Cell Treatments: 
 
2.2.5.1.1 Cell treatment of lymphocytes: Eppendorf® tubes were thawed in 
water before use. Tubes were centrifuged and the supernatant was discarded. 
400 µl of fresh RPMI medium was used to dissolve the cell pellet and create a 
single cell suspension. 100 µl of lymphocytes were then added to each 
treatment tube (100 µl lymphocytes, 890 µl RPMI medium, plus 10 µl of 
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chemical or 900 µl for the negative control). Cells were treated with IAA, BAA, 
CAA, with and without antioxidants in RPMI-1640 medium for 30 min at 37OC.  
(For details of antioxidant usage – see section 2.4.2). 
 
2.2.5.1.2 Cell treatment of sperm: Eppendorf® tubes were thawed in water 
before use. 2µl of sperm were added to treatment tubes (2µl sperm, 988 µl 
medium, 10 µl chemical or 900 µl for negative control). Cells were treated with 
IAA, BAA, and CAA with and without antioxidants for 1 hr at 32OC. 
 
2.2.5.2 Concentrations of HAA treated samples 
 
For each of the three HAAs, dose-responses were obtained and analysed to 
determine the dose that gave the maximum response without toxicity to the 
cells. Two controls with and without water and five different concentrations of 
the HAAs, IAA and BAA were used – 2 µM, 6 µM, 10 µM, 14 µM, 18 µM and 
22 µM. For CAA, millimolar (mM) concentrations were used throughout at the 
same numerical concentrations but a 1000 fold higher, to align this study with 
previous studies, where CAA was investigated at mM level and IAA & BAA at 
µM level in the ranges of concentrations used in this study (Plewa et al., 2002). 
 
The highest dose of each HAA was chosen to be the ideal choice as it was 
able to cause the highest damage without inducing cell cytotoxicity. However 
in this study a dose of 25 µM instead of 22 µM was used to compare with the 
study of Cemeli et al. (2006).  
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2.2.5.3 Antioxidant treated samples 
 
Antioxidants with and without the highest dose of the HAAs were used to 
investigate the oxygen radical mechanism. Three different concentrations of 
the antioxidant butylated hydroxyanisole (BHA) (10, 50 and 100 µM) and a 
concentration of the enzyme, catalase (500 Units/ml) were used. 
 
Treatment samples containing antioxidants in lymphocytes: 100 µl 
lymphocytes, 880 µl of RPMI medium, 10 µl of HAA, plus 10 µl of catalase or 
BHA were added. For antioxidant controls, only the antioxidants were added 
to lymphocytes and RPMI 1640 medium. For the negative controls, neither 
antioxidant nor HAAs were added. 
 
Treatment samples containing antioxidants in sperm: 2 µl sperm, 978 µl 
of RPMI medium, 10 µl of HAA, plus 10 µl of catalase or BHA were added. For 
antioxidant controls, only the antioxidants were added to lymphocytes and 
RPMI 1640 medium. For the negative controls, neither antioxidant nor HAAs 
were added. 
2.2.6 Embedding of cells in Agarose 
 
After treatment, lymphocyte samples were centrifuged and the supernatant 
was discarded, with small amounts retained with the cell pellet. Next, 100 µl of 
1% low melting agarose (LMP) (Invitrogen, Paisley, UK: 15517-022) was 
added to cell pellet to create a cell suspension. The cell suspension was 
transferred to slides pre-coated with 1% normal melting point (NMP) agarose. 
The slides were placed on an ice block for 5 min, after which 100 µl of 0.5% 
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LMP was added on top and slides were placed on ice for 5 min. In the case of 
sperm, the above process was repeated in a similar manner but with 1.5% 
NMP used for the creation of cell suspension and 1% LMP for the second 
layer. 
2.2.7 Cell Lysis 
 
Lymphocytes: Slides were placed in cold lysis solution for 1 hr. minimum. 
This was made up using 178 ml lysis stock solution plus 20 ml DMSO and 2 
ml of Triton® X-100 (Sigma, Poole, Dorset, UK). The lysis solution had final 
concentrations of 2.5 M NaCl (VWR 27800.360), 100 mM EDTA (Sigma, 
Poole, Dorset, UK: E 3154), and 10 mM Trizma base (Sigma, Poole Dorset 
UK: T-6066). The pH of the solution was adjusted to pH10, with sodium 
hydroxide (NaOH). 
Sperm: Slides were lysed in two different solutions, solutions A & B. In solution 
A, a cold lysis solution was prepared, consisting of 178 ml of lysis stock 
solution (as mentioned above), 20 ml H2O and 2 ml of Triton® X-100 (Sigma, 
Poole, Dorset, UK). This solution also contained 10 mM dithiothretiol (DTT), 
(Sigma, Poole, Dorset, UK: D-9779). Slides were lysed in this solution for 1 h. 
After 1h., slides were lysed in solution B which was prepared as solution A, 
but instead of DTT, 0.125 mg/ml proteinase K (Roche Diagnostics, Mannheim, 
Germany: 1000144) was used. Samples were lysed in this solution for 1 hr; 
the total lysis period was 2 hrs. 
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2.2.8 Electrophoresis  
 
Following lysis, electrophoresis was performed on lymphocytes and sperm 
samples based on the methods by Tice et al. (2000). Electrophoresis solution 
was prepared using 1930 ml of H2O, 60 ml of NaOH (BDH: 301675N) and 10 
ml of Na2 EDTA (pH 13.5). The end concentrations for these were 300 mM 
and 1 mM, respectively. 
 
Lymphocyte electrophoresis: Slides were placed in a tank for 30 min and 
electrophoresis was performed at 290-300 mA, at a constant voltage of 25 V 
for 30 min (0.71 V/cm). 
Sperm electrophoresis: Slides were placed in a tank for 20 min and 
electrophoresis was performed at 290-300 mA, at a constant voltage of 25 V 
for 20 min (0.71 V/cm). 
Slides were then washed three times for 5 min with cold neutralising buffer (pH 
7.5) and then stained with 20 µg/ml ethidium bromide (Sigma, Poole, Dorset, 
UK: E-8751). 
 
2.2.8.1 Calculating the Olive tail moment and % tail DNA  
 
Following electrophoresis, two of the parameters used to score for DNA 
damage are Olive tail moment and % tail DNA.  
 
Tail Length: Tail Length is used to describe the distance of DNA migration 
from the body of the nuclear core region (the head of Comet) and is used to 
evaluate the extent of DNA damage. 
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Olive tail moment: The tail moment is defined as the product of the tail length 
and the fraction of total DNA present in the tail. This also includes 
measurements of smallest detectable size of migrating fragmented DNA and 
relaxed and broken pieces of DNA. 
 
 
The Olive tail moment is calculated as follows: 
Olive tail moment = (Mean Tail – Mean Head) × % Tail DNA  
                                                            100  
 
The % Tail DNA is calculated as follows:  
Tail % DNA = 100 – Head percentage (%) DNA. 
 
2.2.9 Scoring of Slides and Statistical Analysis: 
 
All slides were coded before scoring and 50 cells were scored per observation 
using a microscope equipped with a CCD camera and Computer system 
(Andor Technology Ltd, Belfast, UK). Data were generated to measure Olive 
tail moment and % Tail DNA using Comet 6.0 software, Kinetic imaging (Andor 
Technology Ltd, Belfast, UK). Mean data were generated with standard errors. 
Distribution of the response variable departed significantly from normality 
(Kolmogorov-Smirnov goodness of fit test) and thus, non-parametric statistics 
were considered adequate for the analysis of the data. The differences 
between groups were examined using the Kruskal-Wallis test and Mann-
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Whitney U-test. Dose response relationships for IAA, BAA & CAA were 
determined by Pearson’s correlation. A p-value of < 0.05 was considered 
significant. All analyses were performed using SPSS for windows statistical 
package (version 18.0). 
 
2.3 Materials and Methods for Cytokinesis block Micronucleus 
(CBMN) Assay for testing HAA compounds (chapter 4) 
 
2.3.1 Reagents  
 
General Laboratory reagents were purchased from Fisher Scientific Co. 
(Itasca, IL). RPMI 1640 medium (with 2 mM L-glutamine and 25 mM HEPES). 
Cytochalasin B (Cat No. C6762) and mitomycin C (Cat No. M0503) were 
purchased from Sigma-Aldrich (Poole, UK). Phythaemagglutinin (PHA) (Cat 
No. 10576-015), penicillin-streptomycin solution (Cat No.15140-122) were 
purchased from Invitrogen Ltd, UK. Slides and coverslips were obtained from 
VWR international. The Fixogum rubber cement was purchased from (Marabu, 
Germany). As with the Comet assay, the three HAA compounds, (iodoacetic, 
bromoacetic and chloroacetic acids) were dissolved in dimethyl sulfoxide 
(DMSO) and stored at -20OC. The antioxidant, butylated hydroxyanisole (BHA) 
(CAS# 25013-16-5) was dissolved in DMSO and catalase (EC 1.11.1.6) in 
double distilled water (ddH2O). Both antioxidants were purchased from Sigma 
Chemical Co (Sigma, Poole, Dorset, UK).  
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2.3.2 Whole blood sample collection & Study Cohort. 
 
Ethics: See section 2.1 (above) for ethical approval for Micronucleus assay. 
Micronucleus assay: 6 fresh blood samples were used from healthy donors 
(Table 2) Samples were immediately transferred to the laboratory and used 
for cell culture after collection in heparinised tubes. Fresh samples were used 
for the MN assay, since frozen samples do not provide satisfactory results for 
cell culture use. 500 cells were scored from each donor/sample, repeated 
twice (1000 cells in total). Two samples were tested each with IAA, BAA & 
CAA and the results were combined to create a data set for each compound.  
 
Dose Responses: A range of concentrations were used starting with the 
Comet doses (diluting 1:1 each time). 6.25 µM was the optimal concentration 
for IAA and BAA and 62.5 µM for CAA. Catalase responded well; however 
BHA at 10 µM, 50 µM and 100 µM resulted in higher MNi frequencies 
compared to the negative control. Revised concentrations of 0.1 µM, 0.5 µM 
and 1.0 µM were used. 
 
Table 2: Blood samples used in the micronucleus assay  
 
Age Sex 
21  Female 
22  Female 
24 Female 
32 Male 
38  Male 
38 Male 
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2.3.3 Preparation of basic culture medium 
 
Under sterile conditions, basic culture medium was prepared. RPMI – 1640 
medium (containing 25 mM HEPES and L-Glutamine) was supplemented with 
15% foetal calf serum (FCS) and 1% penicillin-streptomycin solution. 100 ml 
of the prepared medium was used to aliquot 4.5 ml into T 25 cm2 Corning 
culture flasks and stored at -20OC. The T25 cm2 flasks were equilibrated in a 
37OC incubator (5% CO2) prior to cell culture use. 
2.3.4 Cell culture of Lymphocyte cultures. 
 
Under sterile conditions, using sterile plastics and solutions cell culture of 
lymphocytes was performed over a 72 hr period. 
Time point 0 hr. /Culture start: Blood was obtained from healthy volunteers. 
500 µl of blood was added to T25 cm2 culture flask containing 4.5 ml medium, 
followed by 100 µl of phythaemagglutinin (PHA). In some flasks HAAs and /or 
antioxidants were added and mitomycin C was added for use as a positive 
control. For treatment types see table 3 below. Cultures were incubated at 
37OC in the presence of 5% CO2 for 44 hours. 
 
 
 
 
 
 
 
61 
 
Table 3: shows the treatment groups in CBMN assay on HAAs (Chapter 4).The 
above 11 flasks represent the 11 different treatment types used when investigating 
each individual HAA at a time The concentrations for IAA & BAA were 6.25 µM and 
for CAA, 62.5 µM. The negative control contained no chemical and the positive 
control contained 0.4 µg/ml mitomycin C. Flasks 3-4 contained antioxidants only, 
while flask 7 was used for the HAA chemical only. Flasks 8-11 contained HAA and 
also antioxidants to determine the antioxidant response on the number of 
micronuclei (MNi). 
Flask 
No. Flask type 
Blood 
(µl) 
PHA 
(µl) Chemical Antioxidant 
Flask 1 Negative Control 500 µl 100 µl  NONE NONE 
Flask 2 Positive Control 500 µl 100 µl  4 mM mitomycin C NONE 
Flask 3 Antioxidant Control 500 µl 100 µl  2,500 U/ml Catalase NONE 
Flask 4 Antioxidant Control 500 µl 100 µl  BHA 0.1 µM  NONE 
Flask 5 Antioxidant Control 500 µl 100 µl  BHA 0.5 µM  NONE 
Flask 6 Antioxidant Control 500 µl 100 µl  BHA 1.0 µM  NONE 
Flask 7 Chemical only 500 µl 100 µl  HAA only NONE 
Flask 8 Chemical + Antioxidant 500 µl 100 µl  HAA  2,500 U/ml Catalase 
Flask 9 Chemical + Antioxidant 500 µl 100 µl  HAA BHA 0.1 µM  
Flask 10 Chemical + Antioxidant 500 µl 100 µl  HAA BHA 0.5 µM  
Flask 11 Chemical + Antioxidant 500 µl 100 µl  HAA BHA 1.0 µM  
 
 
Time point 44 h. /Cytokinesis block: 30 µl of Cytochalasin B with an end 
concentration of 6 µg/ml was added to each flask to halt cytokinesis and arrest 
cells in the bi-nucleate form. 
Time point 72 h. /End of cell culture: Flasks were removed from incubation 
and the contents from each flask were transferred to 15 ml falcon tubes.   
2.3.5 Cell hypotonic shock treatment: 
 
The 15 ml falcon tubes containing blood were centrifuged at 800 rpm/107 x g 
for 8 minutes. The supernatant was discarded using a vacuum pump, retaining 
above 500 µl. The pellet was re-suspended by gently patting the tube. 5 ml of 
cold (4OC) 110 mM potassium chloride (KCl) solution was added to each tube 
on a vortex (gently). Tubes were stored at 4OC for 15 minutes to allow for 
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hypotonic treatment of cells. Tubes were then centrifuged at 800 rpm/107 x g 
for 8 minutes. The supernatant was discarded using a vacuum pump, retaining 
around 500 µl. The pellet was re-suspended by gently patting the tube. 
2.3.6 Fixation of cells 
  
Cells were fixed three times using freshly prepared Carnoy’s fixative (1 part of 
acetic acid was added to 3 parts of methanol) and 38% formaldehyde. 
Fixation 1: 5 ml of fresh Carnoy’s was added to each tube gently over a vortex, 
followed by 3 drops of 38% formaldehyde. Tubes were then centrifuged at 800 
rpm/107 x g for 8 minutes. The supernatant was discarded using a vacuum 
pump, retaining above 500 µl. The pellet was re-suspended by gently patting 
the tube. 
Fixation 2 & 3: The above process for fixation 1 was repeated twice without 
the addition of 38% Formaldehyde. 
Tubes were stored overnight at 4OC. 
2.3.7 Slide Preparation, staining and fixation of slides. 
 
The following day, tubes were centrifuged at 800 rpm/107 x g for 8 minutes. 
The supernatant was discarded using a vacuum pump, retaining above 100 
µl. Then according to cell density/pellet size around 200-600 µl of fresh 
Carnoy’s solution was added. 20 µl of cell suspensions was dropped twice 
onto clean glass slides (centre left and centre right) and left to air dry. Three 
slides were used for each treatment group (6 drops total). After a short while, 
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the slides were stained for 5 minutes in Giemsa solution (5% Giemsa solution 
in phosphate buffer at pH 6.8. Slides were gently washed and left to air-dry.  
Slides were fixed by using rubber Fixogum and placing a 24 mm × 50 mm 
coverslip on top.  
2.3.8 Slide scoring 
 
500 cells were scored per sample group using bright-field light microscope at 
400 x magnification. The experiments were repeated twice for each HAA, 
resulting in a total of 1000 cells scored per each sample as recommended by 
guide lines for the assay (Fenech, 2000, 2002, 2007). MNi were scored per 
500 cells each of binucleated (BiNC) and mononucleated (MonoNC) cells per 
slide. Statistical analysis was carried out using the chi-square test (χ2) to 
determine significant differences with p value set at *** p = < 0.05 to compare 
samples. 
2.3.9 Data Analysis and statistics used 
 
The nuclear division index (NDI) can be used as an indicator of the cytotoxicity 
of HAAs and the calculation below was used to find the NDI 
(Fenech, 2007).  
 
NDI = (M1) + 2 (M2) + 3 (M3) /N  
 
Where:  
M1 = mononucleated cells  
M2 = binucleate cells 
M3 = multinucleated cells  
N = the total number of viable cells scored. 
 
Statistical analysis was carried out using the chi-square test (χ2) to determine 
significant differences with p value set at *** p = < 0.001 for all treated samples 
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vs. the negative control and treatment groups containing both HAA and 
antioxidant treatments versus the HAA only group. 
2.4 Methods for Preparation of NSAIDs - Aspirin nano & 
Ibuprofen nano compounds, (for chapters 5 & 6), sections 2.5 
& 2.6 of Materials & methods. 
 
2.4.1 Reagents.  
 
Two non-steroidal anti-inflammatory drugs – ibuprofen and aspirin were used 
in this study. Aspirin and sodium lauryl sulphate (SLS) were purchased from 
Sigma-Aldrich, Poole, Dorset, United Kingdom. Ibuprofen was purchased from 
Albemarle Europe sprl, Belgium. Pharmcoat 606 (HPMC) was kindly donated 
by Shinetsu, Japan. Kollidon 30 (PVP K-30) was purchased from BASF, 
United Kingdom. Bulk and nano suspensions of Aspirin and Ibuprofen were 
kindly prepared by Lena Nanoceutics, Bradford, United Kingdom.  
2.4.2 Methodology for Aspirin & Ibuprofen nano suspensions.  
 
Suspensions of aspirin and ibuprofen with solid loads of 4% and 3% (w/w) 
respectively were prepared. The suspending medium consisted of: HPMC 
(0.5%, w/w), polyvinylpyrrolidone K-30 (0.5%, w/w) and sodium lauryl sulphate 
(SDS) (0.1%, w/w) in deionised water (Plakkot et al., 2011). HPMC was used 
as it is a lubricant, polyvinylpyrrolidone is a water soluble polymer and SDS is 
detergent that removes residues in the mixture. The millings of these 
compounds were carried out using Lena Nanoceutics technology DM-100 
machine (Sulaiman 2007).  
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250 ml of each suspension were milled using 150 ml of 0.2 mm yttrium 
stabilised zirconium beads (Glen mills, USA). The materials were then 
recycled for 60 minutes in the milling machine before being discharged in an 
opaque glass bottle and stored in the refrigerator at (4°C) for the duration of 
the experiments. Nano-suspensions were then briefly sonicated for 15 
minutes, prior to start of the micronucleus & Comet repair assays. 
2.4.3 Analysis of nano-suspension particle size 
 
Particle size of aspirin and ibuprofen were regularly checked for the duration 
of the micronucleus and Comet repair assay experiments. The particle size 
distribution of aspirin and ibuprofen nano-suspensions were determined using 
the dynamic light scattering technique of the Zetasizer Nano ZS (Malvern 
instruments, UK). Samples were measured at room temperature using 
disposable sizing cuvettes. All measurements were carried out in triplicates. 
The particle size of the stock suspensions were measured in triplicates 
immediately after milling and then rechecked at the end of the experiments to 
ensure no significant change in particle size occurred during the various 
phases of the experiments. The particle size of the bulk powder was measured 
using laser diffraction technique (Sympatec Helos, UK). Approximately 20 mg 
of each drug were transferred into the sample vial and the primary pressure 
was adjusted to 4 bars while the feeder speed was 40mm/s. Three samples of 
each drug were measured using R2 lens (0.25/0.45, 87.5µm). 
Images were obtained using transmission electron-microscope (TEM). 
Samples were prepared by placing a drop of the suspension (Aspirin 4% w/w 
and Ibuprofen 3% w/w) on the TEM carbon grid. The drop was left on the grid 
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for 10 min then the grid was washed by dipping it in water. The grid was floated 
on a drop of Uranyl acetate for 10 min then washed again with water and left 
to dry. The grid was then placed in the TEM and the magnification power was 
100, 000x. The beam intensity was 40 kV for Ibuprofen and 60 kV for Aspirin 
sample. 
 2.4.4 Zeta potential analysis of nano suspensions 
 
The zeta potential for the suspensions was determined using Zetasizer Nano 
ZS (Malvern instruments, UK). The suspensions were diluted 1:100 using 
deionised water and measured at 25OC. clear disposable zeta cells were used. 
Measurement duration was set as automatic with a minimum of 10 runs and a 
maximum of 100 runs. All measurements were made in triplicate. 
2.5 Materials and Methods for Cytokinesis block Micronucleus 
(CBMN) Assay for testing aspirin & ibuprofen (chapter 5) 
 
2.5.1 Reagents.  
 
General Laboratory reagents for cell culture were purchased as described in 
section 2.3.1. In addition, the compounds of aspirin and ibuprofen were 
obtained as described in section 2.4.1. Bulk compounds were dissolved in 
Eppendorf’s with ddH2O and stored at 4OC. Nano compounds were checked 
regularly using spectrophotometer (Zetasizer) to ensure the size of the 
particles did not exceed 400 nanometers (nm) (See section 2.4). 
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2.5.2 Whole blood sample collections & Study cohort 
 
For ethics: See section 2.1 (above) for ethical approval for Micronucleus 
assay. Blood samples for asthma, lung cancer, COPD, COPD & Lung Nodule 
(combined) and lung cancer patients were obtained from Outpatient 
Respiratory Disease Clinic of Dr. Badie K. Jacobs (St Luke’s Hospital, 
Bradford, UK) and healthy control samples were obtained from University of 
Bradford. Cell cultures were set up and run within 3 hours on the day of sample 
collection. 
 
Thirteen different blood samples were used in this study (Table 4). The 
samples consisted of: 3 healthy control individuals, 2 asthma patients, 2 COPD 
patients, 3 COPD & lung nodule patients (which were combined), and 3 lung 
cancer patients. The data for the latter two types were combined and 
considered as 6 samples in the group, for statistical purposes.  
 
Table 4: Blood samples used from healthy non-smoking donors, asthma patients, 
COPD patients, COPD & Lung nodule patients and lung cancer patients. 
Age Sex Ethnic Background Non-Smoker/Smoker Patient Group 
47 Female Asian Non-smoker Healthy Control 
26 Female Caucasian Non-Smoker Healthy Control 
29 Male Caucasian Non-smoker Healthy Control 
24 Male Asian Non-smoker Asthma 
30 Male Caucasian Non-smoker Asthma 
63 Male Caucasian Non-smoker COPD  
55 Female Caucasian Smoker COPD 
63 Male Caucasian Smoker COPD & Lung Nodule 
65 Male Caucasian Non-smoker COPD & Lung Nodule 
63 Female Caucasian Smoker COPD & Lung Nodule 
65 Male Caucasian Smoker Lung Cancer 
68 Female Caucasian Non-smoker Lung Cancer 
55 Male Caucasian Smoker Lung Cancer 
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2.5.3 Cell culture of whole blood 
 
Under sterile conditions, basic culture medium was prepared as described in 
section 2.3.3 
 
2.5.4 Preparation of basic culture medium 
 
Under sterile conditions, using sterile plastics and solutions, the cell culture of 
lymphocytes was performed over a 72 hr period, generally in a similar manner 
as described in section 2.3.4. Nano compounds of aspirin & ibuprofen were 
sonicated using a sonicator for 15 min prior to their addition into flasks for cell 
culture. At the start of the cultures all flasks were prepared as follows for work 
with ibuprofen and aspirin (Table 5). 
 
Table 5: shows the treatment groups in CBMN assay with nano compounds aspirin 
and ibuprofen (Chapter 5). The above 5 flasks represent the 5 different treatments 
types used to test for the effect of both the, bulk and nano form of aspirin and 
ibuprofen in asthma, COPD and lung cancer patients. The end concentrations for 
ASP B, ASP N, IBU B and IBU N in culture were 250 µg/ml. 
Flask 
No. Flask type 
Blood 
(µl) 
PHA 
(µl) Chemical 
Flask 1 Standard Negative Control 500 µl 100 µl  NONE 
Flask 2 Bulk form of compound 500 µl 100 µl  250 µl Aspirin 
Flask 3 Nano form of compound 500 µl 100 µl   250 µl Aspirin 
Flask 4 Bulk form of compound 500 µl 100 µl  250 µl Ibuprofen 
Flask 5 Nano form of compound 500 µl 100 µl  250 µl Ibuprofen 
 
 
2.5.5 Cell hypotonic shock treatment: 
 
Cells were treated as described in Section 2.3.5 
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2.5.6 Fixation of cells 
 
Cells were treated as described in Section 2.3.6 
 
2.5.7 Slide Preparation, staining and slide fixing. 
 
Slides were prepared, stained and fixed as described in Section 2.3.7 
 
2.5.8 Slide scoring 
 
Slides were scored as described in Section 2.3.8 
 
2.5.9 Data Analysis and statistics used 
 
Data analysis and statistics were performed as described in section 2.3.9 
 
2.6 Materials and Methods for testing ibuprofen and aspirin 
using the Comet repair assay. 
 
2.6.1 Reagents.  
General Laboratory reagents were purchased as described in section 2.2.1. 
Aspirin and Ibuprofen were purchased as described in section 2.4.1. 
Bleomycin sulphate was purchased from Enzo Life Sciences Ltd, Exeter, 
United Kingdom (CAS# 9041-93-4). Bleomycin stock solutions was prepared 
using ddH2O and stored at -20OC. Different working solutions (concentrations) 
were also prepared using ddH2O and stored at 4OC.  
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2.6.2 Whole blood collection & study cohort 
 
Samples were obtained as described in the previous section, above (2.5.2). 
All patient samples (for asthma, COPD & lung cancer) came from St. Luke’s 
Hospital. Bradford, UK. Control samples came from Healthy individuals from 
University of Bradford, UK. In this study 25 different whole blood samples were 
used. The samples consisted of:  10 healthy control individuals, 5 asthma 
patients, 5 COPD patients and 5 lung cancer patients.  
2.6.3 Cell Viabilities 
 
For whole blood samples, cell viability was measured in samples up to a cut-
off point of 70% using trypan blue exclusion, so avoiding artefacts due to 
toxicity. Generally, the viability was in excess of 90%. Viability was measured 
in whole blood samples before and after treatment (Gopalan et al., 2011; 
Henderson et al., 1998). 
 
2.6.4 Single cell gel electrophoresis (SGCE) Comet assay with 
repair mechanism 
 
2.6.4.1 Cell treatment of Whole blood cells (General overview): 
Eppendorf® tubes containing whole blood of approximate 1000 µl total volume 
were obtained for each experiment. Seven tubes were used for the Comet 
repair assay; one negative control, two positive controls (Positive controls 1 & 
2) containing bleomycin only and four tubes containing bleomycin and either 
aspirin bulk, aspirin nano, ibuprofen bulk or ibuprofen nano, to study the effects 
of the compounds on the repair of DNA. Bleomycin was used as challenger to 
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induce DNA damage. With the exception of the sample that contained 
bleomycin only (positive control 1), all cells in each tube were first treated for 
30 minutes incubation at 37OC in 5% CO2 and then the cells were left for a 
further 15 minutes incubation at 37OC in 5% CO2 (45 minutes total incubation) 
to allow DNA repair in the presence of NSAIDs before being transferred to 
Agarose coated slides. The cells in the tube containing bleomycin only 
(positive control 1) were treated for 30 minutes incubation at 37OC in 5% CO2 
before being transferred to Agarose coated slides with no repair time 
incubation included. The second positive control (positive control 2) – was 
treated in the same way as the positive control 1, but the cells were left for a 
further 15 minutes of incubation to allow DNA repair with no NSAIDs added. 
 
2.6.4.2 Treatment over duration of 45 minutes  
 
Start of first Incubation/Time point 0 hrs: For each treatment tube (6 tubes) 
- 100 µl of whole blood cells, 890 µl RPMI medium, plus 10 µl of bleomycin 
(end concentration 7.5 µg/ml) were added. For the negative control tube – 100 
µl of whole blood cells, 900 µl RPMI medium were added. Tubes were 
incubated for 30 min at 37 OC in 5% CO2. 
 
End of first Incubation/Time point 0hrs, 30 min: All tubes were briefly 
centrifuged at 2000 rpm/107 x g for 3 minutes.  
For Bleomycin tube with no further repair: 950 µl of supernatant was 
discarded,  and the cell pellet was mixed in 0.5 % LMP Agarose and 
immediately transferred to agarose coated slide, covered on top with a cover-
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slip and placed on ice for 5 min. Cover slip was removed and the slide was 
placed in lysis solution.  
For the negative control, and bleomycin tube with further repair (for 15 
minutes (45 minutes total)): For the negative control and the other five 
treatment tubes, 950 µl of supernatant was discarded and 950 µl of fresh 1640-
RPMI medium was added again to each tube (for cell washing). Cell pellets 
were very gently mixed and centrifuged at 2000 rpm/107 x g for 3 minutes. 
This process was repeated twice and after the second centrifugation, cells 
were then treated with nano compounds. 
 
Treatment with NSAID compounds (for 15 minutes (45 minutes total)): 
For the negative control tube, 950 µl of fresh RPMI was added to the washed 
cell pellet and gently mixed. The same was done for bleomycin with further 
repair but no NSAID addition. To the remaining tubes, (also previously treated 
with Bleomycin), fresh RPMI medium was added, as well as NSAID 
Compounds, see below). 
For treatment of aspirin bulk: 940 µl of Fresh RPMI and 10 µl aspirin bulk 
was added to the cell pellet and gently mixed (end concentration = 250 µg/ml). 
For treatment of aspirin nano: 933.3 µl of Fresh RPMI and 16.66 µl aspirin 
nano was added to the cell pellet and gently mixed (end concentration = 250 
µg/ml). 
For treatment of ibuprofen bulk: 940 µl of Fresh RPMI and 10 µl ibuprofen 
bulk was added to the cell pellet and gently mixed (end concentration = 250 
µg/ml). 
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For treatment of ibuprofen nano: 937.5 µl of Fresh RPMI and 12.5 µl 
ibuprofen nano was added to the cell pellet and gently mixed (end 
concentration = 250 µg/ml) 
 
Start of Second Incubation/Time point 0hrs, 30 min:  
Cells were repaired from minutes (30-45) via incubation for 15 min at 37 OC in 
5% CO2 (see above). 
2.6.5 Embedding of cells in Agarose 
 
After the repair period, all tubes were centrifuged and the supernatant was 
discarded, with small amounts retained with the cell pellet. Then, 100 µl of 
0.5% low melting agarose (LMP) (Invitrogen, Paisley, UK: 15517-022) was 
added to cell pellet to create a cell suspension. The cell suspension was 
transferred to slides pre-coated with 1% normal melting point (NMP) agarose. 
The slides were placed on an ice block for 5 min. 
2.6.6 Cell Lysis 
 
After 5 min, coverslips were removed from the slides and the slides were 
placed in cold lysis solution and stored overnight. This was made up using 178 
ml lysis stock solution plus 20 ml DMSO and 2 ml of Triton® X-100 (Sigma, 
Poole, Dorset, UK). The lysis solution had final concentrations of 2.5 M NaCl 
(VWR 27800.360), 100 mM EDTA (Sigma, Poole, Dorset, UK: E 3154), and 
10 mM Trizma base (Sigma, Poole Dorset UK: T-6066). The pH of the solution 
was adjusted to pH10, with sodium hydroxide (NaOH). 
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2.6.7 Electrophoresis  
 
Following lysis, electrophoresis was performed on whole blood cells based on 
methods by Tice et al., (2000). Electrophoresis solution was prepared using 
1930 ml of H2O, 60 ml of NaOH (BDH: 301675N) and 10 ml of Na2 EDTA (pH 
13.5). The end concentrations for these were 300 mM and 1 mM, respectively. 
Slides were placed in a tank for 30 min and electrophoresis was performed at 
290-300 mA, at a constant voltage of 25 V for 30 min (0.71 V/cm). 
 
Slides were then washed three times for 5 min with cold neutralising buffer at 
pH 7.5 and then stained with 20 µg/ml ethidium bromide (Sigma, Poole, 
Dorset, UK: E-8751). 
 
2.6.8 Scoring of Slides and Statistical Analysis: 
 
All slides were coded before scoring and 100 cells were scored per 
observation using a microscope equipped with a CCD camera and Computer 
system (Andor Technology Ltd, Belfast, UK). Data were generated to measure 
Olive tail moment and % Tail DNA using 6 software, Kinetic imaging (Andor 
Technology Ltd, Belfast, UK). Each experiment was repeated ten times for 
control group, and five times each for asthma, COPD and lung cancer groups. 
Mean data were generated with standard errors. Distribution of the response 
variable departed significantly from normality (Kolmogorov-Smirnov goodness 
of fit test) and thus, non-parametric statistics were considered adequate for 
the analysis of the data. The differences between groups were examined using 
the Kruskal-Wallis test and Mann-Whitney U-test. Dose response relationships 
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for both NSAIDs were determined by Pearson’s correlation. A p-value of < 0.05 
was considered significant. All analyses were performed using SPSS for 
windows statistical package (version 18.0). 
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Chapter 3 – Genotoxic effects of HAAs and 
antioxidant treatments in the Comet assay 
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3.1 Introduction 
 
 
It is important to treat source waters in order to provide clean, odourless and 
tasteless, high quality water for household use. Water treatments commonly 
involve the use of chemical disinfectants. Over the last century, increasing use 
of these disinfectants has given rise to disinfection by products (DBPs) (Akin 
et al., 1982; Plewa et al., 2002) Chlorination is the most commonly used 
disinfectant due its low cost and germicidal potency (Qi et al., 2004). The 
chemical reaction between chlorine and natural organic constituents in source 
waters gives rise to two well-known classes of DBPs, THMs and HAAs (Plewa 
et al., 2002; Plewa et al., 2010). While disinfection of the drinking water has 
helped to eliminate and control water borne infectious diseases (Akin et al., 
1982) the undesired presence of DBPs has led to health issues and these 
DBPs have been identified as carcinogenic (Cantor et al., 1999; Koivusalo et 
al., 1994; Qi et al., 2004; Villanueva et al., 2004). 
 
In this chapter the three chemicals of the HAA DBP group: iodoacetic acid 
(IAA), bromoacetic acid (BAA) and chloroacetic acid (CAA) have been 
discussed. Previous studies have demonstrated that these HAAs are cytotoxic 
and genotoxic DBPs when analysed in the Ames test, and in the mammalian 
CHO cell system (Plewa et al., 2002). Cemeli et al. (2006) have also shown 
the involvement of oxygen radicals with IAA in these cells. 
 
This chapter focuses on previously unreported effects of these HAAs in human 
somatic and germ cells and whether oxidative stress is involved in the HAA 
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mechanism of genotoxic action using the Comet assay. In this study somatic 
cells have been examined in the form of peripheral blood lymphocytes and 
germ cells using human sperm. After determining appropriate dose responses 
in lymphocytes and sperm (See results section 3.3, Figures 1a, 1b, 2a, and 
2b), oxidative radical involvement has been investigated, with the anti-oxidant 
butylated hydroxanisole (BHA) and the enzyme catalase in the single cell gel-
electrophoresis assay (Comet assay) under alkaline conditions, > pH 13. 
 
The single cell gel electrophoresis (SCGE) or Comet assay, (so-called due to 
appearance of Comet like images), is an assay designed to measure DNA 
single-strand breaks in lymphocytes and sperm (Ostling and Johanson, 1984; 
Singh et al., 1988; Wu et al., 2001). Lymphocytes and sperm embedded in 
agarose gel are placed in an electric field at alkaline conditions. The fragments 
of negatively charged single-strand DNA move through the gel from cathode 
(negative) towards the (positive) anode. DNA, which is undamaged, will move 
relatively slowly, forming the head of the Comet, while DNA that is fragmented 
or damaged will move through much faster giving the appearance of tail-like 
structure. The Comet assay has been used to analyse two kinds of damage in 
lymphocytes and sperm: Olive tail moment and % tail DNA. These parameters 
have been described in further detail in section 2.2.8.1 in the Materials and 
Methods chapter. 
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3.2 Materials and Methods  
 
3.2.1 Materials 
 
The materials required for this study have been described in section 2.2.1 
3.2.2 Methods 
 
Sample collection and isolation of lymphocytes has been described in section 
2.2.2.1. Collection of sperm sample(s) and spermiogram analysis has been 
described in section 2.2.2.2. Comet assay was deployed under alkaline 
conditions as described in sections 2.2.4-2.2.8. Treatment groups for 
lymphocytes and sperm have been described in sections 2.2.5.1 and 2.2.5.2, 
respectively. Antioxidant treated samples have been described in section 
2.2.5.3 
3.2.4 Statistical Analysis  
 
All slides were coded and scored using a microscope equipped with a CCD 
camera and Computer system (Andor Technology Ltd, Belfast, UK) as 
described in section 2.2.9.   
Data from Olive tail moment and % Tail DNA values were used to perform 
SPSS statistics (Version 19). Most data were normally distributed, as 
determined using the Mann-Whitney and Kolmogorov-Smirnov Z tests. For 
data that were not normally distributed using these tests, their normal 
distribution was confirmed using non-parametric - 2 independent samples test.  
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One Way ANOVA (Bonferroni) was then performed for significance of data to 
determine significant differences of all treatment groups, including antioxidant 
controls to the negative control group and significant difference of HAA and 
antioxidant treatment groups to the HAA only treatment group.  
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3.3 Results  
 
3.3.1 Cell viability 
 
Cell survival was above 90% for lymphocytes and above 75% for sperm. 
Spermiogram analysis on average from four sperm donors, gave the following 
results: 
Sperm Morphology: 79% normal, 21% abnormal. 
 
Sperm Motility:  
 
44% fast-progressive 
26% slow-progressive 
13% non-progressive,  
17% immobile (no tail movement). 
 
Sperm pH = 8.5. 
 
Sperm Concentration =   23.45 million per ml. 
 
3.3.2 Overview of results 
 
Graphs 1a, 1b and 2a, 2b, show the responses of the 3 HAAs over the 
repeated dose ranges in lymphocytes and sperm, respectively. All these HAAs 
showed similar response patterns. In the presence of antioxidants, BHA and 
catalase, results showed decreased responses in lymphocytes (Graphs 3a & 
3b) and sperm (Graphs 4a & 4b), respectively. BHA and catalase showed no 
significant increases above the control values on their own. Both lymphocytes 
and sperm showed highest damage with HAA (p = *** < 0.001), but reduced 
levels of damage were seen in presence of catalase. In the case of BHA, less 
damage was found in cells that were exposed to the 100 µM antioxidant dose, 
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but damage increased as antioxidant dosage was reduced across both cell 
types, where there was more cell DNA damage with 50 µM BHA and even 
greater damage with 10 µM BHA. Catalase also appeared to cause a greater 
reduction in both sperm and lymphocyte DNA damage than in cells that were 
treated with 10 µM BHA except in CAA treated lymphocytes (Graphs 4A & 4B) 
show otherwise. However in all HAAs, cells treated with 50 µM BHA showed 
further decreases in cell DNA damage and at 100 µM BHA, showed the 
greatest reduction in DNA damage, suggesting BHA at this dosage is very 
effective in the reduction of damage and overall indicates the presence of 
oxygen radical involvement. In general, both cell types showed similar 
response patterns, with slightly higher levels of damage in sperm than 
lymphocytes. Figures 11 & 12 show images of lymphocyte and sperm Comets, 
respectively. 
                                                                                                                                        
3.3.3 Statistics: 
 
Both Lymphocytes and sperm: In general, there is no significance difference 
by comparison with the negative control for the antioxidants on their own (ns) 
but with the HAAs positive responses are generally shown (* p = < 0.05, ** p 
= < 0.01, *** p = < 0.001). When the HAAs are treated with the antioxidants, 
there is a reduction in response. These reductions are generally significant 
compared to the HAAs alone (Δ p = <0.05, ΔΔ p = < 0.01, ΔΔΔ p = < 0.001) 
or at the highest dose of BHA not significant (ns Δ). Both graphs show similar 
response patterns.  
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Exceptions include: 
Lymphocytes - Olive tail moment: There is no significance (ns) of all three 
HAAs with the highest dose of BHA (100 µM) in comparison to the negative 
control (Graph 3a). 
Lymphocytes - % tail DNA: There is no significance (ns) of BAA & CAA with 
the highest dose of BHA (100 µM) in comparison to the negative control 
(Graph 3b). 
Sperm - Olive tail moment: There is no significance (ns) of IAA & CAA with 
the highest dose of BHA (100 µM) in comparison to the negative control 
(Graph 4a).  
When the HAAs are treated with the antioxidants, there is a reduction in 
response. However some treatments groups are not significant (ns Δ) 
compared the HAAs alone. These treatment groups are; CAA with 500 
Units/ml Catalase, IAA & CAA with 10 µM BHA. 
Sperm - % tail DNA: There is no significance (ns) of IAA & CAA with the 
highest dose of BHA (100 µM) in comparison to the negative control. 
3.3.4 Confounding factors: 
 
There were no confounding effects. All individuals were non-smokers. 
Approximately, 50 % were female and 50 % were male for the Comet assay 
and there appeared to be no differences due to gender. The age of the 
volunteers ranged from 21-40 years and the results for all individuals gave 
similar responses, regardless of age. 
84 
 
 
 
 
Graph 1a: Olive Tail moment: Graph shows the response of lymphocytes to IAA, BAA and CAA in the form of Olive tail moments. All curves 
increase over the range from 2µM to 22µM (mM For CAA) respectively after treatment with the three HAAs. 
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Graph 1b: % tail DNA: Graph shows the response of lymphocytes to IAA, BAA and CAA in the form of % tail DNA. All curves increase over 
the range from 2µM to 22µM (mM For CAA) respectively after treatment with the three HAAs. 
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Graph 2a: Olive tail moment: Graph shows the response of sperm to IAA, BAA and CAA in the form of Olive tail moments % tail DNA. All 
curves increase over the range from 2µM to 22µM (mM For CAA) respectively after treatment with the three HAAs. 
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Graph 2b: % tail DNA: Graph shows the response of sperm to IAA, BAA and CAA in the form of % tail DNA. All curves increase over the 
range from 2µM to 22µM (mM For CAA) respectively after treatment with the three HAAs. 
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Graph 3a: Olive tail moment: Bar chart shows the response of lymphocytes to IAA, BAA and CAA. The HAA treatment group contains the 
highest DNA damage compared to controls. HAA treatment groups containing antioxidant result in decreased damage. 
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Graph 3b: % tail DNA: Bar chart shows the response of lymphocytes to IAA, BAA and CAA. The HAA treatment group contains the 
highest DNA damage compared to controls. HAA treatment groups containing antioxidant result in decreased damage. 
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Graph 4a: Olive tail moment: Bar chart shows the response of sperm to IAA, BAA and CAA. The HAA treatment group contains the 
highest DNA damage compared to controls. HAA treatment groups containing antioxidant result in decreased damage. 
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Graph 4b: % tail DNA: Bar chart shows the response of sperm to IAA, BAA and CAA. The HAA treatment group contains the highest DNA 
damage compared to controls. HAA treatment groups containing antioxidant result in decreased damage. 
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Figure 11: Typical image of lymphocyte Comets. Comets can be seen with minimal 
tail DNA damage (Left), high levels of damage (centre) and intermediate damage 
(right) (Image sourced from Professor Diana Anderson, University of Bradford, UK). 
 
 
Figure 12: Typical image of sperm Comets (Image sourced from Professor Diana 
Anderson, University of Bradford, UK). 
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3.4 Discussion 
 
In recent years, considerable interest has been shown in DBP genotoxicity, in 
particular the THM and HAA sub groups, some of which have been extensively 
identified (Richardson et al., 2008; Richardson et al., 2007). Genotoxicity 
assays have been used to determine the exact mechanisms on genotoxic 
actions posed by DBPs. HAAs are a major class of DBPs. This nine-
membered HAA group is regulated to some extent in the United States but not 
in the United Kingdom (Bougeard et al., 2010). Furthermore, the list of DBPs 
is increasing by the day and the mechanisms and genotoxicity of most of them 
are yet to be identified (Richardson et al., 2007). 
 
This investigation followed on the basis of the study by Cemeli et al. (2006) 
who has shown the involvement of oxygen radicals with IAA in these cells.  In 
further developing our understanding of halo acetic acids, IAA was 
investigated in lymphocytes and sperm. The antioxidants butylated 
hydroxyanisole and catalase were also investigated to determine any oxygen 
radical involvement. To determine whether this applies to other HAAs in 
general and not just iodo haloacetic acid, two additional compounds - BAA and 
CAA were also included in this study. 
    
Findings from this study suggest there are potential genotoxic effects involved 
and that there is oxygen radical involvement in both lymphocytes and sperm.   
 
Results showed, all HAAs responded in a similar manner, producing similar 
dose responses over the same dose range in lymphocytes and sperm. In each 
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HAA, the highest dose in the range (22 µM for IAA and BAA, 22 mM for CAA) 
showed the greatest Olive tail moment and % tail DNA values compared to 
controls. The data suggested it would be feasible to work with the highest dose 
of each compound. For comparative purposes a concentration of 25 µM for 
IAA and BAA, 25 mM for CAA were selected. Antioxidants – BHA and catalase 
were used at same concentrations as done in the study of Cemeli et al. (2006). 
 
After treatment with the anti-oxidants, all three HAAs were observed to 
respond in a similar way, with slightly more damage in Olive tail moment and 
% tail DNA in the sperm than in lymphocytes. A similar response pattern with 
sperm being more sensitive than lymphocytes has recently been shown by 
Baumgartner et al. (2012) with 12 genotoxic compounds. Also, the 
lymphocytes have shown a similar response in CHO cells when treated with 
IAA and BHA and catalase and our results thus support these earlier findings 
in mammalian cells (Cemeli et al., 2006).  
 
These observations are of concern to public health since both somatic and 
germ cells show positive responses. These results open up the possibility of 
continuing research of these genotoxic compounds in in-vitro and in-vivo 
studies to try and develop a greater understanding of these compounds. 
Further testing of these cells with other similar HAAs such as diodoacetic acid, 
dibromoacetic, tribromoacetic acid, dichloroacetic acid, and trichloroacetic 
acid could enhance our understanding of HAAs.   
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Chapter 4 – Exposure of haloacetic acids 
(HAAs) in human peripheral blood using 
Cytokinesis-block micronucleus assay 
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4.1 Introduction 
 
 
In the previous chapter (Chapter 3), results from the DBP group - HAAs: IAA, 
BAA and CAA showed the genotoxic DNA damage potential of these 
compounds, as seen via increases in Olive tail moment and % tail DNA using 
the Comet assay. The endogenous antioxidant – catalase, and the exogenous 
antioxidant – BHA, were both able to reduce the damage suggesting an 
oxygen radical involvement with these chemicals. With the Comet assay, it 
has been possible to detect genomic damage and these findings therefore 
indicate a need to investigate the same effect in cytogenetic assays. Therefore 
the aim of this chapter is to assess somatic cells – lymphocytes for cytogenetic 
damage using the cytokinesis-block micronucleus (CBMN) assay as an end-
point. 
 
The cell growth cycle is the process by which cells replicate their DNA, 
allowing them to divide into two daughter cells and eventually enter 
programmed cell death or apoptosis at the end of the life cycle. In eukaryotes 
it occurs over a 24 hr period. The cell cycle consists of four stages: - G1 phase 
(gap 1 phase), S phase (synthesis) of DNA, G2 phase (gap 2 phase) and M 
phase (mitosis) (Collins et al., 1997). The G1, S and G2 phases are classed 
as the interphase. In the G1 phase the cells grow and prepare for chromosome 
replication by synthesising enzymes necessary for S phase. During the S 
phase chromosomes are replicated to produce two identical copies and the 
G2 phase works to prepare the cells for cell division and synthesises cellular 
components needed for the M phase. The next stage, the M phase, is the most 
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important as cells undergo nuclear division through sub processes consisting 
of; prophase, prometaphase, metaphase, anaphase and telophase (Norbury 
and Nurse, 1992). Finally, the cycle comes to an end when the cell splits into 
two daughter cells (cytokinesis) (Vermeulen et al., 2003). 
 
The CBMN assay uses cells undergoing the cell cycle division, such as 
binucleated cells (BiNC). These are  cells that have undergone mitosis after 
being blocked at the cytokinesis stage with Cytochalasin B – which inhibits the 
microfilaments ring assembly important to end the process of cytokinesis 
(Fenech and Morley, 1985). Chemicals and exogenous agents can have 
mutagenic consequences on cells and interfere with chromosome structure 
and separation during the cell cycle (Fenech, 2007). As a consequence, 
micronuclei (MNi) arise and originate from acentric or whole chromosomes 
that lag behind the anaphase stage of mitosis. MNi induction in BiNC cells 
indicates cytogenetic damage. MNi can also be found in mononucleated 
(MonoNC) cells and multinucleated (MultiNC) cells; However scoring for MNi 
in BiNC cells is particularly important since restricting the scoring of MNi in 
BiNC cells prevents confounding effects caused by altered or suboptimal cell 
division kinetics, which is a major variable in the CBMN assay (Fenech, 2000, 
2006).  
 
In more recent developments, research suggests that the CBMN assay can 
be used to measure nucleoplasmic bridges (NPBs) and nuclear buds 
(NBUDs). NBPs form a small narrow ‘bridge-like’ structure between two nuclei 
of a binucleated cell. NPBs act as a biomarker for dicentric chromosomes 
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which arise due to DNA mis-repair or telomere end-fusions. It is recommended 
to score these as they provide measures of chromosome rearrangement, 
which cannot be measured based on scoring MNi on their own (Umegaki and 
Fenech, 2000). NBUDs act as a biomarker for detecting gene amplification. 
Amplified DNA is localised at specific locations within the nuclei. During the S 
phase this amplified DNA is eliminated from the periphery of the nuclei via a 
nuclear ‘budding’ mechanism to form MNi-like buds. These buds remain linked 
to the main nuclei through nucleoplasmic material (Fenech, 2007). 
 
MNi inductions in lymphocytes have been well documented in the CBMN 
assay (Fenech and Morley, 1985). The CBMN assay was performed to detect 
MNi inductions following HAA exposure, albeit at lower concentrations than in 
the Comet assay. In addition, lower catalase and BHA concentrations were 
also used (see chapter 3, results section 3.3) and mitomycin C was used as 
positive control. MNi induction was scored in BiNC, including BiNC with NPBs 
and BiNC with NBUDs as well as in MonoNC. All types of cells up to 500 were 
scored from which percentages of BiNC and MultiNC were calculated and 
together with the number of MonoNC, the nuclear division index (NDI) was 
calculated.  
 
 
 
 
 
99 
 
4.2 Materials and Methods  
 
4.2.1 Materials 
 
The materials required for this study have been described in section 2.3.1 
4.2.2 Methods 
 
The sample collection of whole blood was obtained as described in section 
2.3.2 (see Table 2). The CBMN assay was deployed in three different 
experiments (each with different HAA) as described in sections 2.3.3 - 2.3.8. 
Treatment groups, including antioxidant treated groups per each experiment 
are described in section in section 2.3.4 (See Table 3). 
4.2.4 Statistical Analysis.  
 
All slides were coded and scored as described in protocols (Fenech, 2007). 
500 of all cell types were scored for each sample to determine the percentages 
and NDI values (i.e. every mono, bi and multinucleate cells found in a total of 
500 cells using a multiple counter). BiNC and MonoNC were then scored 
further until 500 cells each, observing for MNi found per 500 cells.  A standard 
Chi-Squared test was performed for statistical analysis for MNi induction using 
the equation: 
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Where, o represents frequency of observed MNi, e represents frequency of 
expected MNi and ∑ represents the sum of (observed – expected MNi) 2 / 500 
(The total possible MNi value achievable/ 500 BiNC and MonoNC scored.   
The Chi-squared test was performed for significance of data to determine 
significant differences of all treatment groups to the negative control group and 
significant difference of HAA with antioxidant treatment groups to the HAA only 
treatment group. A p value was set at *** p = < 0.001. 
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4.3 Results  
 
4.3.1 Determining concentrations of HAAs and antioxidants 
 
Based on the Comet assay data, CBMN assay was initially performed using 
same doses, adjusting in preparation to take into account the end volume in 
T25 cm2 flask at 5 ml. The concentrations of 25 µM for IAA and BAA were toxic 
and it was not possible to score the cells. CAA at 25 mM level was also toxic 
and cells could not be scored. A range of concentrations of these HAAs were 
used (diluting 1:1 each time) and it emerged 6.25 µM was the optimal 
concentration for IAA and BAA and 62.5 µM for CAA. Catalase responded well; 
however BHA at 10 µM, 50 µM and 100 µM were resulting in higher MNi 
compared to the negative control. These were revised until concentrations of 
0.1 µM, 0.5 µM and 1.0 µM were deemed optimal.  
4.3.2 Overview of results 
 
Tables 6, 7 and 8 (after section 4.3.8, below) summarise the responses of IAA, 
BAA and CAA, respectively. In general, results are similar for all the three 
HAAs, with the greatest MNi inductions seen in BiNC in HAA treatment groups 
when compared to the negative control group and a reduction in the presence 
of catalase and/or BHA when compared to HAA alone. MNi induction caused 
by all three HAAs was less, but near to levels of MNi induction following 
exposure to mitomycin C (positive control). MNi in MonoNC were also 
evaluated and the results showed similar patterns to MNi in BiNC. However 
statistics from the Chi-squared showed some unusual results but generally 
indicate MNi reduction in all HAAs following antioxidant exposure. For NDI 
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values, IAA and CAA are more comparable, unlike BAA which shows higher 
NDIs and greater % of binucleated cells. The NDI values decrease in the order 
BAA > IAA > CAA (see individual sections 4.3.3-4.3.5). 
4.3.3 Induction of micronuclei by iodoacetic acid (IAA) 
 
Micronuclei were generated following genotoxic exposure to iodoacetic acid 
(see table 6, after section 4.3.8). A summary of the 11 treatment groups used 
in the experiment is summarised in the Materials and Methods section, see 
section (2.3.4, Table 3). In this experiment cells were treated with antioxidants 
only, 0.4 µM for MMC, 6.25 µM of IAA and 6.25 µM of IAA containing either 
catalase at 2,500 units/ml or BHA at 0.1 µM, 0.5 µM and 1.0 µM. For each 
treatment group, the number of MNi was also determined in 500 cells each of 
BiNC and MonoNC. In addition, the NDI index values were calculated and % 
of BiNC and MultiNC were determined in a total of 500 cells. Each experiment 
was repeated, twice (1000 cells total).  
In the control group, there were approximately 59.2% of BiNC and 10.0% of 
MultiNC. Treatment with iodoacetic acid resulted in a decrease in both % of 
BiNC (2-fold less at 28%) and MultiNC (10 fold less at 1.6%), including IAA 
groups containing antioxidants. MMC exposure also resulted in a decreased 
% BiNC but the percentage was greater than most IAA/IAA with antioxidant 
groups. The % of MultiNC with MMC however, was low and comparable to all 
these groups. These results are reflected in the NDI values which show the 
negative control group having the highest NDI at 1.79 compared to all other 
treatment groups that have NDIs in the range of 1.40-1.64. All NDI values fall 
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in the normal expected range of 1.3-1.8 with lymphocyte cultures as described 
by Fenech (2006). 
The effect of iodoacetic acid on MNi formation was measured in 500 cells of 
BiNC and MonoNC (See Table 6). The Chi-Squared test was performed to 
validate the significance of the data amongst individual treatment groups. 
In BiNC cells, no significance difference of MNi was found by comparison with 
the negative control for the antioxidants on their own (ns), or IAA containing 
catalase and IAA containing 0.1, 0.5 and 1.0 µM BHA. With, MMC and IAA 
alone there is a significant difference of *** p = < 0.001 and ** p = < 0.01, 
respectively when compared to the negative control. This shows that catalase 
and all three doses of BHA (0.1, 0.5 and 1.0 µM) are able to reduce MNi 
formation. When IAA is treated with catalase or the highest dose of BHA (1.0 
µM), there is a reduction in MNi compared to IAA alone († p = < 0.05), but in 
IAA with BHA 0.1 µM and IAA with 0.5 µM BHA there are no significances (ns 
Δ) compared to IAA alone. 
In MonoNC, the results are generally similar to BiNC. Other findings show a 
smaller number of BiNPB in some groups. 
 
4.3.4 Induction of micronuclei by bromoacetic acid (BAA) 
 
BAA shows results similar to those obtained with exposure to IAA (See Table 
7). In the control group, there were approximately 59.3% of BiNC and 13.2% 
of MultiNC. Unlike IAA, treatment with bromoacetic acid did not cause a 
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decrease of both % of BiNC and MultiNC. The % is generally 45-60% BiNC 
and 5-15% MultiNC for each group. These results are reflected in the higher 
NDI values compared to IAA and CAA (see section below) where all groups 
including negative control show NDIs in the range of 1.63-1.83 with exception 
of groups with catalase (1.50). All NDI values fall in the normal expected range 
of 1.7-1.85 with lymphocyte cultures as described by Fenech (2006). 
The effect of bromoacetic acid on MNi formation was measured in 500 cells of 
BiNC and MonoNC. In BiNC cells, no significant difference of MNi was found 
by comparison with the negative control for the antioxidants on their own (ns), 
or BAA containing catalase and all three doses of BHA (0.1, 0.5 and 1.0 µM). 
With, MMC and BAA alone there is a significant difference of *** p = < 0.001 
and ** p = < 0.01, respectively when compared to the negative control. This 
shows that catalase and all three doses of BHA (0.1, 0.5 and 1.0 µM) are able 
to reduce MNi formation as is case with the IAA. When BAA is treated with 
catalase there is a reduction in MNi compared to BAA alone († p = <0.05) while 
BAA with the 0.1 and 0.5 µM doses of BHA are not significant (ns Δ) compared 
to BAA alone. However, the higher dose of BHA (1.0 µM) is significant († p = 
<0.05). 
In MonoNC, the results are generally similar to BiNC, where treatment of 
samples with BAA alone is significantly different compared to the negative 
control at († p = < 0.05). BAA treated with catalase and 0.1 µM BHA are not 
significantly different (∆ p = < 0.05) compared to BAA alone, but higher doses 
of BAA and BHA (0.5 µM and 1.0 µM) are significant († p = < 0.05). Like IAA, 
in addition to NPBs, NBUDs were also observed in some treatment groups. 
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4.3.5 Induction of micronuclei by chloroacetic acid (CAA) 
 
CAA shows similar patterns of results to IAA (See Table 8). In terms of % BiNC 
and % MultiNC, like IAA, the negative control group contain more binucleated 
cells - 52% of BiNC, slightly more compared to most other treatment groups 
including the positive control. The % of MultiNC, is 11.3%, slightly more than 
all other treatment groups. The NDI value of negative control is 1.74, while the 
NDI values for rest of all treatment groups is in the range of 1.45-1.70, falling 
within normal NDI range for lymphocytes.  
The effect of chloroacetic acid at the micromole (µM) level on MN formation 
was measured in 500 cells of BiNC and MonoNC. In BiNC cells, no significant 
difference of MNi was found by comparison with the negative control for the 
antioxidants on their own (ns), or CAA containing catalase and CAA containing 
and all three doses of BHA (0.1, 0.5 and 1.0 µM). With, MMC and CAA alone 
there is a significant difference of *** p = < 0.001 and ** p = < 0.01, respectively 
when compared to the negative control. When CAA is treated with catalase or 
the highest dose of BHA (1.0 µM), there is a reduction in MNi compared to 
CAA alone († p = <0.05) but CAA with BHA 0.1 µM and CAA with 0.5 µM BHA 
are not significant (ns †) compared to CAA alone, similar to IAA and BAA. 
In MonoNC, the results are generally similar to BiNC. MMC and CAA are 
significantly different compared to the negative control at *** p = < 0.001 and 
* p = < 0.05, respectively. Unlike BAA in MonoNC, neither antioxidant is able 
to reduce MN formation (ns †). 
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4.3.6 General overview of all HAAs: 
 
In general, results are similar for all three HAAs, with the greatest micronuclei 
(MNi) induction seen in bi-nucleated (BiNC) cells in the HAA treated samples 
when compared to the negative control group (p = ** < 0.01) and a reduction 
in the presence of catalase and/or BHA when compared to HAA alone. MNi 
induction caused by all three HAAs was less, but near to levels of MNi 
induction following exposure to MMC (positive control), which showed the 
greatest significant difference for all three HAAs experiments of p = *** <0.001.  
 
4.3.7 Statistics: 
 
Statistics from the Chi-squared test generally indicated MNi reduction in all 
HAAs following antioxidant exposure to catalase or BHA 1.0 µM with a 
significant difference of p = † < 0.05 in BiNC cells. The nuclear division index 
(NDI) values are the same for all three HAAs, within the normal expected 
range of 1.3-2.0.  
 
4.3.8 Confounding factors: 
 
There were no confounding effects. All individuals were non-smoking. 
Approximately, 50 % were female and 50 % were male for the micronucleus 
assay and there appeared to be no differences due to gender. The ages 
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ranged from 21-40 years and results for all individuals gave similar responses, 
regardless of age. 
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Table 6: shows various cytological scoring parameters, including cell mitotic status (BiNC, MonoNC and MultiNC), NDI and chromosomal 
damage/instability parameters in the form of NPBs and NBUDs in lymphocytes following exposure to iodoacetic acid. In general, MNi induction 
increase in presence of IAA but reduce with addition of antioxidants as shown by the above cytological scoring parameters. 
 
    
NDI % BiNC % Multi 
MNi in BiNC cells  Mono 
  Treatment Group BiMNi BiNPB BiBuds  MNi  
  Control 1.79 ± 0.02 59.20 ± 2.60 10.10 ± 2.10 2.5 ± 2.50 0 ± 0.00 0 ± 0.00 1 ± 1.00 
  MMC (0.4 µM) 1.61 ± 0.03 49.10 ± 4.30 5.30 ± 1.30 62.00*** ± 4.00 0 ± 0.00 0.5 ± 0.50 21.00 ns ± 14.50 
  Catalase (2,500 U/ml) 1.57 ± 0.13 50.40 ± 15.00 3.20 ± 1.40 0.50 ns ± 0.50 0 ± 0.00 0 ± 0.00 1.00 ns ± 1.00 
  BHA (0.1 µM)  1.63 ± 0.02 46.70 ± 3.70 8.00 ± 0.60 7.50 ns ± 2.50 0.5 ± 0.50 0 ± 0.00 4.00 ns ± 2.50 
IAA 
BHA (0.5 µM)  1.64 ± 0.28 47.10 ± 13.50 8.30 ± 7.10 2.00 ns ± 1.00 0 ± 0.00 0 ± 0.00 1.00 ns ± 4.50 
BHA (1 µM)  1.60 ± 0.15 44.70 ± 11.50 7.70 ± 1.70 5.50 ns ± 1.50 1 ± 1.00 1 ± 1.00 0.00 ns ± 3.50 
  IAA (6.25 µM) 1.40 ± 0.09 40.80 ± 12.80 1.50 ± 0.10 48.00** ± 3.00 0 ± 0.00 0 ± 0.00 28.00 ns ± 11.50 
  IAA (6.25 µM)  + Catalase (2,500 U/ml) 1.44 ± 0.11 42.90 ± 11.10 0.23 ± 0.18 15.50 ns (†) ± 1.50 0 ± 0.00 0 ± 0.00 8.00 ns (ns†) ± 14.00 
  IAA (6.25 µM) + BHA (0.1 µM)  1.55 ± 0.16 40.10 ± 7.70 7.80 ± 4.20 28.50 ns (ns†) ± 14.50 3 ± 3.00 0.5 ± 0.50 2.00 ns (ns†) ± 22.00 
  IAA (6.25 µM) + BHA (0.5 µM)  1.43 ± 0.06 39.90 ± 8.10 1.25 ± 1.15 28.50 ns (ns†) ± 11.50 1.5 ± 1.50 0.5 ± 0.50 2.00 ns (ns†) ± 19.50 
  IAA (6.25 µM) + BHA (1.0 µM)  1.59 ± 0.07 52.60 ± 4.80 3.10 ± 1.50 15.00 ns (†) ± 3.00 1 ± 1.00 0 ± 0.00 4.00 ns (ns†) ± 5.50 
 
 
NDI = the nuclear division index 
BiNC = Binucleated cells, % BiNC, is % expressed out of all types of 500 cells scored. 
MonoNC = Mononucleated cells 
MultiNC = Multinucleated cells % MultiNC, is % expressed out of all types of 500 cells scored. 
MNi = Micronuclei score/500 cells each of BiNC and MonoNC 
 
Chi-Squared Statistics X2 was used determine significant differences:  
Where * is used to compare all groups to the negative control. * p = < 0.05, ** p = < 0.01, *** p = < 0.001 and * ns ‘(ns*)’ = not significant. 
Where † is used to compare IAA with antioxidant to IAA alone. † p = < 0.05, † p = < 0.01, † p = < 0.001 and † ns ‘(ns†)’ = not significant. 
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Table 7: shows various cytological scoring parameters, including cell mitotic status (BiNC, MonoNC, and MultiNC), NDI and chromosomal 
damage/instability parameters in the form of NPBs and NBUDs in lymphocytes following exposure to iodoacetic acid. In general, MNi induction 
increase in presence of BAA but reduce with addition of antioxidants as shown by the above cytological scoring parameters. 
 
    
NDI % BiNC % Multi 
MNi in BiNC cells  Mono 
  Treatment Group BiMNi BiNPB BiBuds  MNi  
  Control 1.86 ± 0.03 59.30 ± 2.70 13.20 ± 3.20 3 ± 1.00 0 ± 0.00 0 ± 0.00 0.5 ± 0.50 
  MMC (0.4 µM) 1.74 ± 0.11 56.60 ± 4.80 12.50 ± 1.10 56.00 *** ± 3.00 1.5 ± 1.50 0.5 ± 0.50 21.50 ns ± 14.50 
  Catalase (2,500 U/ml) 1.68 ± 0.25 53.40 ± 15.00 7.50 ± 4.90 3.00 ns ± 2.00 0 ± 0.00 0 ± 0.00 1.00 ns ± 1.00 
  BHA (0.1 µM)  1.73 ± 0.10 55.80 ± 0.80 16.50 ± 0.50 1.50 ns ± 0.00 0 ± 0.00 0 ± 1.50 1.50 ns ± 11.10 
BAA 
BHA (0.5 µM)  1.82 ± 0.02 67.90 ± 4.10 12.20 ± 6.20 2.00 ns ± 1.00 0 ± 0.00 0 ± 0.00 0.50 ns  ± 0.50 
BHA (1 µM)  1.74 ± 0.10 66.70 ± 5.70 7.50 ± 6.30 3.00 ns ± 1.00 0.5 ± 0.50 0 ± 0.00 0.00 ns ± 0.00 
  BAA (6.25 µM) 1.69 ± 0.08 57.40 ± 4.20 6.80 ± 3.20 50.00 ** ± 2.00 1.5 ± 0.50 0.5 ± 0.50 36.00 * ± 8.00 
  BAA (6.25 µM)  + Catalase (2,500 U/ml) 1.50 ± 0.08 44.00 ± 4.40 3.70 ± 0.90 16.50 ns (†)  ± 1.50 0 ± 0.00 1 ± 1.00 8.50 ns (ns†) ± 2.50 
  BAA (6.25 µM) + BHA (0.1 µM)  1.74 ± 0.09 55.10 ± 4.90 15.50 ± 9.70 32.00 ns (ns†) ± 10.00 0.5 ± 0.50 0 ± 0.00 21.50 ns  (ns†) ± 6.50 
  BAA (6.25 µM) + BHA (0.5 µM)  1.76 ± 0.00 62.70 ± 3.70 11.40 ± 3.00 24.50 ns (ns†) ± 12.50 0.5 ± 0.50 0 ± 0.00 3.50 ns (†) ± 0.50 
  BAA (6.25 µM) + BHA (1.0 µM)  1.78 ± 0.02 51.30 ± 2.70 13.10 ± 2.10 18.00 ns (†) ± 8.00 0.5 ± 0.50 0 ± 0.00 7.50 (ns †) ± 7.50 
 
 
NDI = the nuclear division index 
BiNC = Binucleated cells, % BiNC, is % expressed out of all types of 500 cells scored. 
MonoNC = Mononucleated cells 
MultiNC = Multinucleated cells % MultiNC, is % expressed out of all types of 500 cells scored. 
MNi = Micronuclei score/500 cells each of BiNC and MonoNC 
 
Chi-Squared Statistics X2 was used determine significant differences:  
Where * is used to compare all groups to the negative control. * p = < 0.05, ** p = < 0.01, *** p = < 0.001 and * ns ‘(ns*)’ = not significant. 
Where † is used to compare BAA with antioxidant to BAA alone. † p = < 0.05, † p = < 0.01, † p = < 0.001 and † ns ‘(ns†)’ = not significant. 
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Table 8: shows various cytological scoring parameters, including cell mitotic status (BiNC, MonoNC, and MultiNC), NDI and chromosomal 
damage/instability parameters in the form of NPBs and NBUDs in lymphocytes following exposure to iodoacetic acid. In general, MNi induction 
increase in presence of CAA but reduce with addition of antioxidants as shown by the above cytological scoring parameters. 
 
    
NDI % BiNC % Multi 
MNi in BiNC cells  Mono 
  Treatment Group BiMNi BiNPB BiBuds  MNi  
  Control 1.74 ± 0.28 52.00 ± 6.20 11.30 ± 10.90 3 ± 1.00 0 ± 0.00 0 ± 0.00 1.5 ± 1.50 
  MMC (0.4 µM) 1.62 ± 0.27 47.90 ± 12.90 7.10 ± 6.50 58.50*** ± 4.50 3 ± 1.00 1.5 ± 0.50 57.50*** ± 33.50 
  Catalase (2,500 U/ml) 1.59 ± 0.21 45.20 ± 12.80 7.10 ± 4.10 1.50 ns ± 0.50 0 ± 0.00 0 ± 0.00 1.50 ns ± 1.50 
  BHA (0.1 µM)  1.56 ± 0.22 43.20 ± 12.80 5.90 ± 5.10 3.50 ns ± 0.50 0 ± 0.00 0 ± 0.00 3.00 ns  ± 0.00 
CAA 
BHA (0.5 µM)  1.61 ± 0.23 44.80 ± 7.20 8.90 ± 7.10 3.50 ns ± 1.50 0 ± 0.00 0 ± 0.00 3.00 ns ± 3.00 
BHA (1 µM)  1.47 ± 0.05 44.80 ± 11.20 2.90 ± 1.30 3.00 ns ± 0.00 0 ± 0.00 0 ± 0.00 3.00 ns  ± 0.00 
  CAA (62.5 µM) 1.59 ± 0.27 44.40 ± 13.20 7.50 ± 6.70 45.00** ± 7.00 1 ± 1.00 1 ± 1.00 40.50* ± 20.50 
  CAA (62.5 µM)  + Catalase (2,500 U/ml) 1.55 ± 0.17 44.00 ± 12.20 5.30 ± 2.50 14.00 ns (†) ± 2.50 1.5 ± 1.50 0.5 ± 0.50 24.00 ns (ns†) ± 11.00 
  CAA (62.5 µM) + BHA (0.1 µM)  1.59 ± 0.21 46.60 ± 9.00 6.20 ± 6.20 24.50  ns (ns†) ± 11.50 0 ± 0.00 0.5 ± 0.50 22.50 ns (ns†) ± 17.50 
  CAA (62.5 µM) + BHA (0.5 µM)  1.51 ± 0.10 38.90 ± 5.10 5.80 ± 2.60 21.00 ns (ns†) ± 18.00 0.5 ± 0.50 1.5 ± 1.50 23.50 ns (ns†) ± 19.50 
  CAA (62.5 µM) + BHA (1.0 µM)  1.56 ± 0.18 43.60 ± 10.00 6.20 ± 4.20 12.50 ns (†) ± 8.50 1.5 ± 0.50 0.5 ± 0.50 21.00 ns (ns†) ± 19.50 
 
 
NDI = the nuclear division index 
BiNC = Binucleated cells, % BiNC, is % expressed out of all types of 500 cells scored. 
MonoNC = Mononucleated cells 
MultiNC = Multinucleated cells % MultiNC, is % expressed out of all types of 500 cells scored. 
MNi = Micronuclei score/500 cells each of BiNC and MonoNC 
 
Chi-Squared Statistics X2 was used determine significant differences:  
Where * is used to compare all groups to the negative control. * p = < 0.05, ** p = < 0.01, *** p = < 0.001 and * ns ‘(ns*)’ = not significant. 
Where † is used to compare CAA with antioxidant to CAA alone. † p = < 0.05, † p = < 0.01, † p = < 0.001 and † ns ‘(ns†)’ = not significant. 
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4.4 Discussion 
 
The CBMN assay is a test deployed to measure the ability of genotoxic agents 
to induce both clastogenic and/or aneugenic effects in cells (Fenech, 2000; 
Liviac et al., 2010). Haloacetic acids have not been examined or reported as 
such using the Cytokinesis-block Micronucleus assay, in particular with 
lymphocytes. This opened up the feasibility to explore and establish MNi 
induction in lymphocytes exposed to HAAs using this technique. As discussed 
in the introduction, ingestion, showering, bathing and swimming are alternative 
routes of exposure to DBPs in addition to tap water consumption (Kogevinas 
et al., 2010; Nieuwenhuijsen et al., 2000). The closely related DBPs group – 
the trihalomethanes (THMs) have been studied by Kogevinas et al. (2010). 
Blood obtained from swimmers exposed to chlorinated water was obtained 
before and an hour after swimming and it was found that MNi frequency was 
increased in lymphocytes after swimming, with higher concentrations of 
brominated THMs. However, another study has demonstrated that five doses 
each of IAA, BAA and CAA were not able to increase significantly the 
frequency of MNi in BiNC TK6 cells (Liviac et al., 2010).  
 
In this study, results from the CBMN assay performed on lymphocytes 
exposed to IAA, BAA and CAA has demonstrated MNi induction with all HAAs, 
unlike in TK6 cells. Together with the findings of (Kogevinas et al., 2010) these 
results suggest that MNi can form in lymphocytes when exposed to DBPs and 
whilst in TK6 lymphoblastoid cells this is not the case. However, further work 
will be needed to confirm this point (repeating of experiments), since the data 
for the micronucleus test only act as an indicator at this point. Although the 
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general trend shows greater MNi frequency in HAA alone and a reduction in 
the presence of either catalase or BHA or both, there are differences of MNi in 
binucleated cells and mononucleated cells, where for example with CAA, MNi 
in BiNC are significantly reduced with exposure to CAA in the presence of 
catalase or 1.0 µM BHA, but not in the MonoNC and there are cases of the 
opposite effects as in IAA and BAA, suggesting cell division kinetics may be a 
factor. However as mentioned by Fenech (2006), restricting MNi data in BiNC 
is important as it addresses any confounding effects due to suboptimal cell 
division kinetics. The Chi-squared data showed catalase as being effective 
antioxidant in reducing MNi in all three HAAs; however, data for BHA showed 
mixed results but nevertheless the results provides a good indication and 
direction for further investigation.  
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Chapter 5 – Implications of nano-compounds 
in lymphocytes from on respiratory disease 
patients using the Cytokinesis-block 
Micronucleus assay 
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5.1 Introduction  
 
Good health and wellbeing is an important aspect of life. Healthcare scientists 
and professionals around the world work to address health issues and find 
solutions, diagnosis and treatments to diseases. Respiratory diseases, like 
asthma and lung cancer are amongst the most common health conditions 
affecting individuals. In this project respiratory diseases (asthma, COPD and 
lung cancer) have been the focus of the study.  
Asthma is a common and potentially serious chronic disease, affecting people 
of all ethnic backgrounds, children and adults alike. The disease is 
characterised by reversibility of airways constriction, with recurring symptoms, 
like coughing, wheezing, tightness of the chest and shortness of breath. 
Serious consequences of the condition can lead to individuals with the 
conditions to have, limitations to activity, and asthma attacks and can prove 
fatal. The disease itself is affected by genetics and/or the environmental 
factors and often the inflammatory nature of this disease affects people with 
asthma at night or in the morning (Buist, 2002; Masoli et al., 2004).  
Chronic obstructive pulmonary disease (COPD), is also a chronic 
inflammatory disease, and has similar features to asthma. These include, 
small airways, limited airflow, and also arises due to genetic and 
environmental factors and is characterised by mucus and bronchoconstriction 
(Buist, 2002). Cigarette smoking is the major cause of COPD (Bhattacharya 
et al., 2011). However, the difference between asthma and COPD patients is 
the type of inflammation which can subsequently affect the response to 
pharmacological agents. In asthma the airway can be remodelled, with partly 
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reversible airflow obstruction, but COPD is a disease, in which the air flow 
limitation is not fully reversible. This limitation is slowly progressive and usually 
results from an abnormal response of the lungs to noxious particles or gas 
(Bhattacharya et al., 2011; Buist, 2002)  
Lung cancer is a leading cause of cancer, with 1.4 million deaths worldwide 
(Thun et al., 2008). In lung cancer, uncontrolled hallmarks of cancer, like cell 
proliferation are triggered by exposure to chemicals in cigarette smoke, either 
through primary exposure (smoking) or indirect exposure to second hand 
smoke. Common symptoms include, weight loss, coughing, wheezing and 
shortness of breath (Thun et al., 2008). If there is another factor involved in 
combination with smoking, such as exposure to asbestos, the chance of lung 
cancer incidence greatly increases (O'Reilly et al., 2007). Hence, on-going 
research is important to help and manage individuals with these conditions. In 
this chapter, blood from healthy control individuals, asthma, COPD and lung 
cancer patients have been analysed using the CBMN assay after exposure to 
NSAIDs.   
The significance of the Cytokinesis-block micronucleus assay (CBMN) assay, 
has been described in the previous chapter (4), discussing the importance of 
using the cell cycle regulation as a means of detecting damaged DNA in cells 
that have been exposed to genotoxic agents (Collins et al., 1997; Fenech, 
2000). The assay has emerged as one of the preferred methods for assessing 
chromosome damage because it enables both chromosome loss and 
chromosome breakage to be measured reliably. Certain chemicals can be 
mutagenic and may lead to the induction of micronuclei in cells at the 
interphase stage. This occurs as a consequence of interference with 
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chromosome structure and/or segregation (Fenech, 2002, 2007; Kirsch-
Volders et al., 1997; Kirsch-Volders et al., 2000). 
Various studies have shown the direct effects of NSAIDs on tumour biology, 
with an anti-tumour effect on several of the hallmarks of cancer, including 
proliferative capacity, evasion of apoptosis and cell cycle regulation, and 
invasive capability of tumour cells (Park et al., 2014). The focus of this study 
is to observe the effects of NSAIDs in patients with respiratory diseases. DNA 
damage in peripheral whole blood of healthy individuals and respiratory 
disease patients (asthma, chronic COPD and lung cancer) have been 
compared following the exposure to the bulk and nanoparticle versions of 
aspirin and ibuprofen in the and in the micronucleus assay and the nano 
compounds were compared to their bulk equivalents for each blood sample. 
This is the first study to our group’s knowledge that the nano forms of these 
compounds have been investigated at the cellular level ex-vivo / in-vitro.  
The CBMN assay was performed to detect MNi inductions following exposure 
to the NSAIDs - ASP B, ASP N, IBU N and IBU B at concentrations of 250 
µg/ml. 13 samples were used in this study, 3 healthy control individuals, 2 
asthma patients, 2 COPD patients, 3 COPD & lung nodule patients (which 
were combined), and 3 lung cancer patients. MNi induction was scored in 
BiNC, including BiNC with NPBs and BiNC with NBUDs as well as in MonoNC. 
All types of cells up to 1000 were scored, from which percentages of BiNC and 
MultiNC were calculated and together with the number of MonoNC, the nuclear 
division index (NDI) was calculated. 
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5.2 Materials and Methods  
 
5.2.1 Materials 
 
The materials required for this study have been described in section 2.4 of 
Materials and Methods chapter. 
5.2.2 Methods 
 
The sample collection of whole blood was obtained as described in section 
2.5.2. The CBMN assay was deployed in thirteen different experiments as 
described in sections 2.5.3 -2.5.8. Treatment of standard controls, ASP B, ASP 
N, IBU B and IBU N for each experiment are described in section in section 
2.5.4 (See Table 5). 
5.2.3 Statistical Analysis.  
 
All slides were coded and scored as described in protocols (Fenech, 2007). A 
total of 1000 of all cell types (mononucleated, binucleated and multinucleated 
cells) were scored to determine percentages and NDI values. BiNC and 
MonoNC were then scored further until 1000 cells each, observing for MNi 
found per 1000 cells.  A standard Chi-Squared test was performed for 
statistical analysis for MNi induction using the equation as described in chapter 
4. 
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5.3 Results 
 
5.3.1 Particle size analysis 
 
The particle size distribution of aspirin and ibuprofen nano-suspensions (Table 
9a, below) and bulk powders (Table 9b, below) were determined using the 
dynamic light scattering technique of the Zetasizer Nano ZS machine, (See 
Table 9a and 9b below). 
Images of the nanoparticles were obtained using transmission electron 
microscopy (TEM), as described in Materials and Methods (Section 2.4.2 and 
2.4.3). The images showed that the aspirin crystals are slightly larger than 
those of ibuprofen as was shown by the laser diffraction measurements (see 
Figures 13 & 14 below). The images show some smaller particles on the side 
which might be small crystals of the drugs or it could be aggregates of the 
polymer used to stabilise the crystals.  
5.3.2 Preliminary work 
 
Three different dosages of both bulk and nano, of aspirin and ibuprofen each, 
were used to test for MNi frequency in blood samples. The number of MNi is 
an indicator of DNA damage. The doses used were 250, 500, 1000 µg/ml. In 
the tests it was determined that the 250 µg/ml dosage was optimum to use for 
all four compounds without inducing total cell cytotoxicity. Graph(s) 5a-b 
(below), are a visual representation of the MNi frequencies observed in BiNC 
and MonoNC cells, and Table 10 (also below) is the tabulated form of these 
data. This shows additional information like the NDI, percentages of 
binucleated cells (BiNC) and multi-nucleate cells (MultiNC), the number of MNI 
119 
 
in BiNC cells, and also the cells which have nuclear budding or nuclear 
plasmid bridges (Fenech, 2007). 
5.3.3 General overview of data in Binucleated Cells (BiNC) 
 
For healthy control individuals and all patients groups (See graphs 5a-5d) 
there was an increase in the number of MNi in BiNC cells treated with both 
aspirin and ibuprofen, in the bulk form when compared to the negative control. 
When blood samples were treated with the nano form, the number of MNi was 
generally similar to control values in healthy individuals and all three patient 
groups. Generally, there is a pattern, in the form of reduction in the number of 
MNi seen for the nano form of the aspirin compared to the bulk form and this 
is much the same for ibuprofen with a reduction of MNi frequencies for the 
nano form compared to its bulk equivalent.  
5.3.4 General overview of data in mononucleated Cells (MonoNC) 
 
For healthy control individuals and all patient groups, the number of MNi is 
generally higher in MonoNC cells compared to BiNC cells, for all samples. 
There is an increase in the number of MNi found in cells treated with both 
aspirin and ibuprofen, in the bulk form when compared to the negative control. 
For comparisons between the bulk and the nano form, there is a reduction for 
the nano form of aspirin and ibuprofen, when compared to their bulk 
equivalents, except in the Lung Cancer group with contrasting results that 
show reduction for the bulk form, compared to the nano form.  
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5.3.5 Exceptions in the general trends of data described above  
 
Performing Chi-squared tests was not possible due to the nature of large 
sample size (1000 cells), but fewer patient numbers. Graphs 5a-d were 
constructed and standard errors were calculated. These standard errors can 
be seen as error bars on the graphs. As can be seen in many sample groups, 
the upper and lower error bars for some samples do not overlap, 
demonstrating a strong indication for differences between these samples. 
Alongside the similar trends of results in healthy individuals and all asthma, 
COPD and lung cancer patients, there were some contrasting results. For the 
patient groups of asthma and COPD, it can be seen that in BiNC cells, there 
are lower MNi frequencies found in samples that were treated with Aspirin 
nano compared to the negative controls, suggesting that nanoparticle of 
aspirin may show some benefits in reducing DNA damage. These data are 
based on MNI recorded per 1000 cells observed – a strong statistical power 
with high number of cells scored (Fenech, 2007). 
5.3.6 Data for NDI, NPBs and NBUDs in cells 
 
Table 10 further below, shows the data for various cytological scoring 
parameters on each sample, per treatment group.  
Nuclear division index (NDI): NDI values for almost all cell cultures are 
between 1.3-1.6, which is within the expected NDI range of 1.3-2.0, indicating 
that the cell cultures were satisfactory to use with a good rate of cell divisions. 
The only minor exception is the aspirin nano samples of healthy individuals, 
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which was 1.27, based on an average of three blood samples. In these 
samples, scoring was still possible as scoring had been achieved up to 1000 
cells on all three control samples. 
Percentage of dividing cells: The percentage of BiNC cells out of 1000 cells 
are between ~20% to 45%, and MultiNC cells, percentage ranges from 
between ~1.1% to 10 % out of 1000 cells, sufficient to enable scoring of all 
samples. 
BiNC cells with nucleoplasmic bridges (NBPs): NPBs – a biomarker for 
dicentric chromosomes, were observed in all samples. In all samples the 
number ranges from 1-8 NPBs, showing some evidence of chromosome 
rearrangements occurring during cell division.  
BiNC cells with nuclear buds (NBUDs): NBUDs – a biomarker for gene 
amplification, were also observed and their presence was even less than 
NPBs, between 1-2 NBUDs were found in some samples in patient groups, 
but not in the healthy individuals group. 
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Graph(s) 5a-d: show the MNI frequency data in BiNC and MonoNC for the control 
group (Figure 5a), asthma (Figure 5b), COPD (Figure 5c) and Lung cancer patients 
(Figure 5d) with mean standard error values +.  
 
 
 
Figure 5a: Healthy control samples treated with ASP B, ASP N, and IBU B & IBU N: 
Negative standard control show the lowest MNi frequency per 1000 cells in healthy 
individuals, with ASP N, showing also similar levels to the control sample. Both ASP 
N and IBU N have a lower MNi frequency than their respective bulk equivalents 
(ASP B& IBU B). 
 
 
 
Figure 5b: Asthma patient samples treated with ASP B, ASP N, and IBU B & IBU B: 
In asthma patients, the lowest MNi frequency per 1000 BiNC cells is seen in sample 
treated with ASP N, lower than the negative control.  All other NSAID samples have 
higher MNi frequencies than the negative control. Both ASP N and IBU N also have 
a lower MNi frequency than their respective bulk equivalents (ASP B & IBU B). 
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Figure 5c: COPD Patient samples (including Lung Nodule) treated with ASP B, 
ASP N, and IBU B & IBU B: In COPD patients, the lowest MNi frequency per 1000 
BiNC cells is seen in sample treated with ASP N, lower than the negative control.  
All other NSAID samples have higher MNi frequencies than the negative control. 
However, IBU N in BiNC cells not so by much. Both ASP N and IBU N also have a 
lower MNi frequency than their respective bulk equivalents (ASP B & IBU B). 
 
 
 
 
Figure 5d: Lung cancer patients samples treated with ASP B, ASP N, and IBU B & 
IBU B: Negative control levels show the lowest MNi frequency per 1000 cells in lung 
cancer samples, with ASP N and IBU N showing higher MNI frequencies. Both ASP 
N and IBU N also have a lower MNi frequency than their respective bulk equivalents 
(ASP B & IBU B). 
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Table 9a: Average particle size, polydispersity index and zeta potential values of 
the nano-suspensions. (n=3). This table was provided by Mohammed Isreb, School 
of Pharmacy, University of Bradford. 
 
Suspension 
name 
Time of 
measurement 
Average 
particle size 
(nm) 
Polydispersity  
index 
Zeta 
potential 
value (mV) 
Ibuprofen 
nano-
suspension 
3% 
Before cells 
treatment 
323±6.4 0.2± 0.01 -2.1 
After cells 
treatment 
340±1.2 0.3±0.001  
Aspirin nano-
suspension 
4% 
Before cells 
treatment 
289±3 0.3±0.03  -6.1 
After cells 
treatment 
299±6.3 0.3 ± 0.05  
 
 
Table 9b: Average particle size (x90) and the volume mean diameter of the bulk 
powder (as received) of aspirin and ibuprofen (n=3). This table was provided by 
Mohammed Isreb, School of Pharmacy, University of Bradford. 
 
 
Suspension 
name 
Average 
particle size 
(µm) 
Volume Mean 
Diameter(µm) 
Ibuprofen 52.80 ± 4.37 20.50 
Aspirin 78.30 ± 0.23 44.57 
125 
 
Table 10 (on the next page) shows various cytological scoring parameters, including cell mitotic status (BiNC, MonoNC, and MultiNC), NDI and 
chromosomal damage/instability parameters in the form of NPBs and NBUDs in lymphocytes following exposure to both bulk and nano forms of 
aspirin and ibuprofen. Control samples for each patient group exhibit fewer MNi than found in samples treated with aspirin and ibuprofen. Table 
9 also shows that in general, when observing numbers of MNi in both cell types, there are less MNi in the nano form of aspirin and ibuprofen 
compared to the bulk form, thus indicating that nano compounds show a reduction in DNA damage, levels of which are comparable to control 
levels in some cases. 
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Subject Treatment Group 
NDI % BiNC % Multi 
MNi in BiNC cells  Mono 
  (Conc. 250 mg/ml) BiMNi BiNPB BiBuds  MNi  
Healthy Untreated Lymphocytes 1.56 ± 0.06 45.6 ± 6.21 5.2 ± 1.67 4.33 ± 1.20 0 ± 0.00 0 ± 0.00 11 ± 4.04 
individuals Aspirin - B 1.34 ± 0.03 21.47 ± 3.67 6.43 ± 0.81 19.67 ± 0.67 0.67 ± 0.67 0 ± 0.00 22.33 ± 2.19 
  Aspirin - N 1.27 ± 0.02 21.27 ± 1.13 2.47 ± 0.73 5.67 ± 2.33 0 ± 0.00 0 ± 0.00 15.33 ± 1.20 
  Ibuprofen - B 1.41 ± 0.03 26.67 ± 4.29 7.33 ± 2.47 15.33 ± 4.48 0.67 ± 0.67 0 ± 0.00 24.67 ± 5.78 
  Ibuprofen - N 1.32 ± 0.06 23.27 ± 2.17 4.53 ± 2.54 8.67 ± 2.03 0 ± 0.00 0 ± 0.00 18 ± 2.52 
Asthma Untreated Lymphocytes 1.59 ± 0.07 34.9 ± 6.50 11.9 ± 6.90 15 ± 9.00 1.5 ± 0.50 0 ± 0.00 14.5 ± 9.50 
  Aspirin - B 1.4 ± 0.10 34 ± 1.70 12.7 ± 13.00 29 ± 13.00 0.5 ± 0.50 1.5 ± 1.50 49 ± 26.00 
  Aspirin - N 1.41 ± 0.02 21 ± 1.60 10 ± 1.60 10.5 ± 3.50 0.5 ± 0.50 0 ± 0.00 23.5 ± 6.50 
  Ibuprofen - B 1.37 ± 0.14 24.25 ± 6.15 6.55 ± 6.15 44.5 ± 1.50 8 ± 8.00 4 ± 4.00 60 ± 6.00 
  Ibuprofen - N 1.42 ± 0.06 25.85 ± 4.40 8 ± 4.40 27.5 ± 15.50 6 ± 6.00 0.5 ± 0.50 30 ± 8.00 
Lung Untreated Lymphocytes 1.4 ± 0.06 32.67 ± 6.91 3.73 ± 0.48 8 ± 2.08 0.33 ± 0.33 0 ± 0.00 12.33 ± 4.41 
Cancer Aspirin - B 1.32 ± 0.06 20.53 ± 0.67 5.87 ± 2.77 23.33 ± 1.33 0.67 ± 0.33 1 ± 0.58 33.67 ± 7.75 
  Aspirin - N 1.35 ± 0.12 19.33 ± 0.27 8 ± 5.94 18 ± 6.51 1.67 ± 1.20 3 ± 2.00 43.67 ± 4.63 
  Ibuprofen - B 1.31 ± 0.02 24.53 ± 5.09 3.57 ± 1.70 35.67 ± 6.67 2 ± 2.00 0 ± 0.00 41 ± 16.46 
  Ibuprofen - N 1.28 ± 0.34 22.87 ± 0.34 2.6 ± 2.48 20 ± 7.25 1.67 ± 0.87 0.33 ± 0.96 49.67 ± 10.62 
COPD &  Untreated Lymphocytes 1.43 ± 0.05 34.92 ± 7.10 3.88 ± 1.71 15.8 ± 2.52 2 ± 1.30 2.2 ± 1.50 16.4 ± 3.41 
COPD with Aspirin - B 1.34 ± 0.04 27.28 ± 1.62 3.12 ± 1.11 25.8 ± 5.89 2.4 ± 1.29 1 ± 0.55 34.2 ± 4.31 
Lung Aspirin - N 1.37 ± 0.03 20.84 ± 2.06 8.2 ± 1.67 11.2 ± 4.09 0.8 ± 0.37 0.2 ± 0.20 24 ± 8.30 
Nodule Ibuprofen - B 1.35 ± 0.06 30.56 ± 6.61 2.32 ± 0.50 25.6 ± 3.28 1.2 ± 0.37 2.4 ± 1.94 32.8 ± 9.44 
  Ibuprofen - N 1.47 ± 0.05 33.62 ± 9.72 7.92 ± 2.81 17.8 ± 4.21 0.6 ± 0.40 0.4 ± 0.40 26.8 ± 5.30 
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Figure: 13: TEM image of aspirin nanoparticles. 
 
 
Figure 14: TEM image of ibuprofen nanoparticles. 
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5.4 Discussion 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX enzyme activity, 
a significant mechanism of action of NSAIDs. The COX enzyme consists of 
two isoforms, the COX-1 enzyme and the COX-2 enzyme. They play a 
significant role in the synthesis of prostaglandins, which plays a role in tumour 
progression (Day and Graham, 2013; Rao and Knaus, 2008). Several studies 
have shown that NSAIDs, like aspirin and ibuprofen exhibit anti-cancer 
activities on several hallmarks of cancer, such as cell proliferation, evasion of 
apoptosis and cell cycle regulation (Burn et al., 2011; Mansouri et al., 2013; 
Park et al., 2014).  
This focus of this study was to investigate aspirin and ibuprofen compounds in 
blood samples from healthy individuals and respiratory disease patients. 
Nanotoxicology has become a vast significant area of interest to scientists, 
who are using this technology to find better ways to improve and/or develop 
current or new forms of diagnosis or treatment. Nanoparticles have the biggest 
advantage of having a smaller size, resulting in a large surface area to volume 
ratio, thereby increasing the reactivity of cells (Dhawan and Sharma, 2010). 
Such particles, are those that are defined as being under 100 nm, however the 
pharmaceutical industry considers sizes up to 1000 nm to be classified as 
nano compounds (Carlin, 2014; Teeguarden et al., 2007). Nanoparticles 
possess the unique capability to accumulate at the site of inflammation, and 
thus are suitable for targeted drug delivery (Elzoghby et al., 2012). 
Nanoparticles are delivered to the targeted site via several nano-carriers which 
protect the drugs from degradation and enhance drug absorption by facilitating 
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diffusion through cell epithelium. These systems can also withstand 
physiological stress or improved biological stability and alter the release 
pattern of the drug (Elzoghby et al., 2011).  
In this study, suspension solutions of aspirin and ibuprofen were prepared with 
solid loads of 4% and 3% (w/w), respectively in deionised water using a 
method described by (Plakkot et al., 2011). The suspension solution of 
deionised water also contained HPMC, polyvinylpyrrolidone K-30 and sodium 
lauryl sulphate (Plakkot et al., 2011). This is followed by a process in which 
milling of these compounds were carried out using Lena nanoceutics 
technology DM-100 machine (Sulaiman 2007). 
Data from the CBMN assay showed an increase in the number of MNi in BiNC 
cells treated with both aspirin and ibuprofen, in the bulk (ASP B & IBU B) form 
when compared to the negative control. In the blood samples that were treated 
with the nano forms of aspirin (ASP N) and ibuprofen (IBU N), the number of 
MNi was generally similar to control values for each of the healthy individuals 
and all three patient groups. Generally, there is a pattern, with lower MNi 
frequency in ASP N compared to ASP B and this is much the same for 
ibuprofen with a reduction of MNi frequency in IBU N compared to IBU B. Cells 
were observed for MNi seen in BiNC and MonoNC, where up to 1000 cells 
were counted.  
The data for MNi frequencies in BiNC was very similar to those in MonoNC. 
The MonoNC cells had higher numbers of MNi in comparison BiNC cells. 
However, the main result of interest is MNi numbers found in BiNC, since this 
constitutes damage occurring after exposure to NSAIDs and during the cell 
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cycle at the cell culture stage. The NDI numbers were found to be within the 
normal expected range, indicating successful division of cells, which were later 
used to score for the MNi data. 
An interesting result seen was that in asthma and COPD patients, where the 
number of MNi was less than the number of MNi at the control levels in BiNC, 
thus providing some early indication that those nanoparticles may have an 
advantage in reducing DNA damage. A parallel study was conducted in the 
Comet assay by Dr. Mojgan Najafzadeh (Researcher at University of 
Bradford). That investigation also showed a reduction in ASP N and IBU N, 
compared to ASP B and IBU B, respectively. Similarly, ASP N had less DNA 
damage compared to the negative controls in healthy individuals, COPD and 
lung cancer patients. Similar reductions were also found with IBU N compared 
to the negative controls in healthy individuals and lung cancer group. This 
study in the CBMN assay and also the one on the Comet assay provide some 
interesting results on NSAID nanoparticles in peripheral lymphocytes (Comet) 
and whole blood (CBMN) and show some potential benefits of nanoparticles. 
Further work and study will be needed to verify and strengthen these data. 
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Chapter 6 – Role of NSAIDs on the repair of 
DNA following exposure to bleomycin 
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6.1 Introduction  
 
The Comet assay is a micro-electrophoretic technique used for direct 
visualisation of DNA damage in mammalian cells (Ostling and Johanson, 
1984). The Comet assay has been recognised for its time efficiency, simplicity, 
sensitivity, and cost effectiveness for analysing genotoxic DNA damage in 
sperm and lymphocytes as shown in previous studies (Anderson et al., 1997a; 
Anderson et al., 1997b; Anderson et al., 1998b; Anderson et al., 2003; Singh 
et al., 1988; Tice et al., 2000). The assay has been a useful method to access 
chemicals for their genotoxicity, usage in human biomonitoring, epidemiology, 
and importantly, also in DNA damage and repair (Collins, 2004). Monitoring 
the repair of DNA is one of the important determinants of cancer susceptibility 
(Gaivao et al., 2009). All cells possess mechanisms of repairing or correcting 
DNA damage before there are permanent changes made to DNA. The method 
of DNA cellular repair is also sometimes known as the challenge assay (Au et 
al., 2010; Azqueta et al., 2014).  
One approach to accessing DNA repair of cells is a process called the in-vitro 
cellular repair assay (also known as the mutagen challenge assay). In this 
method, a genotoxic agent such as mitomycin C, doxorubicin, or bleomycin 
are used to treat cells in order to induce DNA damage to cells, which are then 
incubated. This allows for the monitoring of single stand breaks that re-join 
(and repair themselves) (Azqueta and Collins, 2013; Azqueta et al., 2014). 
After incubation, cells were transferred into fresh buffer and further incubations 
with short time intervals (like 10, 15 minutes etc.) were allowed for DNA repair 
to occur in the absence of genotoxic agents. Levels of DNA damage are then 
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measured from samples at the end of repair and compared to those samples 
not repaired, by analysing and comparing DNA damage repair capabilities in 
the form of a reduction of the DNA damage parameters a reduction of the DNA 
damage parameters - Olive tail moment and % tail DNA. Other than observing 
the repair of single strand breaks, the monitoring of other lesions, like oxidised 
bases (using base excision repair) or altered bases (using nucleotide excision 
repair) can be made possible, by using enzymes which recognise these 
lesions and subsequently, convert these lesions into strand breaks (Azqueta 
and Collins, 2013; Azqueta et al., 2014).  
This study design looks at the former methodology as mentioned above. Cells 
from healthy individuals, asthma, and COPD and lung cancer patients are 
challenged using bleomycin and then allowed to repair DNA damage with no 
bleomycin (BLM) present. Some samples have been allowed to repair DNA 
damage in the presence of NSAIDs. Previous work on NSAIDs using the 
micronucleus assay (Chapter 5) and the Comet assay (personal 
communication with Dr. Mojgan Najafzadeh, University of Bradford) have 
shown the reductions in DNA damage when treated with NSAIDs and to a 
greater extent with the nanoparticle versions. Investigating the influence of 
DNA repair of cells, this study is designed to determine whether these 
compounds also facilitate the repair of DNA or have the opposite effect. 
Bleomycin was used in this study as it has been extensively used in other 
repair assay studies. Several studies have investigated DNA damage and 
repair in cells from cancer patients following bleomycin exposure, such as lung 
cancer and psoriasis patients with basal carcinomas, to name a few (Moller et 
al., 2000; Wei et al., 2005; Zheng et al., 2003). Bleomycin, first discovered in 
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1966, is glycopeptide antibiotic agent that was first isolated from Streptomyces 
verticillus. Bleomycin has been extensively studied in cancer studies because 
of its anti-tumour activities (Chen and Stubbe, 2005; Kawai and Akaza, 2003; 
Umezawa et al., 1966). Bleomycin is commonly used as part of chemotherapy 
regimens for various cancer treatments, such as testicular cancer (Chen and 
Stubbe, 2005; Kawai and Akaza, 2003). Bleomycin that is administered in 
chemotherapy treatment, uses two separate forms of the drug – bleomycin A 
(60%) and bleomycin B (30%), with the addition of other components (Chen 
and Stubbe, 2005). Bleomycin causes damage to the DNA by binding to the 
transition metals (Fe(II) or Cu(l)) and oxygen. In the presence of one-electron 
reductant, the drug is then able to catalyse the formation of single stranded 
breaks (SSBs) and double stranded DNA lesions (Chen and Stubbe, 2005).  
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6.2 Materials and Methods  
 
6.2.1 Materials 
 
The materials required for this study have been described in section 2.6.1 
6.2.2 Methods 
 
Sample collection and isolation of whole blood cells has been described in 
section 2.6.2. The Comet assay was deployed under alkaline conditions as 
described in sections 2.6.4-2.6.7. Treatment groups for all samples have been 
described within this section. Scoring of cells and statistical analysis has been 
described in section 2.6.8 
6.2.3 Study design  
 
This study was conducted to determine the DNA repair capabilities of whole 
blood cells, following bleomycin exposure from healthy control individuals and 
asthma, COPD and lung cancer patients. Following bleomycin exposure for 
30 minutes, cells were allowed to carry out DNA repair in the presence of or in 
the absence of aspirin and ibuprofen, each in nano form and the standard bulk 
form. The aim was to determine the effect of these compounds on the repair 
of DNA Comet cells, by comparing these to two samples; one treated with 
bleomycin and not repaired, and the other treated with bleomycin and repaired 
without any NSAIDs. Three different kinds of statistical analysis were deployed 
(see section 6.2.4 below). 
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6.2.4 Statistical Analysis  
 
All microgels were coded before scoring and 100 cells were scored per 
observation using a microscope equipped with a CCD camera and Computer 
system using Comet Kinetic Imaging Software© 6.0, Liverpool/Andor 
Technology, Belfast, UK. Each experiment was repeated ten times for samples 
from healthy individuals and five times each for asthma, COPD and lung 
cancer samples. Mean data were generated with standard errors.  
Data from Olive tail moment and % Tail DNA values were used to perform 
SPSS statistics (Version 20). Most data were normally distributed, as 
Gaussian normality did not depart for normality for most treatment samples in 
all groups (controls and asthma, COPD and lung cancer patients), as 
determined using Smirnov goodness of fit test. For data that were not normally 
distributed using these tests, their normal distribution was confirmed using 
non-parametric - 2 independent samples test.  
 
Three different kinds of significance were determined:  
Firstly, the significance was compared from all samples to the negative control 
sample, including the bleomycin sample where DNA repair was disallowed (*** 
p = < 0.001, ** p = < 0.01, * p = < 0.05, ns* = > 0.05 not significant).  
 
Secondly, the five samples, (4 samples treated with bleomycin and allowed for 
repair in the presence of NSAIDs (ASP B, ASP N, IBU B & IBU N) and one 
sample that was treated with bleomycin allowing DNA repair in the absence of 
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all four NSAIDs), were all compared to the sample treated with bleomycin 
without allowing DNA repair (††† p = < 0.001, †† p = < 0.01, † p = < 0.05, ns† 
= > 0.05 not significant). 
 
Finally, the samples that were treated with bleomycin and repaired in the 
presence of NSAIDs were compared with each other. ASP N was compared 
to ASP B and IBU N was compared to IBU B (∆∆∆ p = < 0.001, ∆∆ p = < 0.01, 
∆ p = < 0.05, ns∆ = > 0.05 not significant). 
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6.3 Results  
 
6.3.1 Particle size analysis 
 
The particle size distribution of aspirin and ibuprofen nano-suspensions (Table 
9a) and bulk powders (Table 9b) were determined using the dynamic light 
scattering technique of the Zetasizer Nano ZS machine, (See Table 9a and 9b 
in the previous chapter). 
Images of the nanoparticles were obtained using transmission electron 
microscopy (TEM), as described in Materials and methods (Section 2.4.2 and 
2.4.3). The images showed that the aspirin crystals are slightly larger than 
those of ibuprofen as was shown by the laser diffraction measurements (see 
Figures 15 & 16 below). The images show some smaller particles on the side 
which might be small crystals of the drugs or it could be aggregates of the 
polymer used to stabilise the crystals.  
 
6.3.2 Cell viability 
 
Cell survival was measured before samples were used. Cell viability was 
measured in samples up to a cut-off point of 75% using trypan blue exclusion, 
so avoiding artefacts due to toxicity. Generally, the viability was in excess of 
90%. Viability was measured in samples immediately before and after 
treatment. (Gopalan et al., 2011; Henderson et al., 1998). 
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6.3.3 Preliminary investigations 
 
Dose response experiments with bleomycin (BML) were implemented, to find 
the dose that gave the maximum repair difference, from the unrepaired 
samples (incubation only) and to those incubated and repaired. End-
concentration dose ranges of 1 µg/ml, 2.5 µg/ml, 5 µg/ml, 7.5 µg/ml and 10 
µg/ml were used in dose response experiments, which were repeated twice 
and 7.5 µg/ml of bleomycin was found to be the most appropriate 
concentration to deploy with NSAIDs. 
6.3.4 Statistics 
 
Data did not depart from normality using Gaussian normality for most 
treatment samples in all groups, as determined using Smirnov goodness of fit 
test. For samples where Gaussian normality was violated (non-normally 
distributed samples), non-parametric statistics were considered adequate for 
the analysis of the data. A p-value of < 0.05 was considered significant. All 
analyses were performed using SPSS for windows statistical package (version 
20). 
6.3.5 Overview of results 
 
In general, the data for Olive tail moments and % tail DNA are similar for all 
groups of patients and the individual treatment types within them. All treatment 
samples have greater levels of DNA damage which are, significantly different 
compared to the negative control sample (p = ** < 0.01 or p = *** < 0.001), with 
the exception to both nanos (nano aspirin & nano ibuprofen). Statistics are 
described below (Section 6.3.5). The reduction in DNA damage after repair is 
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greater to the extent that DNA damage found in these groups is not 
significantly different from DNA damage in the control groups. However, there 
are some individual differences between results, which are described below. 
6.3.6 Olive tail moment data 
 
 
Healthy control individuals:  
Results were analysed using Olive tail moment data. In healthy individuals 
(Graph 6a), all samples showed significant increase of DNA damage 
compared to the negative control at a level of significance of *** p = < 0.001, 
except for ASP B was significantly different at ** p = < 0.01 and both ASP N 
and IBU which are not significant (ns*) when compared to the negative control, 
suggesting the nanoparticles are able to increase DNA repair. All samples 
were then compared to the sample treated with bleomycin only (no repair), 
and all were significant with a significance of ††† p = < 0.001. When the 
nanoparticles were compared to the bulk samples, DNA damage in ASP N 
was significantly lower compared to ASP B (∆∆ p = < 0.01), however IBU N 
compared to IBU B was not significant (ns∆), although a reduction can be 
seen. 
 
Asthma patients:  
In asthma patients (Graph 6b), all samples were significantly different 
compared to the negative control with a significance of *** p = < 0.001, except 
for ASP B, ASP N and IBU N, which were not significant (ns*) when compared 
to the negative control. This suggests, that the nanoparticles are able to 
increase DNA repair, as is the bulk form of aspirin. All samples were then 
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compared to the sample treated with bleomycin only (no repair), and all were 
significantly different with a significance of ††† p = < 0.001, expect for sample 
with bleomycin treatment and repair without NSAIDs, which was significantly 
different by †† p = < 0.01. When the nanoparticles were compared to the bulk 
samples, DNA damage in ASP N was lower compared to ASP B but not 
significant (ns∆), however, IBU N when compared to IBU B was significant  (∆∆ 
p = < 0.01). 
 
COPD patients:  
In COPD patients (Graph 6c), all samples were significantly different 
compared to the negative control with a significance of *** p = < 0.001, except 
for ASP B, ASP N and IBU N, which are not significant when compared to the 
negative control, suggesting the nanoparticles are able to increase DNA 
repair, as is the bulk form of aspirin. All samples were then compared to the 
sample treated with bleomycin only (no repair), and all were significantly 
different with a significance of ††† p = < 0.001. When the nanoparticles were 
compared to the bulk samples, DNA damage in ASP N, IBU N was lower 
compared to ASP B and IBU B, respectively, although not significant for Olive 
tail moment data (ns∆).  
 
Lung cancer patients:  
In lung cancer patients (Graph 6d), all samples are significantly different 
compared to the negative control with a significance of *** p = < 0.001, except 
for all NSAIDs (ASP B, ASP N, IBU N and IBU B) which are not significant 
(ns*) when compared to the negative control. All samples were then compared 
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to the sample treated with bleomycin only (no repair), and all were significantly 
different with a significance of ††† p = < 0.001, expect for sample with 
bleomycin treatment and repair without NSAIDs, which was not significant 
(ns†). As with COPD data above, when the nanoparticles were compared to 
the bulk samples, DNA damage in ASP N, IBU N was lower compared to ASP 
B and IBU B, respectively, although not significant for Olive tail moment data 
(ns∆).  
 
6.3.7 Percentage (%) tail DNA data 
 
Healthy control individuals:  
Results were analysed using % tail DNA data. In healthy individuals (Graph 
7a), all samples were significantly different compared to the negative control 
with a significance of *** p = < 0.001, except for ASP N which is not significant 
(ns*) when compared to the negative control, suggesting ASP N is able to 
increase DNA repair. All samples were then compared to the sample treated 
with bleomycin only (no repair), and all were significant with a significance of 
††† p = < 0.001. When the nanoparticles were compared to the bulk samples, 
DNA damage in ASP N and IBU N were significantly lower compared to their 
bulk equivalents - ASP B and IBU B, respectively (∆∆∆ p = < 0.001). 
 
Asthma patients:  
In asthma patients (Graph 7b), all samples are significantly different compared 
to the negative control with a significance of *** p = < 0.001, except for ASP B 
which is significantly different by * p = < 0.05 and both ASP N and IBU N which 
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are not significant (ns*) when compared to the negative control. All samples 
were then compared to the sample treated with bleomycin only (no repair), 
and all were significantly different with a significance of ††† p = < 0.001). When 
the nanoparticles were compared to the bulk samples, DNA damage in ASP 
N was lower compared to ASP B but not significant (ns∆), however IBU N 
when compared to IBU B was significant  (∆∆∆ p = < 0.001). 
 
COPD patients:  
In COPD patients (Graph 7c), all samples were significantly different 
compared to the negative control with a significance of *** p = < 0.001, except 
for IBU N which is significantly different at * p = < 0.05, IBU B which is 
significantly different by ** p  = < 0.01, and ASP B and ASP N, which are not 
significant when compared to the negative control. All samples were then 
compared to the sample treated with bleomycin only (no repair), and all were 
significantly different with a significance of ††† p = < 0.001 except IBU N (†† 
p = < 0.01). When the nanoparticles were compared to the bulk samples, DNA 
damage in ASP N and IBU N was lower compared to ASP B and IBU B, 
respectively, although not significant for % tail DNA data (ns∆).  
 
Lung cancer patients:  
In lung cancer patients (Graph 7d), all samples were significantly different 
compared to the negative control with a significance of *** p = < 0.001, except 
for IBU B which was significantly different at ** p = < 0.01, and ASP B, ASP N 
and IBU B which were not significant (ns*) when compared to the negative 
control, suggesting both the bulk and nanoparticles are able to increase DNA 
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repair. All samples were then compared to the sample treated with bleomycin 
only (no repair), and all were significantly different with a significance of ††† p 
= < 0.001, expect for the sample with bleomycin treatment and repair without 
NSAIDs, which was not significantly (ns†). As with COPD data above, when 
the nanoparticles were compared to the bulk samples, DNA damage in ASP 
N, IBU N was lower compared to ASP B and IBU B, respectively, although not 
significant for Olive tail moment data (ns∆).  
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Graph(s) 6 (OTM)/ 7 (%tail DNA) a-d: show the levels of DNA damage for the 
healthy individuals group (Figure 6a/7a), asthma (Figure 6b/7b), COPD (Figure 
6c/7c) and Lung cancer patients (Figure 6d/7d) with mean standard error values +.  
 
Graph 6a (above): Healthy individuals: Repair of DNA, in the presence and 
absence of NSAIDs following treatment with bleomycin. NSAIDs compounds reduce 
DNA damage during the repair process. The nano versions showed greater DNA 
damage reductions than bulk. 
 
Graph 6b (above): Asthma patients: Repair of DNA, in the presence and absence 
of NSAIDs following treatment with bleomycin. NSAIDs compounds reduce DNA 
damage during the repair process. The nano versions showed greater DNA damage 
reductions than bulk. 
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Graph 6c: COPD patients: Repair of DNA, in the presence and absence of NSAIDs 
following treatment with bleomycin. NSAIDs compounds reduce DNA damage 
during the repair process. The nano versions showed greater DNA damage 
reductions than bulk.  
 
 
 
Graph 6d: Lung cancer patients: Repair of DNA, in the presence and absence of 
NSAIDs following treatment with bleomycin.  NSAIDs compounds reduce DNA 
damage during the repair process. The nano versions showed greater DNA damage 
reductions than bulk.  
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Graph 7a: Healthy individuals: NSAIDs compounds reduce DNA damage during the 
repair process. The nano versions showed greater DNA damage reductions than 
bulk equivalents. 
  
 
 
Graph 7b: Asthma patients: NSAIDs compounds reduce DNA damage during the 
repair process. The nano versions showed greater DNA damage reductions than 
bulk equivalents. 
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Graph 7c: COPD patients: NSAIDs compounds reduce DNA damage during the 
repair process. The nano versions showed greater DNA damage reductions than 
bulk equivalents. 
 
 
 
 
 
Graph 7d: Lung cancer patients: NSAIDs compounds reduce DNA damage during 
the repair process. The nano versions showed greater DNA damage reductions 
than bulk equivalents. 
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Figure: 15: TEM image of aspirin nanoparticles. 
 
 
Figure 16: TEM image of ibuprofen nanoparticles. 
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6.4 Discussion 
 
The present study has examined DNA damage in whole blood cells from 
healthy control individuals and patients of respiratory disease (asthma, COPD 
and lung cancer). Cells were subjected to DNA damage with bleomycin using 
the Comet assay. Cells were treated and allowed to carry out DNA repair 
without the genotoxins present in absence and presence of NSAIDs as 
previously discussed. In the Comet assay, the process of lysis ensures the 
nuclear region of all whole blood cells were kept intact. These are regions that 
contain the DNA, both damaged and undamaged DNA. Through 
electrophoresis, the damaged DNA (lose pieces which move under electric 
gradient), could be identified and compared as percentage or fraction in 
relation to undamaged DNA (Singh et al., 1988; Tice et al., 2000).  
All cells are capable of DNA repair, and mutagens like bleomycin and ultra-
violet C (UVC) have been used as clastogens to induce DNA damage in cells 
to test repair abilities (Wei et al., 2005; Zheng et al., 2004). Bleomycin plays 
an important role in treating cancers with its anti-tumour effects and NSAIDs 
(aspirin and ibuprofen) have previously been shown to inhibit prostaglandin 
synthesis – a promoter of cancer, via inhibition of cyclooxygenase enzymes 
(Peterson et al., 2010). The present study is able to combine the effects of 
bleomycin with NSAIDs. 
In this study some interesting results have been found after treating cells with 
7.5 µg/ml of bleomycin (end concentration). The data for both Olive tail 
moment and % tail DNA was found to be similar for all groups. Olive tail 
moment and % tail DNA were used as DNA damage is reflected more 
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accurately in results obtain using these two parameters for the measurements 
of Comets and there are no statistical differences between them (Dusinska 
and Collins, 2008; Kumaravel and Jha, 2006).  
Generally, data from all groups showed that all treated bleomycin samples had 
greater levels of DNA damage (OTM & % tail DNA) which were, significantly 
different compared to the negative control sample (p = ** < 0.01 or p = *** < 
0.001), with the exception to both ASP N and IBU N, which showed that in the 
presence of these two compounds for 15 minutes, most DNA was able to 
repair itself as the majority of samples show no significant difference compared 
to the control.  
For healthy individuals, asthma and COPD patients, reductions in DNA 
damage can be seen in the sample treated with bleomycin and repaired in the 
absence of NSAIDs, compared to the bleomycin treated sample with no repair. 
ASP and IBU samples show even greater reductions in DNA damage 
compared to the bleomycin with no repair, but the biggest reductions in DNA 
damage are those of the nano versions of aspirin and ibuprofen as mentioned 
above. Data for asthma and COPD patients show similar results, which could 
possibly be linked to the similar nature of both of these conditions 
(bronchorestriction and blockage of respiratory airways) (Buist, 2002; Masoli 
et al., 2004). 
For lung cancer patients the general pattern of the results are the same as 
with healthy individuals, asthma and COPD groups. However samples of 
bleomycin treated cells which were repaired in the absence of NSAIDs were 
unable to show any reductions in DNA damage compared to the treatment 
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with bleomycin (and no repair), with no significant difference between them. 
When samples are treated in the presence of the ASP B & IBU B, there are 
reductions in DNA damage and even greater reductions with the nano versions 
(ASP N & IBU N), demonstrating the importance of NSAID compounds in 
reducing DNA damage and especially with the increased surface reactivity of 
nanoparticles as result of their large surface area to volume ratio. Although the 
present system is an in-vitro study, nevertheless, these data are thus early 
indicators of showing the potential of nano compounds. Perhaps, the usage of 
bleomycin in combination with nanoparticle NSAIDs could be a future avenue 
for research.  
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Chapter 7 – General Discussion 
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7. Discussion 
 
 
Genotoxicity studies play an important role in the diagnosis or the prevention 
of disease. The focus of this PhD thesis has been to investigate the genotoxic 
damage to the DNA in human cells that are diploid, more specifically, 
peripheral lymphocytes and whole blood cells or haploid in the form of sperm 
cells. These cells are from healthy control individuals or patients and the 
general theme was to determine and analyse the impact HAAs and NSAIDs 
have on DNA and cell damage.  Blood cells are of interest because damage 
to the DNA could give rise to cancer, and damage to the DNA in sperm could 
give rise not only to cancer but also to heritable defects. 
This discussion focuses on two important topics. The first is based on side 
effects of by-products following treatment of drinking water with disinfectants. 
The Comet assay has been used as a means of testing genotoxicity by 
observing the % tail DNA and Olive tail moments of Comets. The micronucleus 
assay is also used to assess the cytotoxic and cytogenetic potential of these 
by-products in lymphocytes by observing the number of micronuclei (MNi) in 
mononucleated and binucleated cells (See sections 7.1-7.4 below).  
The second part of the discussion focuses on nanoparticles in human 
peripheral blood cells. Nanoparticles of the non-steroidal anti-inflammatory 
drugs, aspirin and ibuprofen, have been investigated in patients with 
respiratory diseases, using the micronucleus assay and the Comet repair 
assay (See sections 7.5-7.7). This is followed by conclusions (Sections 7.8). 
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7.1 Discussion of Halo acetic acids (HAAs) 
 
In today’s society, many people are at different levels of health. The Scientific 
and Research industries work together to address current health issues, to try 
to find solutions and cures for diseases and various other ailments. This is in 
order to develop a better picture of good health essential for human welfare. 
The World Health Organization (WHO), is an established globalised agency 
for the United Nations, responsible for international public health matters 
across many countries. It works to provide leadership guidelines on health 
matters, shaping health and research agendas, setting rules and regulations 
in research, provides support and assesses and monitors health trends 
worldwide. The purpose of which is to globally provide a sustainable social 
and economic benefit for all (WHO, 2010a). A branch of the WHO focuses on 
environmental health, which considers all aspects of human health and 
disease that are determined by factors in the environment. The environment 
plays a critical role in health and disease and in general several factors such 
as; air quality, climate change, housing and health, noise, occupational health, 
water and sanitation all contribute to health and disease.  
 
According to WHO, almost 20% of deaths in Europe and worldwide involve an 
environmental factor. Water sanitation is a major issue to address; in 
particularly in developing nations where in some parts there is a lack of clean, 
safe and quality drinking water, exposing people to pathogens and disease 
causing organisms present in the water. In order to disinfect water, water 
companies and suppliers make use of disinfectants, mainly chlorine but also 
including alternatives: chloramines, chlorine dioxide and ozone (Plewa et al., 
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2002; Richardson et al., 2007; Zhang et al., 2000). While disinfectants have 
provided a novel method as a means to clean water, their usage leads to the 
formation of unwanted drinking water disinfection by-products (DBPs). DBPs 
form as a consequence of reactions between the chemical disinfectant and 
organic constituents, bromide and iodide that are naturally present in water 
(Cemeli et al., 2006, Plewa et al., 2010). 
 
DBPs are a major public health concern and they have become one of the 
important areas in investigations of toxicology. In epidemiological studies, 
consumption or exposure to water above the maximum containment levels of 
DBPs in water have been associated with problems of liver, kidney, the central 
nervous system and increased risks of bladder, and colorectal cancers (Bull 
et al., 2011; Rahman et al., 2010; Villanueva et al., 2004; Villanueva et al., 
2007). Other studies have reported adverse pregnancy outcomes; DBP 
exposure has been associated with spontaneous abortions, low birth weight, 
still births and late pregnancy preterm delivery (Grellier et al., 2010; Hinckley 
et al., 2005; Wright et al., 2003; Yang et al., 2007). 
 
These findings demonstrate an important cause for concern, suggesting the 
need to further study the effect of DBPs in cells that have not been reported in 
current literature. Both the Comet assay and the micronucleus assay have 
shown positive results of HAA damage in lymphocytes and sperm. Damage to 
somatic and germ cells can give rise to cancer, but in germ cells damage could 
also produce heritable defects. There is indirect evidence that shows this is so 
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(Baumgartner et al., 2012; Dubrova et al., 1996; Gardner et al., 1990a; 
Gardner et al., 1990b). 
 
 
7.2 Methods of reducing DBP related health issues 
 
The prime method of reducing DBP-related health issues is by using new 
approaches in treating water. Therefore adopting new methods to disinfect 
water might be one avenue for researchers in this field. Some of these 
methods have demonstrated the benefits. One suggestion is targeting the 
removal of DBP precursors. The major advantage in targeting DBP precursors 
over managing the DBPs is that removing precursors will minimise DBP 
formation that includes both known and unknown DBPs, either regulated or 
unregulated. Over 600 DBPs have been identified and the toxicological effects 
of many of these compounds are not exactly known, especially as it deemed 
not feasible to monitor and assess every DBP. Hence targeting DBP precursor 
is more appropriate and a simple approach to use (Watson et al., 2012). 
 
Other strategies to remove DBP precursors (present in natural organic matter) 
from source waters include membrane techniques such as membrane filtration 
including; reverse osmosis, nano-filtration, ion exchange membrane and 
electro dialysis that been determined as effective in removing natural organic 
matter – important for controlling DPB precursors, However, these techniques 
remain expensive and energy inefficient but other approaches like absorption 
techniques; carbon aerogels; ion-exchange resins and aluminium coagulation 
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appear to show better progress in a bid to eradicate DBP-precursors (Watson 
et al., 2012).  
 
Finally, further research has shown some interesting findings in DBPs found 
from tap water in households. DBPs can vary indoors, as people may 
additionally, generally use indoor water handling strategies in a bid to improve 
taste and smell of water and reduce chances of microbiological contamination 
that includes: boiling of water before use, use of water filtration units, 
refrigeration and storage and these can all contribute in reduction of DBPs 
(Levesque et al., 2006). Trihalomethanes (THMs) levels were greatly reduced 
in two studies after boiling water for between 1-5 minutes (Batterman et al., 
2000; Krasner and Wright, 2005). Similar findings have shown reductions in 
other DBPs; chloroform and HAAs reductions after boiling water and using 
carbon filters (Weinberg et al., 2006; Wu et al., 2001).  
 
Wu et al. (2001) observed an 83% reduction of chloroform after 5 min of 
boiling, a two-fold increase of dichloroacetic acid (DCAA) levels and a 30% 
decrease of trichloroacetic acid (TCAA) after 1 min of boiling. Weinberg et al. 
(2006) reported that different types of activated carbon filters removed from 
93% to 99% of THM levels and from 68% to more than 95% of HAA levels. 
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7.3 Genotoxic effects of HAAs and antioxidant implications on 
their damage in the Comet assay 
 
The Comet assay is a micro-electrophoretic technique for the direct 
visualisation of DNA damage in mammalian cells (Ostling and Johanson, 
1984). The damage was measured by investigating the proportion of head 
DNA (undamaged DNA) with respect to Tail DNA (damaged DNA) (Anderson 
et al., 1997a; Anderson et al., 1997b; Anderson et al., 1998b; Anderson et al., 
1997c; Anderson et al., 2003; Singh et al., 1988; Tice et al., 2000).  
In this study, dose response experiments demonstrated that the increasing 
dosage of all three chemicals was proportional to DNA damage, and hence, 
reaffirms the necessity to keep HAAs regulated in line with THMs. As the 
antioxidants, catalase and BHA were able to reduce damage in CHO cells, the 
findings of this investigation contribute to these findings, suggesting catalase 
and BHA may be able reduce HAA-induced DNA damage in other mammalian 
cells.  
HAAs can have various modes of action in cells. These include; induction of 
uncontrolled cell proliferation, the accumulation of endogenous mutations by 
sustained DNA synthesis during hyperplasia, and the generation of reactive 
oxygen species (ROS) as a consequence of imbalanced production of 
peroxisomal enzymes (Cemeli et al., 2006). ROS can cause DNA damage and 
can induce DNA strand breaks and damage bases such as 8-
hydroxydeoxyguanosine (8-OH-G) that can lead to tumour progression. Male 
mice B6C3F1 exposed to HAAs had expressed a dose-dependent increase of 
8-OH-G isolated from nuclei of liver cells (Parrish et al., 1996) 
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Catalase is present in almost every cell of the human body where it works to 
prevent oxygen radicals (ROS) forming by breaking down H2O2 into harmless 
H2O and O2 (Zamocky et al., 2008). BHA is an exogenous antioxidant that 
functions as a free radical scavenger. Its aromatic ring is able to stabilise ROS 
and sequester them. Previous studies have shown dietary administration of 
BHA increases hepatic glutathione (GSH) (Eaton and Hamel, 1994). GSH is 
an important reagent with antioxidant properties, protecting cells from toxic 
substances such as carcinogens, pollutants and drugs. Importantly, GSH also 
regulates the nitric oxide cycle (Hogg et al., 1996). The dipeptide - gamma-
glutamylcysteine plays a vital role in bio synthesis of GSH (Sun et al., 1996). 
Eaton and Hamel (1994), found the rate-limiting enzyme gamma-
glutamylcysteine ligase and GSH to be elevated in mice following BHA diet. In 
addition, another study showed BHA levels increased GSH-S-transferase 
activity in mice hepatocytes induced with a carcinogen - 3-
methylcholantherene (3MC) following BHA induction, suggesting BHA has a 
detoxifying effect on chemical carcinogens and the GSH—transferase levels 
can be used as diagnostic biomarker in cancer (Chen, 1990). 
Although, catalase and BHA were able to reduce DNA damage they were 
unable to entirely eradicate the damage in lymphocytes and sperm, as is the 
case of IAA in CHO cells. This indicates there are other routes involved in the 
mechanism of genotoxic action. If oxygen radical involvement was the only 
mechanism, this would have been demonstrated by no damage in the 
presence of antioxidants. However a considerable reduction in IAA, BAA and 
CAA-induced genomic damage in the presence of these antioxidants does in 
itself highlight the importance of ROS damage to genomic DNA. The 
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implications of these findings suggest that, perhaps, it could also be 
appropriate to increase the units of catalase and increase dosage of BHA and 
determine if there is a complete eradication of DNA damage. Moreover, GSH 
levels could be investigated and used as a biomarker for antioxidant effect as 
it is known be elevated by BHA. Arbuckle et al. (2002) have also mentioned 
the possibility of using GSH as a biomarker, as DBP-metabolising enzymes 
like gamma-glutamylcysteine is polymorphically expressed in humans.  
 
 
7.4 Micronuclei (MNi) induction following HAA exposure 
 
Genomic DNA damage was prevalent in peripheral lymphocytes using the 
Comet assay. The micronucleus test was deployed as a cytogenetic end point 
using these cells. The mitosis stage of the cell cycle growth can lead to the 
creation of small distinct extra-nuclear bodies called micronuclei (MNi) 
(Fenech, 2006, 2007). MNi develop from acentric parts or whole chromosomes 
that fail to interact with metaphase spindles during mitosis resulting from 
chromosomal damage and cell damage and as a consequence, they do not 
form part of the two newly divided daughter cells. In this study, amongst 
various types of cell scoring, particular attention was emphasised on MNi 
presence in treatment groups since MNi presence equates signs of 
chromosomal loss, breakage, rearrangement, non-disjunction and apoptosis 
(Fenech, 2007). 
Related DBPs - THMs have shown an increase of MNi induction in 
lymphocytes; the findings from this investigation agree with these results, but 
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they contrast with those of another study using HAAs, which has found no 
increase in MNi frequency in the TK6 cell line (Liviac et al., 2010). In this study, 
HAAs were initially tested at same doses as deployed in the Comet assay and 
all three HAAs were found be too toxic and thus cells could not be scored. 
Subsequently, dose-response experiments were performed, by halving 
dosage each time) to determine the highest dose that could be used to score 
for genotoxicity as that immediately lower than the dose-inducing total 
cytotoxicity. With IAA and BAA a dose of 6.25 µM was used, which compared 
to the range investigated by Liviac et al. (2010) in TK6 cells. Our findings differ 
for CAA where a concentration of 62.5 µM was used, lower than the minimum 
concentration of 100 µM used in TK6 cells, as investigated by Liviac et al. 
(2010), possibly indicating cell-specific differences. 
In this study, all three HAAs caused MNi inductions but for all three this was 
lower than the positive control MMC. MMC is a compound of the mitomycin 
family of drugs, which was first discovered in 1956 (Hata et al., 1956). This 
group contains several functional groups, including aminobenozquinone and 
aziridine-ring systems (Mao et al., 1999). MMC works as a potent DNA cross 
linker that has absolute specificity for the DNA sequence CpG and has been 
shown to have the highest tumour-specificity and has an important clinical use 
as a chemotherapeutic agent, due to its anti-cancer antibiotic activity (Tomasz 
and Palom, 1997). In all three HAA experiments, MMC showed the highest 
frequency of MNi. 
In the micronucleus assay, it must be noted that other factors can play a 
contributory role to the results obtained. For example there are issues with the 
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experimental design of the CBMN assay and results can vary due to individual 
factors. Firstly the age and sex of the blood donor can impact on MNi scored 
in the CBMN assay. MNi frequency increases with age and in females there is 
a higher frequency of MNi by approx. 1.4 fold as a result of random loss in the 
inactive X chromosome, which like acentric and other whole chromosome 
fragments may lag at the anaphase (Fenech and Morley, 1985; Hando et al., 
1994). Secondly, hypotonic treatment is used as a method to remove red blood 
cells, but it can also alter cell morphology and structural detail of viable cells, 
which can have negative implications for results (Fenech, 2002). Also results 
from the Human MicroNucleus (HUMN) project, a worldwide collaboration of 
30 laboratories aiming at improving application and understanding of the 
lymphocyte CBMN assay, has shown that even if all laboratories follow and 
use the same scoring procedure, from same cell cultures prepared in the same 
manner, there would still be large differences found amongst the results 
between each scorer and the laboratories reflecting differences in visual 
discrimination of the cell structures scored and their interpretation of the 
scoring criteria (Fenech, 2002). This might perhaps, explain why Chi-Squared 
data showed different results of BHA in reducing HAA-induced damage on 
lymphocytes, compared to catalase, further repeat experimentations should 
resolve this issue. 
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7.5 Discussion of NSAIDs & nanoparticles 
 
7.5.1 Respiratory diseases (Asthma, COPD & Lung cancer) 
 
Cancer and disease are the biggest threats to the health and wellbeing of 
animals and humans. The factors that trigger the onset of these diseases are 
often through the varying factors of lifestyle (mutagens and carcinogens like 
smoking), diet, occupational health, environment (exposure to chemicals) and 
genetics. As humans there are ways on addressing some of these issues by 
taking everyday approaches, such as maintaining a good diet with regular 
exercise and avoid smoking for example, however sometimes the dogma of 
disease and cancer is such that these external factors are insufficient to 
prevent their onset. As such understanding of health and disease is critical to 
survival.  
The discovery of deoxyribonucleic acid (DNA) several decades ago has 
opened a wealth of knowledge and much has been done to gain a better 
understanding of DNA which encodes genetic information and has an 
important role in the development and functions of all cells. Certain chemicals 
can be mutagenic to the DNA in cells and this can cause changes to the cell 
and it’s functioning, sometimes leading to cancer. This gives rise to the term, 
genotoxicity – which involves studies of these chemicals possessing the 
capability of causing damage to the DNA or chromosomes (Phillips and Arlt, 
2009). Damage to the DNA can be in the form of strand breaks (single and 
double), loss of repair (BER, NER), point mutations and chromosomal 
aberrations (Phillips and Arlt, 2009).  
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Several assays like the Ames test and the Comet and micronucleus assays 
have been developed to aid better understanding of the potential of chemical 
mutagens which can ultimately cause cancer, by causing changes to the DNA 
(Ames et al., 1973; Phillips and Arlt, 2009; Singh et al., 1988; Tice et al., 2000). 
Two of these assays – the micronucleus and the Comet assays, have been 
deployed in in-vitro experiments, testing the role of non-steroidal anti-
inflammatory drugs (NSAIDs) on the blood from respiratory disease and 
cancer patients. 
 
In patients with respiratory diseases, conditions like asthma, COPD, the 
organs and tissue involved in the gas exchange of inhaled and exhaled air is 
greatly affected. These diseases have serious consequences, since they can 
cause common-colds, to life threatening conditions of pulmonary embolism, 
pneumonia and even lung cancer.  
 
7.5.2 NSAIDs – aspirin and ibuprofen 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX enzyme activity, 
a significant mechanism of action of NSAIDs. These enzymes play a 
significant role in the modulation of prostaglandin synthesis and subsequently, 
tumour progression (Day and Graham, 2013; Rao and Knaus, 2008). Several 
studies have shown that NSAIDs, like aspirin and ibuprofen exhibit anti-cancer 
activities on several hallmarks of cancer, such as cell proliferation, evasion of 
apoptosis and cell cycle regulation (Burn et al., 2011; Mansouri et al., 2013; 
Park et al., 2014). Some of these consist of a large number of clinical and 
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preclinical studies that have presented strong data to show NSAIDs could 
inhibit various types of cancers as described earlier (Brady et al., 2011; Coghill 
et al., 2011; Coghill et al., 2012; Kang et al., 2013; Kawahara et al., 2010; 
Retsky et al., 2012; Seufert et al., 2013; Thapa et al., 2010). 
Nanotoxicology has become a vast significant area of interest to scientists, 
who are using this technology to find better ways to improve / develop current 
or new forms diagnosis or treatment. Nanoparticles (100 nm – 1000 nm) have 
the biggest advantage of having a smaller size, resulting in a large surface 
area to volume ratio, thereby increasing the reactivity of cells (Dhawan and 
Sharma, 2010). Nanoparticles are better candidates in accumulating at the site 
of inflammation, and thus are suitable for targeted drug delivery (Elzoghby et 
al., 2012).  
 
7.6 Implications of ASP & IBU on lymphocytes from 
respiratory disease and cancer patients using the 
Cytokinesis-block Micronucleus assay (Chapter 5) 
 
The ability of NSAID’s anticancer properties combined with effectiveness of 
nanoparticles was tested using the micronucleus assay in peripheral blood 
lymphocytes of patients with respiratory diseases and healthy individuals 
using nanoparticle and bulk versions of the NSAIDs, aspirin and ibuprofen.  
This investigation has showed a reduction of MNi in binucleated cells in the 
nano forms of aspirin and ibuprofen, compared to aspirin and ibuprofen bulk 
forms, respectively. For aspirin and ibuprofen nano, the MNi frequency was 
found to be generally similar to the negative controls and in asthma and COPD 
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patients, the MNi frequency was even lower, demonstrating possible benefits 
of using nanoparticles. 
Similar findings were found using Comet assay as part of a parallel study in 
our laboratory (conducted by Dr. Mojgan Najafzadeh, University of Bradford). 
  
7.7 Role of NSAIDs on the repair of DNA following exposure 
to bleomycin (Chapter 6) 
 
Previous works on NSAIDs using the micronucleus assay (Chapter 5) and the 
Comet assay (by Dr. Mojgan Najafzadeh, University of Bradford) have shown 
the reductions in DNA damage in lymphocytes when treated with NSAIDs and 
to a greater extent with the nanoparticle versions. With these findings, this 
study was performed to investigate the influence of DNA repair of cells in the 
presence and absence of NSAIDs in order to determine whether these 
compounds facilitate the repair of DNA or have the opposite effect or no effect. 
Monitoring the repair of DNA is one of important determinants of cancer 
susceptibility (Gaivao et al., 2009). Cells from healthy individuals, asthma, and 
COPD and lung cancer patients are challenged using bleomycin and then 
allowed for DNA repair without bleomycin (BLM). Some have been allowed to 
carry out DNA repair in the in the presence of NSAIDs, as previously 
discussed.  
Following exposure to bleomycin, the greatest efficiency in the repair of DNA 
was found in samples which were allowed for repair in the presence of 
NSAIDs. The nano forms in particular, showed the best repair of DNA 
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compared to their bulk equivalent forms, where DNA damage had reduced to 
negative control levels. 
In lung cancer patients, most DNA was still not repaired in the samples where 
DNA repair was allowed in the absence of NSAIDs, however reductions in 
DNA damage is seen in the presences of the bulk versions of the NSAIDs, and 
this reduction is even greater in presence of the nano versions. These results 
demonstrate the importance of NSAIDs compounds in reducing DNA damage 
and especially with the increased surface reactivity of nanoparticles as result 
of their large surface area to volume ratio. Although the present system is an 
in-vitro study, these data obtained are thus early indicators of the potential of 
nano compounds. Perhaps, the usage of bleomycin in combination with 
nanoparticle NSAIDs for cancer treatments could be a future avenue for 
research.  
 
7.8 Conclusions 
 
Data from the Comet assay has shown that HAAs responded in a similar 
manner, producing similar dose responses over the same dose range in 
lymphocytes and sperm.  After treatment with the antioxidants, all three HAAs 
responded in a similar way, with slightly more damage in both the Olive tail 
moment and % tail DNA in the sperm than in lymphocytes, suggesting that 
haploid cells maybe more sensitive to genotoxic events. Data with the 
micronucleus assay showed a similar pattern in the form of micronuclei. 
Frequency of micronuclei increased in presence of HAAs but reduced with 
catalase, with reductions also seen in some dosages of BHA, following a 
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similar trend to results in the Comet assay where the DNA damage may initially 
be greater but generally less as primary DNA is able to repair itself over time. 
However, here we have shown fixed DNA damage as a consequence of 
exposure to HAAs. Our study, thus demonstrates the genotoxic effects of 
these compounds to both somatic and germ cells. 
 
These observations are of concern to public health since both somatic and 
germ cells show positive responses and further contribute to existing literature 
demonstrating the importance DBPs have in relation to health and the 
environment, in particular HAAs which are not regulated in the United 
Kingdom. A joint project – HIWATE (Health Impacts of long term exposure to 
WATEr) has recently been established in the European Union to investigate 
potential human health risks associated with long term exposure to DBPs 
(Nieuwenhuijsen et al., 2009). This should provide greater insight and better 
understanding of DBPs and their impact on human health and environment. 
These were the first studies to show that all three HAAs act through an oxygen 
radical involvement. (Cemeli et al. (2006)), had previously shown that IAA 
acted in this way. No enzyme treatments were necessary in the Comet assay, 
since the antioxidant effect was detectable without the necessity of these 
enzymes, so strengthening the case of the antioxidant response.  
 
Similarly, investigating NSAID nanoparticles have also yielded some 
interesting findings using both the micronucleus and the Comet repair assays 
in healthy individuals, asthma, and COPD and lung cancer patients. Using the 
micronucleus assay we are able to show that nanoparticle NSAIDs (aspirin 
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and ibuprofen) have beneficial effects. Micronuclei (MNi) – an indicator of DNA 
damage in fixed cells, was found to be in lower numbers compared to their 
equivalent bulk standard sized equivalents (aspirin and ibuprofen). With the 
Comet repair assay we were able to show that NSAIDs bulks greatly enhance 
the repair of DNA, following exposure to bleomycin. This enhancement is 
increased further, when the repair of cells occurs with the addition of NSAID 
nanoparticles. NSAIDs are known for their anti-cancer effects and 
nanoparticles are known for their benefits, via their physiochemical properties 
and effective drug delivery (Osman et al., 2010). With this in mind, findings 
from these two in-vitro studies have provided some useful information that 
might be of relevance for further research, including research in-vivo. 
 
The doses that are used in all four of these studies (Chapters 3, 4, 5 & 6) might 
be higher than those found in real life situations. They have been optimised to 
detect a response as is the case in all genotoxicology assays. We do not know 
the situations for water samples in all countries around the world, but our 
studies indicate the potential for a positive response with these chemical in 
both somatic and germ cells, and therefore should be considered with caution. 
 
These data have been generated in vitro. As for all in vitro experiment, it is 
difficult to extrapolate from in vitro to the in vivo situation. These ex vivo / in 
vitro are the next best approach to extrapolating to the in vivo situation. We 
know from many experiments of this nature conducted in our laboratory that 
lymphocytes and sperm possess some metabolic activity relating to the human 
situation since cells are freshly removed from the human body. Whilst we 
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cannot directly do experiments in man, this approach gives some indication of 
what might be expected if man were exposed directly to these compounds. 
 
Future work 
 
It would be interesting to determine the nature of chromosome damage lesions 
using micronucleus FISH (Fluorescence in situ hybridisation) in both studies 
on HAAs and NSAIDs. FISH in combination with micronucleus assay, consists 
of a probe that is used to label the pan-centromeric regions of the 
chromosome. This technique allows for discrimination between micronuclei 
containing a whole chromosome (centromere positive micronucleus) and a 
centric chromosome fragment (centromere negative micronucleus). 
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